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Abstract 
Thesis abstract
The work of this thesis presents novel genome engineering strategies for assembling 
complex targeting vectors for functional studies in the mouse. With the objective of 
establishing a conditional mouse model of the human acute leukemia associated with the 
t(4;ll)(q21;q23) translocation, an approach based on the Cre-loxP technology was chosen, 
and two mouse lines and one ES cell line were engineered starting from BACs.
For the Af4 mouse line, a combinatorial mutant allele was designed, which supports 
Cre-driven interchromosomal translocation, can result in a knock-out or hypomorphic allele 
(also amenable to conditional gene repair strategies) and can report endogenous expression 
of the gene through |3-galactosidase staining. The work utilised several variations of the ET 
cloning methodology and served to establish their feasibility for BAG engineering as a novel 
approach to the generation of complex mouse knock-in/knock-out targeting vectors. 
Particularly noteworthy was the application of ET technology to the direct subcloning of 
very large BAG fragments.
The Mil targeting construct constitutes the first example of a BAG based, very large 
knock-in vector (about 70 kb) which was successfully used to target the endogenous Mil 
locus by homologous recombination in mouse ES cells. The construct was engineered via 
ET recombination approaches. The major novelty consists in the targeting design which can 
simultaneously mutate two sites of the gene located very far from each other. Gombined with 
the power of site specific recombinases (SSRs) technology, this opens the way to 
establishing complex, versatile mouse lines with only one round of ES cell targeting.
For the second mouse line, a BAG transgenesis approach was chosen to place Gre 
recombinase under the control of the Ikaros gene, in a new configuration which can yield
either constitutive or regulated Cre activity. Several BAG modifications were applied, and 
the usefulness of Tnpl recombinase in BAG engineering was established.
Some of the results presented here appear in the following publications:
Muyrers, J. P., Zhang, Y., Testa, G., and Stewart, A. F. (1999). Rapid modification of 
bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res 27, 1555-1557
Testa, G. and Stewart, A.F. (2000). Creating a transloxation. Engineering interchromosomal 
translocations in the mouse. EMBO Rep. 1, 120-121
Zhang, Y., Muyrers, J. P., Testa, G., and Stewart, A. F. (2000). DNA cloning by 
homologous recombination in Escherichia coli. Nat Biotechnol 18, 1314-1317.
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INTRODUCTION
Chromosomal translocations in human leukemias
LI Introductory remarks
Chromosomal aberrations are a hallmark of many neoplasias. They were first 
connected to cancer at the end of the 19* century, with von Hansemann’s thorough 
investigation of cell division in malignant tumours. Starting in the middle of the last century, 
karyotyping techniques gradually became available which started to identify recurrent 
chromosomal abnormalities in a variety of human cancers. This led to the discovery in 1960 
of the Philadelphia chromosome (Ph) in chronic myelogenous leukemia (CML), the first 
karyotype abnormality consistently associated with a disease condition, and since then a 
paradigm in the study of chromosomal translocations in human leukemias. The next 
decisive leap forward came at the beginning of the 1970s with the introduction of
chromosome banding techniques (Caspersson et al., 1970). These enabled one to identify
each individual chromosome unequivocally, and constituted a prerequisite for the precise 
characterisation of translocations and other aberrations. Soon after it became apparent that 
the Ph chromosome did not represent a unique case; recurrent chromosomal aberrations were 
consistently identified in a variety of human neoplasms, mostly leukemias, lymphomas and 
soft tissue solid tumours.
Four main classes of cytogenetic aberrations can be recognised: interchromosomal 
translocations, deletions, duplications and inversions. While deletions and duplications result 
in a loss or gain of genetic material, in both translocations and inversions it is the
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rearrangement of a specific locus or loci which carries a pathogenic effect. This class of 
rearrangements can have two consequences (Look, 1997; Rabbitts, 1994).
A gene, usually a proto-oncogene, can be relocated under the regulatory influence of 
a new control region, which in turn leads to a derangement in its expression profile. This 
mechanism is exemplified by translocations involving the c-myc proto-oncogene in Burkitf s 
lymphoma. This is a B-cell malignancy, which can arise as a consequence of three possible 
distinct translocations. In all cases, the C-MYC proto-oncogene is translocated to either the 
immunoglobulin (more frequently) or the T-cell receptor gene. Chromosomal fusions happen 
within the joining or diversity segments of those loci, leading to inappropriate expression of 
c-myc. A constitutive alteration in the levels of the c-myc protein is believed to shift the 
overall equilibrium of a network of transcription factors complexes (comprising MAX, 
MAD and Mxi-1) towards MYC containing, activating complexes. Inappropriate expression 
of the respective target genes initiates an oncogenic cascade.
A number of other hematological neoplasms are associated with analogous 
translocations causing disregulation of the rearranged gene. These often encode transcription 
factors, like H O Xll, TALI ox RBTN  in acute T-cell leukemias (T-ALLs). These genes are 
not normally active in T-cells, and their ectopic expression driven by the T-cell receptor 
gene has been shown to be the key pathogenic event.
A notable example of genes other than transcription factors involved in this kind of 
rearrangements comes from some of the translocations identified in chronic forms of 
lymphoma or leukemia. BCL-2, which normally protect B and T lymphocytes from 
apoptosis, is involved in the translocation t(14;18)(q23;q21), where it is juxtaposed to the 
IgH-joining segment, resulting in its inappropriate expression.
This class of chromosomal translocations, observed exclusively in lymphoid
malignancies, has been shown to result almost invariably from mistakes in the V(D)J
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recombination process which normally takes place in lymphoid cells to assemble the antigen 
receptors. This comes mainly from two observations. First, some of the breakpoints which 
have been molecularly chracterized display canonic heptamer or nonamer sequences which 
can be recognised by the lymphoid recombination machinery. Second, both translocated 
chromosomes show an N-nucleotide addition, which is a hallmark of RAG activity. Thus, it 
seems that mistakes in the normal recombinational activity of lymphoid cells can account for 
most of these translocations.
Exhaustive analysis of both leukemias and solid tumors has clearly defined that the 
most common visible outcome of interchromosomal translocations is actually the creation of 
new chimeric proteins (Rabbitts, 1994). In these cases, the breakpoint occurs in the introns 
of the genes involved, and the resulting product is a fusion of the domains contributed by 
each of the two partner genes. Besides the already mentioned Ph chromosome resulting from 
translocation t(9;22)(q34;ql 1), the t(4;l I)(q21;q23) translocation fusing MLL WiihAF4 is an 
example of this type of rearrangement, along with the great majority of all rearrangements 
affecting the MLL gene.
If one considers the whole spectrum of chromosomal aberrations in human cancer, 
some common themes emerge, raising some of the most outstanding questions which still lie 
unanswered in our understanding of neoplasia.
First of all, non-random, recurrent chromosomal aberrations have been identified in 
all human neoplasms which have been analysed in sufficient numbers to allow robust 
conclusions. Recently, a comprehensive map of all recurrent chromosomal rearrangements
was assembled (Mitelman et al., 1997), which analysed 26,523 cases reported in the
literature, and identified 215 balanced and 1588 unbalanced recurrent chromosomal 
aberrations. Balanced aberrations include translocations and some inversions, where the
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chromosomal topography is altered without loss of genetic material. Deletions, duplications 
and inversions accompanied by changes in the amount of genetic material constitute 
unbalanced aberrations. Balanced aberrations (ie. mostly translocations) exhibit much higher 
disease specificity, whereas only a few of the unbalanced abnormalities are consistently 
associated with specific tumors. The reasons for this difference are largely unknown, but it 
possibly indicates that unbalanced aberrations may not represent the initiating event but 
rather contribute to later stages of the neoplastic process. The loci affected may encode for a 
diverse range of proteins, whose disregulation could confer similar selective advantages to 
diverse tumor types.
The second clear outcome of this comprehensive analysis has been to confirm an 
older observation, namely that chromosomal translocations are much more frequent in 
hematologic neoplasms than in solid tumors, among which they occur much more 
commonly in soft tissue tumors (of mesenchymal origin) than in epithelial ones. This may 
simply reflect the less advanced state of solid tumor cytogenetics, in which case the 
introduction of new techniques like multicolour fluoresence in situ hybridisation 
(chromosome painting) should gradually eliminate the difference in translocation frequency 
between mesenchymal and epithelial neoplasms. However, this discrepancy may well reflect 
a genuine biological phenomenon, possibly related to the different sensitivity of various 
tissues to chromosomal rearrangement per se or to its molecular consequences. Needless to 
say, thorough investigation of this fundamental difference could be extremely rewarding.
The third major conclusion which can be drawn from such a catalogue is that 
virtually all chromosome bands of the human genome are involved, albeit at different 
frequencies. Although some regions of the genome are more prone to recombination events 
and the products of certain rearrangements more often result in selective growth advantages.
21
clearly a very large number of genes can contribute to the multistage process of 
carcinogenesis.
The second part of this chapter deals exclusively with interchromosomal 
translocations, and some of the emerging concepts in their origin and significance.
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1.2. Seed versus soil: chimeric fusion proteins and the question of 
specificity
From a thorough overview of the data gathered so far, it appears that most clinically 
manifested leukemic translocations involve genes which are required for normal 
hematopoiesis. This conclusion is largely based on in vivo experiments, in which genes 
translocated in human leukemias have been knocked out in the mouse and found to be 
essential for various aspects of blood development. It should be emphasised that, although 
this correlation is now considered obvious and predictable, it need not be necessarily so 
(Orkin, 2000). Genes disrupted in human leukemias could have been for example just related
to the master regulators of hematopoiesis, belonging to the same protein family. Instead, the 
precision of this correlation clearly points to an intimate relationship between perturbed 
hematopoiesis and leukemogenesis. As the list of leukemogenic rearrangements continues to 
expand, an unprecedented opportunity unfolds to understand the physiological basis of blood 
development and its pathological derangements. For chimeric fusion proteins constitute 
natural experiments in shuffling together domains of different proteins, often impinging on 
disparate signaling pathways affecting growth, differentiation and apoptosis.
Animal studies to investigate the normal function of genes disrupted by specific 
chromosomal translocations have provided evidence as to the specificity of various 
translocations with respect to the disease phenotypes they are associated with. This central 
issue framed the "seed versus soil" debate, which usually involves consideration of two 
alternative scenarios (Barr, 1998; Westervelt and Ley, 1999). According to one hypothesis,
the consistent association of a certain translocation with one or a few specific tumours could 
reflect the fact that this translocation can only happen or exert its pathogenic effect in a
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given lineage or at a specific stage of commitment. This could reflect a number of different 
reasons:
1) The two genes could be accessible for interchromosomal recombination only at 
certain stages of development, due to the chromatin organisation of their loci or 
the relative topology of chromosomal territories within the nucleus. Though very 
intriguing, this is one of the least characterised factors possibly underlying 
translocation specificity. As an example, the RET/PTCl inversion causing thyroid 
papillary cancer was recently investigated by two colour fluorescence in situ 
hybridisation coupled with three-dimensional microscopy. Though separated by a 
linear distance of more than 30 megabases on chromosome 10, this study showed 
that at least one pair of RET  and PTCl loci was actually juxtaposed much more 
frequently in thyroid cells than in other tissue types, possibly providing a high- 
order structural basis for the exclusive occurrence of this rearrangement in thyroid 
neoplasms (Nikiforova et al., 2000).
2) The recombination machinery which catalyses the translocation reaction could 
operate only in specific cell types and/or at defined points of development. This is 
obviously relevant for lymphoid neoplasms (see above), where the activity of the 
V(D)J recombination apparatus is essential for the translocation to occur.
3) Once the translocation has taken place, the resulting fusion protein needs first of 
all to be adequately expressed. The availability of the relevant machinery at all 
levels of the gene expression flux (ie. transcription, post-transcriptional 
processing, nuclear-cytoplasmic export of the mRNA, translation and post- 
translational modifications) constitutes an obvious prerequisite.
4) Assuming proper expression, the fusion protein might initiate the oncogenic
cascade only under certain conditions. For example, it might need the
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simultaneous presence of cofactors (transcription factors, chromatin modifying 
complexes, signal transducers), whose expression may in turn be tightly regulated 
both in space and time. Along the same line of logic, potential target genes of the 
fusion protein might not be always amenable to transactivation or repression, 
depending for instance on their chromatin accessibility. In such cases, the effect of 
the fusion protein might be negligible, and its presence tolerated by the cells 
without further consequences.
5) Finally, the fusion protein might be toxic to certain cell types and/or at specific 
stages of development. The availability of cellular factors, or extracellular cues, 
promoting tolerance to these toxic effects would add an additional layer of 
selection for the permissive lineage and/or cell type.
Thus, in all of the above cases, it would be the lineage (“soil”) which actively selects the 
possible translocation product, by imposing various constraints on its occurrence and/or on 
its function.
The alternative scenario predicts that it is the translocation which actively determines the 
lineage. According to this model, a given translocation would randomly occur in a relatively 
undifferentiated progenitor cell. The resulting fusion protein, by virtue of the intrinsic 
specificity of its domains, then executes a determined genetic programme leading to 
expansion of a defined lineage with neoplastic features.
It is clear that these models represent two possible extremes, and that it is reasonable to 
envision a complex developmental system in which they are not mutually exclusive. There 
probably are numerous constraints for a specific translocation to occur and to propagate, so 
that not any translocation can be expected to arise in any tumor. However, it is equally likely 
that the fusion protein could at least contribute to specifying, if not fully determining, which
25
developmental decision the target cell will take, among the restricted number of options 
available at that stage in space and time.
Two approaches have been used to address the issue of specificity, cell culture studies and 
mouse models.
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II
Current approaches to modelling leukemia
II. 1 Cell culture studies of fusion proteins
Most studies of cells in culture have underscored the importance of the cellular 
compartment (“soil”) in the transformation process. The strategy of such studies is usually to 
force expression of a fusion protein in various cell culture systems and assess for the effects 
on growth and/or differentiation. An obvious limit is that the use of heterologous cell lines, 
bearing little or no resemblance to the original tumour histotype, can lead to results and 
interpretations of questionable in vivo relevance. However, this very setting can also prove 
rather useful to dissect the issue of “seed” vs. “soil”.
The following examples are representative of the type of conclusions which can be expected 
from such approaches.
Like many other fusion proteins identified in human leukemias, the BCR-ABLl product 
cannot transform NIH3T3 mouse fibroblasts, despite very high levels of expression (Daley 
et al., 1987). However, transforming activity has been established for certain BCR-ABL-1
constructs harbouring C-terminal rearrangements, and specific subclones of NIH3T3 cells 
have been identified which are readily transformed by the BCR-ABL-1 fusion protein, 
strongly arguing for a complex interplay between distinct domains of the fusion protein and 
the specificity of the cellular milieu (Renshaw et al., 1995; Shore et al., 1994).
Again from the N1H3T3 system, it emerged that although the fusion protein may itself exert 
a transactivation function on gene expression, this readout can be of no relevance unless it 
involves genes of functional importance for a specific lineage.
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Twelve genes were identified as being induced in NIH3T3 cells upon expression of the 
oncogenic fusion product E2A-PBX1, usually associated with pre-B acute lymphoblastic 
leukemias. Most of these genes are not expressed either in human pre-B leukemia lines, or in 
E2A-PBX1 immortalised mouse myeloblasts, both arguably much closer to the original 
leukemic cells than NIH3T3 fibroblasts (Fu and Kamps, 1997).
The results obtained with the PML-RARa translocation are even more telling. As with many 
other fusion products, it proved impossible to stably express the PML-RARa protein in a 
variety of cell lines, including the majority of hematopoietic cell lines (Ferrucci et al., 1997). 
In contrast, high levels of expression were readily achieved in hematopoietic cell lines 
derived from myeloid leukemias. The introduction of inducible expression systems revealed 
that this fusion protein induces apoptosis in the majority of cell lines tested. The myeloid 
lineage seems to be exquisitely resistant to this toxic effect, providing a rational framework 
for the specific association of this translocation with acute promyelocytic leukemia (APL). 
The use of more relevant cell culture systems can certainly obviate some of the problems 
described, as for example in the studies which investigated the potential of the PML-RARa
and FUS-DDIT3 fusion proteins in myeloid and adipocytic cell lines, respectively (Grignani
et al., 1993); (Kuroda et al., 1997). Nonetheless, cell lines pose a conceptual problem for a 
meaningful interpretation of this kind of experiments. In fact, being already transformed or 
else immortalised, they provide a dubious background against which to test the genuine 
oncogenic potential of specific fusion proteins.
II.2 The rationale behind mouse models
Although cell culture experiments can provide interesting clues for a preliminary 
understanding of the leukemogenic process, especially at the biochemical level, it is clear
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that a thorough characterisation of cancer can only come from suitable animal models. There 
are several reasons for this:
1) Though initially triggered in a single cell, cancer invariably becomes a disease of 
the organism, in which a myriad of host-tumor interactions contribute to the final 
biological outcome. Arguably, this is the biggest challenge for phenotypic 
characterisation, and yet it is essential for a complete and genuine understanding 
of the disease.
2) Cancer is a dynamic process, where several genetic and epigenetic lesions appear 
and are selected over time. This temporal and evolutionary aspect can be only 
partially recapitulated in cell culture systems.
3) The ability to metastasise (and in the case of leukemias to infiltrate different 
tissues) is the single most relevant feature of a tumour, certainly from the 
standpoint of clinical management. Although this process can greatly benefit from 
pilot in vitro experiments, it can only be fully addressed in the context of the 
whole organism.
4) The generation of meaningful mouse models of human cancers constitutes a 
platform for the identification of modifier loci by genetic screening methods. The 
characterisation of cancer risk modifying genes will help elucidate the complex 
molecular network which underlies cancer development. It will also constitute a 
key step for the coming of age of preventive and predictive oncology.
5) Finally, the availability of mouse models which faithfully mirror human 
neoplasms is a prerequisite to test the feasibility and efficacy of novel therapeutic 
approaches.
The next sections summarise the various methodological approaches which have been used 
to engineer mouse models of human leukemias, highlighting their respective strengths and
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weaknesses in the light of the results obtained and the paradigms which are beginning to 
emerge.
II.3 Standard transgenic approaches
Standard transgenesis approaches were the first ones to be applied. In this type of 
experiment, a cDNA coding for the desired fusion protein under the control of a suitable 
promoter element is integrated into the mouse genome by injection into fertilised oocytes. 
As with any transgenic experiment, the overall expression levels achieved with a given 
promoter are strongly influenced by the site of genome integration and sometimes by the 
number of copies of the construct which have been integrated. The site of integration is a 
particularly relevant variable, as local control regions can override the transgene’s own 
promoter elements causing either inappropriate silencing or inappropriate expression. Hence 
the need to characterise multiple founder lines to identify the most faithful pattern of 
expression.
An additional concern comes from the possibility of insertional mutagenesis following 
integration of the transgene, resulting in disruption of an unrelated gene or alteration of its 
chromatin environment. In either case, a spurious source of phenotypic variation can 
confound the interpretation of results.
While these limits are inherent in any transgenic experiment, in the case of translocation
models, this approach has additional shortcomings.
First of all, in the vast majority of cases, interchromosomal translocations constitute
acquired somatic mutations which occur sporadically. In the first transgenic models of
leukemias, on the contrary, the fusion protein was expressed throughout the development of
the organism. In some cases, this resulted in embryonic lethality, demonstrating a toxic role
of the fusion product for certain lineages and certain phases of development. This occurred
30
for example in experiments in which the expression of the BCR-ABLl fusion protein was 
driven by the BCR promoter itself (which would have seemed at first to be a relatively 
faithful approach to model CML) (Heisterkamp et ah, 1991).
Even in those cases in which the animal survived, and a leukemia eventually ensued, a 
conceptual flaw remained, in that all the cells in the whole lineage from which the disease 
eventually originated were constantly confronted with the presence of the translocation 
product; an artificial situation whose outcomes might not be easily applicable to the human 
disease.
In order to partially overcome these problems, more sophisticated transgenic approaches 
were pursued in which the regulatory element was carefully selected on the basis of the 
suitability of its spatio-temporal expression profile to the lineage and/or developmental stage 
thought to be important for leukemogenesis. This type of design can avoid general 
expression of the fusion protein throughout the organism. However, it still results in the 
activity of the translocation protein in all cells in which the regulatory element is switched 
on. Again, this exposes the animal to a “mutational burden” which has no counterpart in 
human pathogenesis.
A second important limitation is that in transgenic models of leukemias, only one of
the two fusion proteins is expressed. For some neoplasms, the relevance of both
translocation products to the development of the disease has been questioned, mainly
because only one of the two derivative chromosomes is consistently detected. Such findings
must be interpreted carefully, however, as they might simply indicate that one of the two
fusion proteins contributes to the initial transforming steps, but becomes then dispensable
once the cell has acquired additional genetic lesions, which is the stage at which most
leukemias come to clinical attention. And even if only one fusion protein were instrumental
in the development of the disease, the reciprocal product could play a role in the leukemic
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phenotype, as demonstrated in at least one mouse model, where the presence of both 
translocation products affected both the penetrance and the phenotype of the disease, 
probably via a heightened predisposition to accumulate additional genetic lesions (Pollock et
al., 1999; Zimonjic et al., 2000).
Third, transgenic models do not recapitulate the relative gene dosage of a cell which 
has undergone an interchromosomal translocation. Such a cell will express only one wild 
type allele for each of the two genes involved, and this could well contribute to the 
transformation process if the function of these genes is dosage sensitive. In transgenic 
models, in contrast, the fusion product is expressed in addition to the normal alleles of both 
target genes.
Fourth, there has been very little investigation into the long range consequences that 
interchromosomal translocations can have on genes other than the ones which are actually 
interrupted. In recent years, functional meaning has been attributed to the non random 
positioning of chromosomal territories in interphase nuclei. Together with observations 
which have identified distinct subsets of subnuclear compartments or bodies, this has led to a 
fluid model of nuclear organisation in which specific domains are defined by the local 
concentration of specific proteins (chromatin regulators, transcription factors, DNA and 
RNA processing enzymes, nuclear signal transducers). It is not hard to imagine how the 
violent perturbation resulting from the joining of two unrelated chromosomal territories 
could have pleiotropic effects on nuclear physiology. Furthermore, it is not even necessary to 
invoke such higher order interactions; a variety of long range enhancer-promoter circuits are 
likely to be affected by interchromosomal translocation. The phenotype we eventually 
observe could indeed be the combined result of a major oncogenic hit (the fusion protein) 
and a concomitant array of more subtle molecular changes.
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Despite these drawbacks, some previous transgenic attempts did result in useful 
models of leukemia. Transgenic models of the PM L-RARa  translocation are here 
summarised as a prototypic case study, since the differences between the various models 
produced constitute a useful framework from which to explore in vivo the question of “seed 
vs. soil”.
II.3.1 The PML-RARa paradigm
Four different transgenic models have attempted to recapitulate acute promyelocytic 
leukemia (APL) in the mouse. At one end of this group stand the two experiments which 
yielded leukemia in the mouse, albeit with different phenotypes. At the other extreme lies 
the interesting case in which no leukemia was observed, bur rather an impairment in 
myelopoiesis. Adding one more colour to the puzzle, in a fourth model, the expression of the 
fusion protein resulted in neoplasm of a different tissue (hepatic neoplasms).
In the two successful models, the same PML-RARa fusion protein was expressed under the
control of either cathepsin-G or MRP8 promoter (Brown et al., 1997; Grisolano et al., 1997).
The cathepsin-G construct restricts expression of the cDNA only to the promyelocytic 
compartment, while the MRP8 gene is expressed throughout myeloid development. In both 
cases, a myeloid leukemia recapitulating many aspects of the human disease did develop. 
However, the frequency of occurrence and the preleukemic phenotype were dramatically 
different. All of the mice expressing PML-RARa under the control of cathepsin-G showed 
myeloid expansion with terminal differentiation, and 30% of those animals developed acute 
leukemia; interestingly, the leukemic blasts could not be differentiated in vitro with all-trans 
retinoic acid (ATRA), one of the main features of APL cells in humans.
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Mice expressing the same fusion protein under the control of the MRP8 gene showed a 
substantially normal bone marrow with minor myeloid abnormalities. In 5% of the animals a 
promyelocityc leukemia developed with a complete block in granulocyte maturation (in 
contrast to the cathepsin-G animals where full myeloid maturation was observed 
concomitant to the leukemia). Strikingly, these blasts could be differentiated in vitro by 
ATRA treatment.
The difference in differentiation phenotype between these two models (partial versus 
complete differentiation block in cathepsin-G versus MRP8 mice, respectively) could be due 
to the fact that while cathepsin-G expression is restricted to the promyelocytic compartment, 
the MRP8 gene stays active throughout terminal differentiation. An even stronger support 
for the importance of the targeted “soil” in determining the leukemic phenotype comes from 
the analysis of the “unsuccessful” model. In this case, the PML-RARa protein was placed
under the control of the GDI IB promoter (Early et al., 1996). The CDU gene is expressed
in granulocytes, but not in myeloid precursors. No leukemia was observed, but rather a mild 
impairment of myelopoiesis, suggesting that this fusion protein can only unfold its 
oncogenic potential at specific stages of myeloid development.
The parallel importance of the “seed” comes from experiments in which the PLZF- 
RARa fusion (the product of one of the variant translocations leading to APL) was expressed
under the same cathepsin-G promoter described above (He et al., 1998). While the 
preleukemic phenotype was similar to the CG-PML-RARa, penetrance was in this case 
100%, and in addition the differentiation block appeared less severe. While differences in 
transgene integration site and/or dose could theoretically explain these findings, it is 
intriguing to speculate that this variation is specifically due to the different fusion proteins 
employed.
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Finally, mice in which the promyelocytic leukemia fusion protein was expressed under the 
control of the metallthionein-1 promoter developed hepatic preneoplastic and neoplastic 
lesions, showing that more than one lineage appears sensitive to the transforming effect of 
PML-RARa (David et ah, 1997).
II.4 Knock-in approaches
A more sophisticated variation in leukemia modelling involves targeting of the 
fusion protein cDNA to an endogenous locus by homologous recombination rather than 
random integration. As for standard transgenic approaches, the endogenous locus is selected 
for the suitability of its spatio-temporal expression profile to the lineage and/or 
developmental stage thought to be important for leukemogenesis. These type of designs 
avoid most of the general problems encountered with standard transgenesis, namely 
variegation of expression and multiple copy integration. All other drawbacks are still 
relevant though, with an added complication resulting from the necessary disruption of the 
endogenous targeted allele, which obviously severely restricts the choice of possible loci.
A step forward in leukemia models was achieved in 1996, when Rabbitts and 
CO workers applied a more sophisticated “knock-in” strategy, in which the 3' terminal portion 
of the cDNA of one of the two target genes was inserted into the endogenous locus of its 
translocation partner at the site of the breakpoint, yielding expression of the fusion protein 
under the control of the endogenous upstream partner. Four studies have been carried out 
with this approach. Rabbitts et al. first applied it by knocking the cDNA of the Af9 gene into
the Mil locus (Corral et al., 1996). Analogous experiments were then performed with BCR- 
ABLl, CBFB-MYHll, and AMLl-ETO (Castellanos et al., 1997; Castilla et al., 1996; 
Yergeau et al., 1997; Okuda et al., 1998).
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An extensive account of the M//-Af9 leukemia model is given in chapter IV.8.1. Here, the 
findings of these four studies are collectively analysed in the context of their modelling 
potential.
There are several advantages to this kind of approach. First, it avoids the intrinsic caveats of 
standard transgenesis. Only a single copy of the fusion protein is expressed, and its 
expression is predictably controlled by the endogenous locus of the 5’ partner gene. This at 
least partially mirrors the human disease. More, the very nature of the technique employed to 
generate the mice (blastocyst injection of modified ES cells) enables the analysis of chimeric 
mice, with varying degrees of contribution from the mutated ES cells. Only a subset of the 
lineages in which the endogenous locus is active will therefore express the fusion protein, 
leading potentially to a lower oncogenic burden and a more faithful model. On the contrary, 
in transgenic experiments, chimeras are only rarely generated (10-30% of cases), and more 
importantly the percentage of chimerism cannot be controlled.
However, this methodology also has its shortcomings. Again, only one of the fusion proteins 
is expressed, and the overall gene dosage, though closer to the human disease, is still not 
fully recapitulated. Investigation of the effects of disrupting long-range chromatin 
interactions also falls beyond the possibilities of such models.
Another very important limitation actually coincides with one of its potential merits, namely 
the use of the endogenous promoter of the 5’ gene to drive expression of the fusion protein. 
This can be a very powerful approach for genes with specific expression restricted to the 
lineage from which the leukemia originates. However, many of the genes translocated in 
human leukemias are often normally expressed in multiple cell types, sometimes from early 
on in development. A more global expression of the fusion protein can have diverse effects, 
as exemplified by the case of M/-Af9 on the one hand, and Amll-Eto and Cbfb-Myhl 1 on 
the other.
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Although the MU promoter is active in a wide spectrum of tissues from early development, 
only leukemias developed (Corral et al., 1996), providing an adequate system with which 
unravel the “seed vs. soil” issue. On the contrary, in both Amll-Eto and Cbfb-Myhl 1 
experiments, modified ES cells were excluded from the hematopoietic lineage of chimeric 
animals and no leukemia developed. Upon germline transmission, mice died at midgestation 
because of grossly impaired hematopoiesis. Thus the widespread and early activity of the 
endogenous promoters had a catastrophic effect in these two models. The similarity of these 
phenotypes with the ones of Amll or Cbfb homozygous mutants strongly suggested that the 
fusion proteins exert a dominant negative function to disrupt hematopoiesis. Furthermore, 
the fact that with these approaches the expression of the fusion protein is dependent on the 
regulatory pattern of the endogenous promoter precludes the possible use of temporal 
regulation to dissect the role of the translocation product at different stages throughout 
development and hematopoiesis.
To conclude, some previous approaches have resulted in very relevant mouse models which 
partially mirror some aspects of the leukemogenic process. None of them however was 
designed to be able to exactly recapitulate the human disease. Cre-loxP technology is ideally 
suited for this purpose, and will be described in the next section.
II.5 Cre-loxP technology based approaches
II.5.1. Cre recombinase in genome engineering
Cre recombinase (cyclization recombination) is a 38KDa site specific recombinase
(SSR), isolated from bacteriophage PI, which catalyses recombination between two 34 bp
recognition elements, called loxP sites. The loxP site is composed of two 13 bp inverted
repeats flanking an asymmetrical 8 bp spacer sequence, which confers directionality to the
recombination reaction. Thus, depending on the relative orientation of the two loxP sites,
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Cre can catalyze either deletion or inversion of the intervening sequence. If the two loxP 
sites are located on different chromosomes, the product is an interchromosomal 
translocation.
The use of this system for developing mouse models of human leukemias that are associated 
with interchromosomal translocations relies on the introduction in the mouse germline, 
through ES homologous recombination, of loxP sites in the particular introns of the two 
genes involved in the human translocation. Upon Cre expression, recombination between the 
loxP sites is expected to result in the desired chromosomal translocation. The main 
advantages of the system are the following:
1) As in the human disease, both derivative chromosomes are created in the target 
cell, potentially resulting in the expression of both fusion proteins and therefore in a 
more faithful phenotype.
2) The dosage of the two genes perfectly mimics the situation of a leukemic cell. 
This could be particularly important in the case of the MLL  gene, whose 
haploinsufficiency in hematopoiesis has been postulated to play a role in initiating 
leukemogenesis.
3) Any potential effect due to the aberrant joining of distinct chromosomal domains 
and/or to the concomitant disruption of long-range chromatin interactions is also 
recapitulated.
4) The translocation is present in only a subset of somatic cells. Therefore, it cannot 
interfere with normal embryonic development and adult hematopoiesis, and enables 
assessment of the functional relevance of the translocation in the presence of 
ongoing, normal hematopoiesis.
5) By selecting appropriate Cre expressing mouse lines, it should in principle be 
possible to define precisely in which lineages and at what stages of blood
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development the translocation exerts an oncogenic effect. Plus, by tightly regulating 
the expression and/or activity of Cre recombinase in a certain lineage, it could be 
possible to answer one of the fundamental and most open questions in leukemia (and 
cancer) biology, namely, how often and/or in how many cells a potentially oncogenic 
rearrangement must occur in order to give rise to an overt malignancy.
Potential disadvantages of this approach mainly include the efficiency at which Cre catalyses 
the interchromosomal translocation in vivo (see below), and the necessity that in the mouse 
the two genes are in the same centromere-telomere orientation as in humans. Otherwise, Cre 
recombination would result in a dicentric and an acentric chromosome, leading to the death 
of the targeted cell.
Recently, interchromosomal translocations were achieved in vivo in the mouse. The 
seminal relevance of these results can be fully appreciated in the context of the substantial 
research activity which has over the years explored the potential of SSRs (in particular Cre) 
as tools in chromosome engineering. FLP-mediated translocation between homologous 
chromosomes in Drosophila was one of the first applications of site specific recombination 
in genome engineering (Colic, 1991). However, for a long time it remained an open question 
whether an SSR driven non-homologous translocation could be achieved in the mouse at a 
detectable frequency. It was clear from other (“easier”) genome engineering exercises that 
efficiency dropped as a function of the distance between intrachromosomal SSR target sites 
(Ramirez-Solis et al., 1995; Ringrose et al., 1999; Zheng et al., 2000). Additionally, 
evidence indicating that reasonable efficiencies of SSR translocations require the pairing of 
homologous chromosomes achieved during mitosis (Colic and Colic, 1996), or meiosis 
(Hérault et al., 1998) was obtained in both flies and mice. A further source of doubt arose 
with the emergence of the chromosomal territory model of nuclear organisation (Cremer and 
Cremer, 2001; Lamond and Earnshaw, 1998; Zink et al., 1998), which led one to wonder
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how the two SSR target sites, buried in distinct and possibly distant chromosomal territories, 
would ever manage to be brought together for Cre recombination to take place in interphase. 
Hints for optimism, but also pessimism, came from successful pioneering experiments with 
Cre mediated translocations between non-homologous chromosomes in mouse ES cells 
(Smith et al., 1995; Van Deursen et al., 1995), as these studies provided a first indication of 
the frequency of this event. Smith and coworkers used an approach in which the 
translocation event was positively selected through the reconstitution of the Hprt minigene in 
a hypoxanthine phosphoribosyltransferase (HPRT) deficient ES cell line. The translocation 
efficiency was on the average 5 X 10 '^ . However, Cre expression was achieved with a 
transient transfection strategy, hence the above figure is likely an underestimation of the 
effective translocation frequency among cells expressing Cre. This was confirmed by the 
other study exploring interchromosomal translocation in ES cells (Van Deursen et al., 1995). 
The authors obtained Cre mediated translocations without exerting any selective pressure, 
and the translocation was detected by nested PCR. On the basis of a PCR serial dilution 
analysis, and taking into account the transfection efficiency of the Cre expressing plasmid, 
the translocation was estimated to occur in 1 in 1200-2400 ES cells expressing the 
recombinase. Still, despite the considerable achievement represented by these two works, the 
fact that the experiments were limited to cells in culture gave rise to legitimate doubts as to 
whether the result could be recapitulated in a living mouse.
The breakthrough occurred when two studies reported successful Cre mediated 
interchromosomal translocation in vivo in an attempt to model the MLL-AV9 and the AMLl-
ETO leukemias, respectively (Collins et al., 2000; Buchholz et al., 2000). In both cases, the
translocations were detected by PCR. Failure to detect them by Southern hybridisation 
indicates that as expected translocation is a rare event, and in one study it was estimated by
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semiquantitative PCR to occur in 1 in 10000 to 1 in 1000000 cells (Buchholz et al., 2000).
Will these frequencies be sufficient to induce leukemogenesis? It is currently unclear, as 
none of the two studies has yet reported the occurrence of leukemia, a necessary result to 
conclude that this approach is technically superior to all others generated so far. When 
assessing the overall probability that this approach could result in a useful model of 
tumorigenesis, the following aspects need to be taken into account.
First, one decisive factor is the timing and level of Cre expression. In this regard, the 
mouse offers an advantage over cell culture approaches, in that by appropriate breeding the 
two translocation prone chromosomes and Cre expression can be combined in every cell of 
the animal. While this would be by no means a homogeneous population of cells (for 
example the chromosome territory organization could be substantially different among 
tissues), it does constitute a good starting point to assess translocation frequency. 
Furthermore, the fact that in one of the two studies described above (Collins et al., 2000) the 
translocation was not observed in the bone marrow, probably due to insufficient Cre 
expression in this compartment, is a clear demonstration that appropriate Cre mouse lines are 
needed before drawing any conclusion on the feasibility of of Cre-loxP based approaches..
Second, Cre recombination is a reversible reaction, and it is therefore possible that 
the reverse translocation event, which would restore the two normal chromosomes, would 
happen with a similar frequency as the direct rearrangement. Although the paradigm holds 
that the cell hit by the translocation acquires a selective growth advantage through the action 
of the fusion protein, many factors would influence the final outcome in the face of ongoing 
Cre activity: the rate of the reverse translocation; the half life of the fusion protein; the 
doubling time of the hit cell and its variation as a function of the translocation; and the 
timeframe needed by the fusion protein to derange cellular homeostasis. Most of these
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aspects are completely unknown or poorly chracterised. Thus, the best way to address the 
problem of reversibility is to use conditional forms of Cre, which would deliver only 
transient pulses of Cre activity and possibly avoid the reverse.reaction. Important variables 
to consider, when using this approach, are the half life of Cre (which in turn could vary for 
different cell types) and the pharmakokinetics of the molecule administered to switch on the 
enzyme (usually a nuclear hormone receptor ligand analogue). This last parameter will affect 
the overall size of the target cell population, and will thus be a central component in the 
trade-off between a constitutive Cre approach (with the drawback of reversibility) and the 
conditional Cre approach (with the drawback of a smaller cohort of cells able to translocate).
Third, one central unresolved issue of cancer biology is the frequency with which a 
certain rearrangement and/or mutation must occur within an organism in order to give rise to 
a tumor, a factor which is likely to differ considerably according to the kind of 
rearrangement and the cell type involved. This is in the end the crucial parameter which will 
determine the success of Cre-loxP based approaches given the frequencies reported above. 
Recently, a cancer mouse model was reported using, for the first time in vivo, a "hit and run" 
approach to mutagenise the Ras oncogene (Johnson et al., 2001). Aiming at recapitulating 
the sporadic occurrence of carcinomas in humans, the authors engineered mice harbouring a 
mutant copy of the Ras oncogene in a silent configuration ("hit" step), capable of generating 
an active mutant allele following homologous recombination ("run" step) either in an 
intrachromosomal reaction or in an unequal sister-chromatid exchange. The novelty lies in 
the fact that the "run" step was allowed to occur in vivo relying on the spontaneous rate of 
recombination between duplicated genomic sequences, which has been estimated to range 
between 10 and 10 '^per cell division (Hasty et al., 1991; Seperack et al., 1988). All mice 
developed tumours with a wide range of phenotypes. Although these results may not be 
directly related to the Cre-loxP translocation models discussed above since the oncogenic
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products are very different, they constitute initial evidence that relatively low mutagenesis 
frequencies can result in tumorigenesis.
II.5.2 Conditional Cre expression and activation: current strategies
Throughout the remarkable story of Cre applications to mouse genome engineering, 
one of the most significant advances has been the development of regulatable forms of Cre 
obtained by fusing it to ligand binding domains (LBDs) of nuclear hormone receptors. 
Pioneering experiments with Flp and Cre (Feil et al., 1996; Kellendonk et al., 1996; Logie
and Stewart, 1995; Zhang et al., 1996) demonstrated that the ligand-dependent properties of 
steroid hormone receptors could be imposed upon recombinases, allowing regulation of their 
enzymatic activities by administration of the appropriate ligand. In the absence of ligand, the 
LBD, through its interaction with the ubiquitous heat shock protein 90 (HSP90), traps Cre in 
an inactive complex. Upon ligand binding, the Cre-LBD fusion is released from this 
complex and can now bind the loxP sites, where it catalyses the recombination reaction.
This approach opened the way to tightly controlled spatio-temporal somatic mutagenesis in
the mouse (Schwenk et al., 1998). The spatial aspect of regulation is achieved by restricting 
expression of Cre (or Flp) to selected tissues by placing the recombinase expression under 
the control of suitable promoters. This strategy can also partially accomplish a temporal 
control, if the promoter chosen is active in the desired tissue only at a specific stage of 
development. However, true temporal regulation can only be achieved with the Cre-LBD 
fusions described above. To be useful for in vivo mouse mutagenesis, Cre-LBD fusions must 
be activated only by exogenous ligands, as responsiveness to physiologically present steroids 
would undermine the core of the whole strategy. To this end, mutant forms of LBDs 
(LBDs*), which are sensitive only to exogenous steroid analogues were developed. In cell
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culture assays, it has been possible to predictably affect the efficiency of recombination by 
varying the doses of ligands administered.
The steroid receptor LBDs which have so far been employed are those from the estrogen, the 
progesterone and the glucocorticoid receptors (ER, PR and GR). For the ER LBD (EBD), 
several mutations have been described. The G521R mutation in the human EBD (which 
substitutes a glycine with an arginine, also called Cre-ER^) resulted in a more than 10000 
fold reduction of the affinity for the endogenous ligand p-erstradiol (Danielian et al., 1993; 
Feil et al., 1996). The mutation also reduced the affinity for the synthetic antagonist 4-OH- 
tamoxifen by about 100 fold (Schwenk et al., 1998), resulting in the need to treat mice with 
high doses of tamoxifen. While this can be irrelevant in many experimental setups, it clearly 
limits the usefulness of this mutant for more specialised applications, such as for example 
induction of recombination in utero (Danielian et al., 1998).
Another Cre-EBD fusion was recently characterised and shown to be more sensitive to 4- 
OH-Tamoxifen than the previous one, respectively four-fold in cultured cells and ten-fold in 
the mouse epidermis (Feil et al., 1997; Indra et al., 1999) . This mutation has been called
Cre-ER^^ and contains three mutations in the human EBD, glycine to valine at position 400, 
methionine to alanine at postion 543 and leucine to alanine at position 544. Importantly, as 
in the case of Cre-ER^, no background recombinase activity was observed.
As for the GR LBD (GBD), a mutation was identified (isoleucine to threonine at position 
747) which results in complete unresponsiveness to endogenous ligands like cortisol or 
corticosterone, while synthetic analogues like dexamethasone are still able to induce 
transactivation (Brocard et al., 1998; Roux et al., 1996). As expected, higher dexamethasone 
concentrations (100 fold more) were needed for this effect, if compared to the natural GBD.
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The importance of tightly regulating Cre activity in the mouse was recently 
underscored by a report of Cre-mediated illegitimate chromosome rearrangements in
transgenic mouse spermatids (Schmidt et ah, 2000). In this study, Cre was expressed in
postmeiotic spermatids under the control of the protamine promoter. All transgenic males 
were sterile, while males carrying equivalent transgene levels harbouring an inactive form of 
Cre were normally fertile. Analysis of embryos from sterile Cre-transgenic mice 
demonstrated the occurrence of chromosome rearrangements which led to abortion with 
100% penetrance. Thus, directly expressing Cre in spermatids apparently poses an 
insurmountable recombinational burden, and it is hypothesised that inappropriate 
recombination could depend on the presence of spurious loxP sites in the mouse genome. 
These findings are particularly relevant for all mouse models using Cre to induce various 
chromosomal aberrations, as the concomitant presence of undesired rearrangements could 
confound the phenotypic analysis.
In conclusion, conceptual as well as practical reasons strongly advise the generation 
of inducible-Cre mouse lines as robust and reliable tools for contemporary mouse genetics.
45
I ll
Translocations involving the MLL gene
III.l Promiscuity and common themes
Translocations involving band llq23 are found in about 5% of patients with acute 
myeloid leukemia (AML) and 10% of the cases of acute lymphoblastic leukemia (ALL); in 
addition, they are also present in a large portion of leukemias which express markers of both 
lineages (mixed lineage or biphenotypic leukemias) (Rowley, 1998). These features are very 
unusual, since most other translocations are associated with only one leukemic phenotype, 
though this may be broader than the corresponding developmental stage of normal 
hematopoiesis.
Another unique feature of band llq23 translocations is the astounding number of 
partner chromosomes involved. More than 40 chromosomal loci have been shown to be 
translocated to band llq23 in a large variety of hematological neoplasms (mostly, but not 
exclusively, leukemias). The full weight of this observation became clear when positional 
cloning of the breakpoint cluster region identified the gene involved, which was termed MLL 
for mixed-lineage leukemia (Djabali et al., 1992; Gu et al., 1992b; Tkachuk et al., 1992; 
Ziemin-van der Poel et al., 1991). Other names include HRX or HTRX for human trithorax, 
since this gene was the first discovered mammalian homologue of the Drosophila trithorax 
gene (see below). With the concomitant cloning of many of the translocation partners (to 
date 18 fusion partners have been characterised), one of the major tasks has been to classify 
these various translocations in terms of their overall frequency, and on the basis of the 
distinct phenotypes with which they are associated. Although different clinical statistics 
show some variability in the relative frequencies, comparison of data from large patients 
cohorts has established at least two findings: some translocations are by far more common
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than others, and specific translocations are associated, in many but not all cases, with a 
distinct leukemic phenotype. Combined with the important observation that the breakpoint 
cluster region (BCR) of MLL is very short [8.3 kb spanning 6.introns and 7 exons, according 
to the map and nomenclature described in (Nilson et al., 1996)], meaning that much the same
aminoterminal portion of MLL is retained in all fusion proteins, this has led to the current 
paradigm holding that the domains contributed by the different translocation partners play a 
pivotal role in lineage determination. This has been partially confirmed by both cell culture 
and animal studies (see below). However, contradictory evidence from some studies, 
together with the observation that the correlation between a specific rearrangement and a 
certain leukemic phenotype is far from complete, argues that the molecular explanation is 
likely to be more complex. The following overview of the most frequent rearrangements 
with the corresponding phenotypes supports this conclusion. The main features of the MLL 
translocation partners most relevant for this discussion are summarised in table 1, largely 
drawn upon the recent conslusions of the European Union Concerted Action Workshop 
which provided a comprehensive analysis, unprecedented for its size and significance, of 
550 cases of leukemias and myelodysplastic syndromes (MDS) associated with MLL 
rearrangements (Johansson et al., 1998; Secker-Walker, 1998).
While on the whole MLL rearrangements account for 5-10% of all acute leukemias 
and myelodysplastic syndromes, they tend to occur with particular frequency in two clinical 
settings, infant leukemias (below 1 year of age) and secondary leukemias arising in patients 
treated with DNA topoisomerase II inhibitors for previous neoplasms. The infant leukemias 
will be discussed in the section dedicated to the t(4;ll)(q21;q23) translocation. As for the 
iatrogenic leukemias, about 5 to 10% of cases of any given MLL rearrangement are 
associated with prior treatment with topoisomerase II inhibitors.
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Table 1; Overview of MLL translocation partners
Translocation
partner
Locus Frequency Leukemic
phenotype
Domains 
retained in 
MLL fusions
Functional
properties
Additional
remarks
References
AF4 (PEL) 4q21 40% Acute
lymphoblastic 
leukemia (ALL) 
o f pre-B 
phenotype with 
coexpression o f  
myeloid antigens
Transactivation domain;
nuclear localization signal; C-terminal domain
homologous to
Drosophila lilli, involved in embryo 
segmentation and eell 
size regulation
Knock-out mice have 
a reduction in the CD4+/CD8+  
thymocyte compartment
Founding member
o f a new family o f  genes which include LAF-4 
and FMR-2.
Gu et al., 1992b
Morrissey et al., 1993; Prasad et al., 
1995; Isnard et al., 2000; Tang et al., 
2001; Wittwer et al., 2001
AF5q31 5q31.1 1 case 
reported
ALL o f  pre-B 
phenotype
Transaetivation domain;
nuelear localization signal; C-terminal domain
homologous to
Drosophila lilli,
Homologous to AF4 in three 
regions: the N-terminal domain 
(62% homology); transaetivation 
domain (57%) and C-terminal 
domain (48%).
Taki et al., 1999
AF9 9p21-22 27% Acute myeloid 
leukemia (AML)
C-terminal domain homologous (82%) to the 
transaetivation domain of AF19; nuclear 
localization signal.
Mil A f9 knock-in mice have 
expansion o f  the myeloid lineage 
and develop AML
Flomologous to yeast protein TFG3, member o f  
SWI/SNF , TFIIF and TFIID complexes.
Nakamura et al., 1993; Cairns et al., 
1996; Corral et al., 1996; Dobson et al., 
1999.
AF19(ENL) 19pl3.3 < 12% AML and ALL C-terminal transaetivation domain; 
nuclear localization signal
Mice infected with a retrovirus 
coding for the M ll-A fl9 cDNA  
develop AML.
When fused to Mil, the 84 C- 
terminal residues o f  A fl9  are 
necessary and sufficient for 
immortalization.
Homologous to yeast protein TFG3, member o f  
SWI/SNF , TFIIF and TFIID complexes.
Tkachuk et al., 1992; Rubnitz et al., 
1994; Lavau et al., 1997; Slany et al., 
1998; Cairns et al., 1996
AFIO 10pl2 4-6% mostly AML leucine zipper; The extended PHD finger 
(ePHD), excluded from MLL 
fusions, mediates homo-oligo 
merization in vitro.
Flomologous to AFI7.
l| has a centromere-telomere orientation opposite 
to MLL, hence the observed rearrangements 
involve at least an inversion and a translocation.
Chaplin et al., 1995a; Chaplin et al., 
1995b; Chaplin et al., 2001; Linder et al. 
2000
AF17 17q21 1-1.5% Mostly AML leueine zipper; Flomologous to AFIO. Prasad et al., 1994
CREB binding 
protein (CEP)
16pl3 overall rare AML and
myelodisplastic
syndrome
(MDS)
secondary to
Topoisomerase
II inhibitors
the whole of CBP except the nuelear hormone 
receptor interacting domain (NID): CREB 
binding domain, PHD finger, Bromo domain
Transcriptional coactivator; it 
possesses histone acetyl 
transferase activity.
It can also be translocated to MOZ gene in t(8;16) 
acute myeloid leukemias.
Taki et al., 1997;
p300 22ql3 1 case 
described
AML Breakpoint is further downstream than with 
CBP, hence only are ineluded in the fusion.
Transcriptional coactivator; it 
possesses histone acetyl 
transferase activity.
Flighly homologous to CBP, however they are not 
functionally equivalent.
Ida et al., 1997
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These two clinical settings both strongly support the notion that MLL translocations act with 
extremely short latency. For example, the latency between treatment with topoll inhibitors 
and leukemia development is almost invariably in the range of few months to a few years, in 
contrast with secondary leukemias associated with other aberrations (most commonly 7q- or 
5q-), which follow treatment with alkylating agents or radiation and for which the latency is 
usually 5 to 10 years, and often longer.
At present, it remains to be proven that MLL rearrangements occurring outside of 
these two selected patient cohorts (infants and treatment related) also cause leukemia with 
the same short latency. If this were indeed the case, it could indicate that derangement of 
MLL function is a particularly powerful oncogenic event, which therefore does not need the 
accumulation of secondary transforming hits. Conversely, if short latency were a specific 
feature only of these two settings, the effect could possibly be attributed to the AF4 
contribution (for the infant leukemias, where MLL-AF4 translocations are exceedingly 
common), or to concomitant treatment-induced genetic lesions, in the case of iatrogenic 
secondary leukemias.
The identification of so many partner genes poses a puzzle in terms of the 
mechanism of leukemogenesis. At first sight, there are no obvious properties shared by all 
partners, and therefore a unified model for MLL leukemogenesis is hard to envision. 
However, some common themes can be outlined (Dimartino and Cleary, 1999).
First, some translocation partners do share important similarities. This is the case for ENL 
and AF9, which are 82% identical at their amino- and carboxytermini, and are both 
homologous to a yeast protein, TFG3 (also called TAF30 or ANCl), a member of both the 
SWI/SNF chromatin remodelling complex and the TFIIF and TFIID transcription complexes
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(Cairns et al., 1996).This in turn has lead to the hypothesis that ENL and AF9 might
contribute to leukemogenesis by recruitment of the human equivalents of the SWI/SNF class 
of chromatin remodelling activities. A transactivation domain has been characterised for 
ENL in cell culture experiments (see below) and is suspected also for AF9 .
Along the same line of similarity among partners, AF4 and^F5q21 are actually 
members of the same gene family. Also for AF4, in analogy to ENL, a transactivation 
domain has been postulated on the basis of GAL4 fusion assays, thus constituting another 
possible element of commonality in the leukemogenic process.
Similarly, both CBP and its highly related cognate gene p300 have been shown to be 
translocated to M IL, although CBP is involved much more often. CBP is a central protein in 
chromatin regulation. It possesses histone acetyl transferase activity (HAT) and has been 
shown to interact with a variety of transcription regulatory proteins through its multidomain 
modular structure. In particular, it interacts with nuclear hormone receptors through an 
aminoterminal domain (NID), with sequence specific transcription factors through two 
cysteine/histidine rich regions, one of which was originally identified as the CREB binding 
domain, and the other as the interaction domain with the E l A protein, and with 
transcriptional coactivators (like SRC-1) via its carboxyterminal domain. Plus, it also 
features centrally located bromo and PHD domains. The relevance of the CBP/p300 pair of 
proteins to cancer development is demonstrated by several findings. Missense mutations and 
whole gene deletions have been found in many solid tumors. Loss of one CBP allele results 
in Rubenstein-Taybi syndrome, a complex developmental disorder which includes cancer 
predisposition. And finally, CBP can be translocated not only to MLL, but also to the MOZ 
gene (the human homologue of the yeast gene SAS) in the t(8;16) acute myelod leukemias. 
In MLL-CBP translocations, almost the whole CBP, except for the NID, is retained in the
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fusion protein, suggesting that abnormal recruitment of its activation functions to the MLL 
target genes could play a central role in leukemogenesis.
AFIO and AF17 both contain triplets of PHD fingers at their N-terminus and leucine 
zipper domains at their C-terminus. As discussed in chapter IV.3.1, the MLZ-AFIO and 
MLZ-AF17 fusions are invariably devoid of the PHD fingers, but contain the leucine zipper 
domains which are likely to mediate dimerization, which could in these cases be the key 
mechanism leading to transformation.
What does the diversity of fusion partners mean in terms of MLL mediated 
leukemogenesis? Currently, we are still far away from the answer, but the following 
considerations can constitute a valuable framework.
MLL leukemogenesis is clearly a very complex phenomenon, which has usually been framed 
along two antithetic models, one holding MLL truncation as the key pathogenic event (the 
"loose cannon" model), and the other emphasising the paramount importance of the fusion 
proteins ("gain-of-function model"). The "loose cannon" hypothesis is supported by the 
following observations:
1) The great diversity of unrelated translocation partners, interpreted to suggest that 
interruption of MLL is the only necessary event.
2) Aberrations which affect only MLL (like partial tandem duplications or deletions) have 
been associated to leukemias and myelodysplastic syndromes.
However, while animal studies have demonstrated haploinsufficiency for MLL, this did not 
result in a predisposition to malignancies of any type. Importantly, the M /-LacZ mouse 
model described below (chapter ) strongly argues that truncation of MLL per se is not 
sufficient, and that the contribution of other domains (in the most minimalistic model the 
tetramerization interface of LacZ) appears to be necessary. This obviously does not rule out
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that the deregulation in hematopoietic differentiation caused by MLL haploinsufficiency 
could constitute a particularly receptive soil for additional oncogenic hits.
In contrast, the role of MLL fusion proteins in gain-of-function scenarios has found support 
mainly in the following findings:
1) All translocations detected in leukemias produce in-frame fusions, indicating that it is the 
creation of a novel aberrant protein, and not disruption of the MLL locus itself, which is most 
often selected during the rise of a leukemogenic clone.
2) A variety of cell culture and especially animal studies have demonstrated a crucial role for 
at least some of the fusion partners (mostly AF9 and AF19)
I would like to propose that neither the "loose cannon" nor the "gain-of-function" 
models can account for the full spectrum of MLL aberrations, and the quest for a unified 
leukemogenic mechanism is possibly misguided. Rather, in each specific leukemia, both the 
loss of one wild type MLL allele and the functions provided by the fusion partner could 
converge in different ways to deregulate cell growth. Such a "combined model" of MLL 
leukemogenesis must also incorporate the notion that some (possibly all?) fusion proteins 
could also exert a dominant negative function on the wild type copy of the protein, and the 
extent of this effect can be different for various translocations, reflecting the distinct 
composition in protein domains. Within this conceptual framework, the following three 
common themes can be recognised.
The aminoterminal portion of MLL is absolutely essential, since it is constantly 
retained. The simultaneous presence of the reciprocal fusion product, which would harbour 
the PHD and SET domains of MLL carboxyterminus fused to the aminoterminal moieties of 
the translocation partners, has not always been detected, arguing that it may not be necessary 
to the process, though it might certainly contribute additional features.
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Transcriptional activation, either in the form of classical transactivation, or as 
enzymatic activities which alter chromatin structure, emerges as one possible domain of 
regulation in which some MLL fusion proteins could be involved (AF4, CBP, AF9 and 
AF19). However, mere transcriptional activation does not seem to be the key event, since 
fusions of MLL with VP 16, unlike MLL-AF19, were unable to transform myeloid cells in 
vitro, pointing to a much more specific and finer mechanism through which fusion partners 
contribute to the abnormal activation of distinct gene programmes (Dimartino and Cleary, 
1999; Slany et ah, 1998). However, as an important corollary, transactivation of different 
sets of genes could contribute to the various leukemic phenotypes observed.
Aberrant MLL homo dimerization through the carboxyterminal fusion partner 
domains is also likely to play a role. While possible in theory for every fusion, it seems 
particularly convincing for AFIO and AF17 (due to their leucine zipper domains) and for the 
partners normally located in the cytoplasm. It is also in agreement with the M/-LacZ mouse 
model.
Finally, another convergent point of regulation might be the control of cell death. 
Clinically, many of the MLL leukemias display hyperleukocytosis, tissue infiltration and 
resistance to chemotherapy, all findings compatible with decreased sensitivity to apoptosis. 
This was observed also in t(4;l 1) cell lines, which displayed prolonged survival upon serum
starvation when compared to other leukemic cell lines without MLL rearrangements (Kersey 
et al., 1998). While cell line experiments do not necessarily mirror the in vivo situation,
other lines of research have also started to uncover the effect of MLL fusions in apoptosis 
control. MLL-ELL was shown to interact in vitro with p53 and to inhibit transcription from
p53 responsive promoters (Maki et al., 1999). Similarly, the N-terminal part of MLL was
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shown to interact with GADD34, which promotes apoptosis following radiation damage 
(Adler et ah, 1999).
III.2 The t(4;ll)(q21;q23) translocation
The t(4;l I)(q21;q23) translocation fuses the MLL and the AF4 genes. It is the most 
frequent translocation involving the MLL gene, accounting for up to 40% of all M LL  
rearrangements (Johansson et ah, 1998).
The t(4 ;ll) translocation is strongly associated with acute lymphoid leukemias (95% of 183 
MLL-AF4+ cases in the cohort mentioned above), although it also occurs with much lower 
frequency in acute myeloid leukemias (AMLs), acute undifferentiated leukemias (AULs), 
acute biphenotypic leukemias (ABLs) and treatment-related acute leukemias or 
myelodysplastic syndromes (sAL/MDSs). It is particularly frequent in infant acute 
lymphoblastic leukemias (iALLs, defined as arising before one year of age), occurring in 
60% of all infant ALL cases. The frequency of this aberration is lower for other age groups 
of ALL patients (2% in children and 3% to 6% in adults).
Numerous studies have clearly correlated this translocation with a particularly 
ominous prognosis, both in children and adults, and screening for MLL rearrangements, 
particularly the MLL-AF4 fusion, is now widely used to identify patients at high risk, who 
receive intensified therapy regimens. Nonetheless, so far results have been largely 
disappointing, with lack of improvement in overall survival or event free survival (EPS)
after bone marrow transplantation in a cohort of 183 t(4;l 1) patients (Johansson et al., 1998).
However, among t(4;l 1) cases, different risk stratifications can be made according to the age 
of the patient and the leukemic phenotype. For example, children between 1 and 10 years of
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age have a longer extended event free survival (EFS) time than infants, older children or 
adults (Johansson et ah, 1998; Pui, 2000; Pui et ah, 1994; Pui et ah, 1991).
In the vast majority of cases, the leukemic phenotype is lymphoblastic or mixed 
lymphoblastic-monocytic. Blasts are usually CD 19+, CD24+, TdT+, and HLA-DR+, while 
they lack CD 10 (the common antigen of acute lymphoblastic leukemia) and sIgM, which 
altogether defines a B-precursor immunophenotype. The presence of myeloid associated 
markers is also frequent, especially CDw65, CD13, CD15 and CD33, suggesting that the 
transformation event might hit a relatively undifferentiated progenitor which then proceeds 
up to a stage of pro-B cell block. In a series of 46 patients, there was indeed significant 
association between MLL-AF4 translocation and coexpression of the myeloid marker 
CDw65, as compared to patients with pro-B ALL lacking the MLL-AF4 translocation 
(Janssen et ah, 1994).
The M LL-AF4  rearrangement is also associated with hyperleukocytosis, 
organomegaly (resulting from blast infiltration) and involvement of the central nervous 
system (CNS), all factors which contribute to its ominous prognosis.
One of the obvious features of infant leukemias is their short latency. Two lines of 
evidence have established that MLL-AF4 translocation can occur in utero. First, studies on 
identical twins with concordant leukemias demonstrated that the MLL gene rearrangement 
was nonconstitutive and hence had to have been transmitted from one twin to the other in 
utero via intraplacental anastomoses (Ford et ah, 1993). Second, in three cases, PCR-based 
methods detected MLL-AF4 genomic fusions in neonatal blood spots of individuals who 
developed ALL between five months and two years of age (Gale et ah, 1997). Taken
together, these data argue that the M LL-AF4  fusion may be sufficient for leukemia 
development, with no or minimal requirement for additional genetic lesions which should
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presumably result in longer latencies. For example, in the case of identical twins with the 
TEL-AMLl translocation, leukemias developed with a substantially longer latency, at 3.5 and 
5 years of age respectively. An even more extreme example concerns a pair of identical 
twins who developed T-cell leukemia at 9 and 10 years of age. Thus, at least for some 
leukemias, fetal origin can be coupled with very protracted latency, and therefore the 
strikingly rapid onset of the MLL-AF4 disease indicates a simple molecular explanation.
On the other hand, diverse lines of research have explored the necessity of secondary 
oncogenic hits, both for MLL rearrangements in general, and for the MLL-AF4 case in 
particular. First, even pediatric patients with MLL translocations (arguably the ones with the 
shortest latency), often display at the time of diagnosis additional genetic lesions, whose role 
in the progression of the disease is however still poorly characterised. Second, some studies 
reported the presence of MLL-AF4 fusion transcripts in children affected by leukemias 
which were negative for MLL rearrangements upon Southern blot analysis, as well as, even 
more strikingly, in a proportion of samples from apparently healthy individuals (Uckun et
al., 1998). Detection of the fusion cDNA was achieved by nested RT-PCR, attesting to the
very high sensitivity needed. Contrary to ALL patients with either cytogenetic or molecular 
(Southern blot detection) evidence of MLL-AF4 rearrangement, patients positive only by 
nested RT-PCR fared just as well as patients without MLL rearrangements. Taken together, 
these observations could mean that the MLL-AF4 transcript was present only in a very small 
subset of cells (below the 1% to 5% threshold of Southern blot detection) which did not 
contribute further to leukemia development. In this case it still remains to be explained why 
these cells were not detectable anymore after chemotherapy induced remission. The same 
could be true for the nested RT-PCR positive cases among apparently healthy individuals 
(including bone marrow and liver samples from both fetuses and infants), which suggested
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that this translocation could be a relatively frequent event in utero, occurring in up to 25% of 
normal newborns. The logical conclusion would hold that the MLL-AF4 product is not 
sufficient to promote leukemogenesis. These reports were conceptually not new and added 
the MLL-AF4 aberration to a growing list of genetic rearrangements which appear in a 
variable percentage of healthy individuals, including the t(14;18), t(9;22) and t(8;14)
translocations, as well as MLL tandem duplication (Biemaux et al., 1995; Dolken et al., 
1996; Hunger and Cleary, 1998).
However, two other studies failed to identify MLL-AF4 transcripts in normal samples 
with an equivalent nested RT-PCR assay (Kim-Rouille et al., 1999). Analysis of the
available data is further confounded by the different experimental strategies taken by 
different groups, which hinders direct comparison of the results. Under these circumstances, 
this issue remains hotly debated, and warrants further examination with alternative methods 
which could validate the nested RT-PCR results, like FISH or genomic single step PCR. 
Still, even i f  MLL-AF4 detection was confirmed among otherwise healthy subjects, this need 
not directly indicate the need for multiple oncogenic hits. Rather, the whole body of 
information concerning MLL translocations indicates that these leukemias do exhibit a 
remarkably short latency in at least two settings, namely infant leukemias (where the MLL- 
AF4 fusion is predominant) and treatment related leukemias This is in sharp contrast with 
most other leukemias, where the available information points to latencies of years to 
decades. One possibility is of course that this fusion protein can per se accelerate the 
accumulation of further genetic lesions. Alternatively, the sporadic occurrence of MLL-AF4 
positive cells in normal individuals would be most consistent with a model in which the 
fusion protein can promote oncogenesis only during a limited time window in hematopoietic 
development. Thus, as soon as the translocation occurs in a permissive compartment,
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progression to a leukemic clone would be both very likely and fast, in agreement with the 
high concordance rate of MLL leukemias among identical twins with a mono chorionic 
placenta, where it is clear that the leukemic clone from one twin has rapidly colonised the 
other. On the other hand, if the rearrangement occurred in a non conducive cellular 
environment, the result could well be the persistence of an otherwise innocuous clone in a 
healthy individual.
This brings us to the related issue of the molecular mechanisms responsible for the 
MLL-AF4 translocation. Initial studies had hypothesised the improper involvement of the 
V(D)J recombinase normally active in the immune system, in analogy to what has been 
shown with translocations which fuse a variety of genes to either the immunoglobulin or the 
T-cell receptor gene clusters. This was largely based on sequence analysis from the 4; 11 
breakpoints of two cell lines ( MV4;11 and RS4;11), which had detected in the immediate 
vicinity of the breakpoints the presence of heptamers and/or nonamers highly homologous to
the recognition target sites of V(D)J recombinase (Gu et al., 1992a).
However, a recent analysis of biopsy material from fourteen t(4 ;ll)  leukemia 
patients strongly challenges the V(D)J recombination hypothesis (Gillert et al., 1999; 
Reichel et al., 1998). In all biopsies, extensive sequence characterisation of the breakpoints
demonstrated deletions, duplications and inversions accompanying the translocation event. 
Filler DNA and mini-direct repeats were also identified at the breakpoint junctions. Thus, at 
the molecular level, these translocations are reciprocal but not balanced, since net loss or 
gain of genetic material does occur. Moreover, in this study (Gillert et al., 1999), neither 
target sites for V(D)J recombinase nor Alu elements (which occur in the MLL gene and had 
been previously implicated in aberrant recombination) were observed at or near the 
breakpoints. Overall, these findings are more compatible with this translocation being the
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aberrant result of DNA repair through the so-called error prone repair mechanism (EPR), 
which incorporates features of the non homologous end-joining (NHEJ) pathway. This led 
the authors to predict that multiple DNA breaks occur in the two genes before the actual 
translocation actually takes place.
A potentially interesting observation which also emerged from this study was a 
speculation regarding a symmetrical relationship between the breakpoints on chromosome 
11 and 4. The closer the chromosome 11 breakpoint was located to the centromeric end of 
MLL, the more often it was fused with the telomeric side of AF4 on chromosome 4 and 
viceversa. A greater number of samples is required to strengthen this observation; however, 
it could reflect rather precise requirements in the relative spatial orientation of the two 
chromosomes during the translocation reaction, possibly connected to a reciprocal position 
of the respective chromosomal territories.
The “DNA repair” hypothesis could be a useful framework with which to interpret 
another set of studies which compared the breakpoints of de novo versus treatment related 
leukemias harbouring MLL rearrangements. MLL translocations occur frequently in therapy- 
related leukemias, after treatment with topoisomerasell inhibitors. One function of 
Topoisomerase II is to unwind the DNA by introducing double strand breaks. By preventing 
religation of these breaks, some of the topoisomerasell inhibitors pose a relatively high risk 
of translocations. An in vivo topo II cleavage site maps near exon 9 in the MLL breakpoint 
cluster region, and 11 additional sequence stretches closely related to topoll consensus 
binding sites are located in the telomeric portion of the MLL BCR (Apian et al., 1996;
Strissel et al., 1998). Moreover, detailed analysis of the BCR has revealed an asymmetric
distribution of the breaks among different MLL leukemias (Cimino et al., 1997; Domer et al.,
1995; Strissel et al., 1996). Thus, in 75% of therapy related, but only 25% of de novo
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leukemias, the breakage maps to the 3’ end of the BCR, in a region which has been 
interpreted as a scaffold attachment region (SAR). Interestingly, infant leukemias show the 
same bias in breakpoint distribution as therapy related leukemias, pointing to a possible 
common mechanism (Cimino et ah, 1997). This in turn has led to the suggestion that during 
pregnancy many known naturally occurring topoisomerase II inhibitors, especially 
flavonoids, could be responsible for this translocation, an intriguing hypothesis which 
requires experimental tests. One clinical study has detected an association between maternal 
exposure to foods containing various topoll inhibitors and infant AML, but, curiously, not 
ALL (Ross et al., 1996). Recent in vivo studies, utilising progenitor hematopoietic cells, 
found that several bioflavonoids can induce site-specific cleavage in the MLL BCR, and that 
these sites colocalise with the ones induced by etoposide and doxorubicine, two known 
Topoll inhibitors (Strick et al., 2000).
As far as the molecular mechanisms of MLL-AF4 leukemogenesis are concerned, 
very little is known, and it is limited to the results coming from several studies which 
investigated the transcriptional regulatory potential of AF4 in a heterologous cell culture 
system. No animal model of any kind has been developed for the MLL-AF4 translocation.
Three different studies identified a domain of transcriptional activation in the AF4 
gene by fusing different portions of the AF4 protein to the GAL4 DNA binding domain and 
assessing the expression of a reporter construct in a variety of cell lines. Although they 
utilised slightly different Lisions, the results are largely overlapping, with the transactivation 
domain mapped respectively to residues 365-572, 480-560 and 347-475 (Ma and Staudt,
1996; Morrissey et al., 1997; Prasad et al., 1995). The region between aminoacids 458 and 
572 is particularly rich in serine, proline and acidic aminoacids, which are collectively
60
present in the activation domains of other transcriptional regulators and thus may contribute 
to the activity of this domain in AF4. This putative transactivation domain is invariably 
retained in all MLL-AF4 fusion proteins described to date, and could contribute an important 
function to the fusion protein.
As expected from similar experiments with other proteins, the transactivation 
potential differed dramatically among different cell lines (Morrissey et al., 1997). 
Specifically, this domain activated transcription in COS-7 cells, HeLa carcinoma cells, 
NIH3T3 and MCF-7 ( a breast tumor cell line), but surprisingly no transactivation was 
observed either in normal B cells or in B cell leukemia cell lines. In another study, FLAG- 
tagged MLL-AF4 fusion was expressed in U937 myeloid leukemia cells under the control of 
a tetracycline responsive promoter. Upon induction, MLL-AF4 caused cell-cycle arrest in 
Go-Gi. Interestingly, this effect was not observed in U937 clones expressing only an MLL 
truncation (Caslini et al., 1996).
These results provide some evidence for a possible function of AF4 in transcriptional 
regulation. At the same time, they highlight the limitations inherent to such heterologous cell 
systems, where the function of the fusion protein or the fusion partner is analysed on the 
background of a differentiation programme and/or of a genomic make-up (in terms of 
additional genetic lesions) which are likely to be fundamentally different from the target cell 
in vivo. However, some general conclusions can be drawn. For example, the observations in 
U937 cells are analogous to the results of MLL-AF19 transduction of hematopoietic 
progenitor cells (Lavau et al., 1997)(see chapter IV.8.2), where only low levels of transcript 
were detected. Plus, the same authors did not manage to express the MLL-AF19 fusion from 
a constitutive promoter in a variety of cell lines. Thus, a pattern is possibly emerging, 
whereby at least some of the MLL fusion proteins are tolerated at relatively low levels in
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many cell types, causing either toxicity or growth arrest when their expression is forced at 
higher levels or in non permissive environments. This provides one more indication for the 
importance of the cellular compartment ("the soil") in leukemogenesis.
Finally, a quantitative RT-PCR analysis recently indicated that MEISl and H0XA9 
are consistently upregulated in the majority of t(4 ;ll) PrePreB ALLs. While they are also 
expressed in most AMLs, they are only rarely expressed in ALLs, including the PrePreB 
types, which lack MLL rearrangements. HOXAIO had a similar expression profile in t(4;l 1) 
leukemias, but it was also expressed in most ALLs tested regardless of the underlying 
translocation. It is too early to conclude whether the MLL-AF4 fusion, and possibly other 
MLL fusions as well, have a direct role in driving expression of these genes. However, in 
view of the following observations, and in the light of the known function of MLL in 
H0XA9 regulation, this result could point to a possible mechanism of oncogenesis. In fact, 
H0XA9  and MEISl cooperate in inducing AML, as shown both by spontaneous AMLs in 
BXH-2 mice and by transplanatation experiments, in which the overexpression of both genes 
was necessary for the development of the disease (Kroon et al., 1998; Nakamura et al.,
1996b). The role of H 0X A 9  deregulation in leukemogenesis is also indicated by its 
involvement in the t(7;l 1) translocation, which fuses it to the nucleoporin NUP98 (Kroon et 
al., 2001; Nakamura et al., 1996a), and by the highly significant finding that its expression in 
human AMLs correlates with treatment failure (Golub et al., 1999). In a similar fashion, 
HOXAIO is also expressed in many human AMLs, and its overexpression in mouse bone 
marrow cells results in AMLs with a long latency (Lawrence et al., 1999; Thorsteinsdottir et 
al., 1997). The molecular basis for this cooperation in leukemogenesis most likely resides in
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the formation of ternary complexes containing respectively H0XA9, MEISl and PBX or 
HOXAIO, MEISl and PBX (Schnabel et ah, 2000; Shen et ah, 1999).
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IV
The MLL gene
IV. 1. Introductory remarks
The MLL gene (for Mixed Lineage Leukemia) was cloned by four independent labs 
in 1992 by positional cloning of the translocation breakpoint 1 lq23, one of the most frequent
chromosomal rearrangements in acute leukaemias (Djabali et ah, 1992; Gu et ah, 1992b;
Tkachuk et ah, 1992; Ziemin-van der Poel et ah, 1991). Sequence analysis identified it as the 
first mammalian homologue of the Drososphila gene trithorax.
It is a large gene, spanning about 100 kb and coding for a 431 kDa protein. Diagrams of the 
human MLL gene and protein are shown in figure 1 and 2 respectively.
The homology to Drosophila trithorax is clustered in the following domains: a 
stretch of zinc fingers of the plant homeo domain (PHD) type, located between residues 
1433-1627, and the C-terminal SET domain, also found in many other chromatin proteins. 
Two other regions of potential functional relevance, which are present in MLL but absent 
from Drosophila trithorax, include an N-terminal stretch of AT hooks and downstream of 
them a cysteine-rich domain with homology to a non-catalytic part of DNA 
methyltransferase. In addition, other regions of partial homology to knovm genes have been 
identified, but their significance is unknown.
It appears likely that MLL, by virtue of these domains, behaves as a modular 
integrator of different functions relating to chromatin dynamics. It is therefore interesting to 
review the most relevant findings for each of these domains, especially focusing on the 
possible relevance of their retention in or exclusion from the MLL fusion proteins which 
play a key role in leukemogenesis.
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Figure 1 Intron phase map of MLL and AF4
The figure shows an analysis of the intron phase maps of MLL and AF4. Exons are represented 
by filled boxes of different colors, according to the phase of the following intron. Red exons are 
followed by type "0" introns. Green exons are followed by type "1" introns and pink exons are 
followed by type "2" introns. Exon numbers are indicated above and below the boxes.
For both genes, the breakpoint cluster region involves only few exons. However, based purely 
on the intron phase, a much greater number of rearrangements could be expected which would 
also result in in-frame fusions. The fact that these translocations are not clinically detected can 
be explained either with a "hot spot" or with a selection type of model. See text for further details 
The domains are aligned with the respective coding exons as a guide to analyse the difference in 
domain composition between the observed and the hypothetical fusion proteins.
Both genomic loci are drawn to scale, with 1 unit corresponding to 5Kb.
Abbreviations: (ALT) AF4-LAF4-FMR2 domain; (NHD) N-terminal homology domain;
(CHD) C-terminal homology domain; (polyA) polyadenylation signal: (SNL) subnuclear 
localization signal.
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Figure 2 Diagram of the MLL and AF4 proteins
Schematic representation of the human MLL and AF4 proteins, highlighting 
the functional domains. The proteins are drawn to scale, with one centimeter 
corresponding to 250 aminoacids. For the AF4 protein, all domains, with the 
exception of the transactivation domain which has been funetionally defined, 
have been assigned on the basis of homology between the AF4, LAF4 and 
FMR2 proteins.
Abbreviations: (NHD) N-terminal homology domain; (CHD) C-terminal 
homology domain; (ALF) AF4-LAF4-FMR2 domain; (C-SAC) C-terminal 
SET domain adjacent cysteine-rich region; (SNL) subnuelear Realization signal.
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IV.2 The aminoterminal domains of MLL retained in the fusion proteins 
IV.2.1 The AT hooks
AT hooks were first described as a DNA binding motif in the high mobility group 
protein HMG-I(Y), a chromatin protein with high affinity for the minor groove of AT rich 
DNA stretches (Huth et al., 1997; Reeves and Nissen, 1990). They have since then been
identified in many chromatin proteins. The AT hook is both necessary and sufficient for 
DNA binding, but, contrary to classical DNA binding motifs, AT hooks are thought to 
recognise a DNA structure rather than a specific nucleotide sequence. Upon binding, they 
can bend and distort DNA, and therefore it is hypothesised that they can regulate the 
architecture of promoter-enhancer interactions to facilitate transcription.
MLL has three AT hooks at its N-terminus. They have been shown to bind both cruciform 
DNA and scaffold attachment region (SAR) DNA (Zeleznik-Le et al., 1994).
Yeast two-hybrid screens have identified two potential protein partners for the 
aminoterminal region of MLL containing the AT hooks: SET and GADD34. As with any 
protein interaction detected under overexpression conditions, the in vivo relevance of these 
observations (summarised in table 2) remains to be elucidated.
Finally, a hint as to the possible relevance of the AT hooks to the leukemogenic 
capacity of the MLL fusion proteins, comes from the observation of chromosomal 
translocations involving the genes HMGI-C and HMGI-Y in a variety of mesenchymal 
tumors (Kazmierczak et al., 1998a; Kazmierczak et al., 1998b; Kazmierczak et al., 1999;
Santulli et al., 2000). Similarly to the MLL fusions, these chimeric proteins also feature a
triplet of AT hooks at their aminotermini, raising the possibility that they could impinge at 
least partially on a similar transforming pathway.
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Table 2: Putative protein-protein interactions of the aminoterminal portion of MLL 
retained in the leukemogenic fusion proteins
Protein name Protein features 
and function
Additional
remarks
Reference 
describing the 
interaction
SET - homologous to the 
nucleosome assembly 
protein NAP 1
(Ito et al., 1996)
- specific inhibitor
of protein phosphatase 2A 
(PP2A)(Li etal., 1996)
-Upon overexpression, the 
aminoterminal 
portion of MLL, the 
SETandthePP2A 
proteins have been 
detected in a ternary 
complex.
- The SET gene is 
translocated to the CAN 
gene in acute undifferentiated 
leukemias
(von Lindern et al., 1992).
-Adler et al. 
1997
GADD34 - induced by genotoxic 
stress
(Adler et al., 1999)
-the interaction was 
reported for the N-terminus 
of MLL, as well 
as for the fusions MLL- 
AF9, MLL-AF19 and 
MLL-ELL.
-Following radiation, 
GADD34
overexpression increases 
apoptosis, an effect which 
is inhibited by concomitant 
expression of MLL fusions.
-upon overexpression, MLL- 
AF19, GADD34 and hSN5 (a 
member of the human 
SWI/SNF complex) were 
detected
in a ternary complex.
-Adler et al., 
1999
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IV.2.2 The Methyl-Transferase Homology domain
A cysteine-rich DNA recognition motif is located in MLL between residues 1147 and 
1194. It is a zinc finger domain of the type "CXXC", which contains eight conserved cystein 
residues that bind to zinc. The identification of this motif in MLL sparked great interest, 
since this motif had previously been identified both in proteins that methylate cytosine, and 
in proteins that bind to methyl-cytosine. The former include DNA methyltransferase I 
(DNMTl), which catalyses the transfer of a methyl group to the cytosine residues of DNA 
(Bestor et al., 1988; Robertson and Wolffe, 2000). In DNMTl, the CXXC type zinc finger
lies towards the N-terminus. Downtream of it, there are two bromo-adjacent homology 
domains (BAH), which have been identified in a diverse range of proteins involved in DNA 
méthylation, DNA replication and transcriptional regulation. Further downstream along the 
DNMTl protein are three DNA methylase domains with catalytic activity. DNMTl 
functions as the main maintenance methyltransferase, which copies patterns of méthylation 
upon DNA replication. The N-terminal half of DNMTl containing the CXXC domain is 
likely to exert a regulatory function on the catalytic activity of the C-terminal domains. In 
fact, while the intact enzyme displays little activity on unmethylated DNA, upon proteolytic 
cleavage of the N-terminal from the C-terminal half, unmethylated DNA is methylated much 
more rapidly (Bestor, 1992). These initial observations suggested that N-terminal domains 
could recognise the méthylation status of DNA, thereby restricting enzyme activity to 
hemimethylated substrates. Thus, it is possible to envision that also MLL, by virtue of this 
CXXC domain, could recognise méthylation patterns, and that this could be an important 
aspect of its function as a chromatin regulator. While this hypothesis still holds validity, 
more recent findings have provided additional insight into the function of DNMTl and the
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role of the CXXC domain. In fact, DNMTl has been found to be associated with histone 
deacetylase activities in at least two different protein complexes which can repress 
transcription (Fuks et al., 2000; Robertson et al., 2000; Rountree et al., 2000), representing 
yet another route whereby DNA méthylation and transcriptional repression can be coupled, 
together with the previously characterised route whereby methylated DNA is recognised by 
methyl-CpG binding protein-2 (MeCP2), which in turn recruits histone deacetylase activity 
(Jones et al., 1998; Nan et al., 1998).
The region of MLL homologous to DNMTl was previously shown to repress 
transcription in cell culture assays upon overexpression of GAL4 fusions (Zeleznik-Le et al.,
1994). This finding prompted the search for an analogous repressive function of the DNMTl
domain. Two DNMTl-GAL4 fusions, both within the region homologous to the MLL 
repressive domain, exhibited repression activity. This repression was at least partially 
relieved by trichostatin A (TSA), a known inhibitor of HDACs. Interestingly, this was true 
only for the construct which did not include the CXXC Zn finger, arguing that alternative
mechanisms might account for the repressive property of this domain (Fuks et al., 2000).
Potentially interesting analogies for MLL can be drawn from an analysis of the two 
complexes containing DNMTl. One of the two complexes contains histone deacetylase 1 
(HDACl), the retinoblastoma tumor-suppressor protein (Rb) and the sequence specific 
transcriptional activator E2F1 (Robertson et al., 2000). Within this complex, DNMTl is
thought to interact directly with both HDACl and Rb, and the Rb interaction domain has
been mapped to the N-terminus of the protein featuring the CXXC motifs. The E2F-Rb
complex was already known to repress transcription at E2F responsive promoters via
recruitment of HDACl, a key feature of Rb function as an inhibitor of cell cycle progression.
The identification of DNMTl in this complex provided a novel link between DNA
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méthylation, histone deacetylation, and the Rb dependent transcriptional repression of 
specific promoters.
In the other complex, DNMTl has been shown to directly interact with histone 
deacetylase 2 (HDAC2) and a newly identified transcriptional repressor called DNMTl 
associated protein 1 (DMAPl) (Rountree et al., 2000). Once again, both of these interactions
have been mapped to the N-terminal half of DNMT-1. Importantly, the repression mediated 
by DMAP-1 is independent of histone deacetylation activities. Taken together, these results 
point to a model for the function of the N-terminal half of DNMTl, based on its interacting 
proteins. Whereas a part of this region, most likely the one which does not contain the 
CXXC motifs, recruits HDACl and HDAC2, the more N-terminal domain, harbouring the 
CXXC fingers, could repress transcription through the association with Rb, DMAPl and/or 
other as yet unidentified protein partners.
This overview of DNMTl function has clear relevance for MLL. By analogy, it is 
possible that the CXXC fingers might allow MLL to sense boundaries of gene expression 
and establish protein complexes which ensure the faithful transmission of epigenetic states 
upon cell division.
As for the CXXC containing proteins which bind to 5-methyl-cytosine, the methyl- 
CpG binding protein 1 (PCMl, also called MBDl) contains three zinc-fingers domains of 
the CXXC type lying downstream of a domain (aa. 7-60) (Hendiich et al., 1999) which binds
to DNA that contains one or more symmetrically methylated cytosines (CpGs) and is found 
in many methyl-CpG binding proteins from many species. PCMl is part of the MeCPl 
complex, and has been shown to repress transcription in a méthylation dependent manner. 
As the CXXC fingers are the only other domains present in PCMl besides the methyl-CpG
71
binding domain (MBD), it is once again likely that they mediate repression via recruitment 
of specific corepressors and/or histone deacetylases, as in DNMTl.
On the whole, the observation that the CXXC zinc-finger, other than in MLL and its 
closely related homologue MLL2, is specifically found only in proteins involved in either 
methylating DNA or in recognising methylated DNA, points to an intriguing connection 
between MLL function and the méthylation status of the genome.
IV.3 The carboxyterminal domains excluded from the fusion protein 
IV.3.1 The PHD Fingers
The PHD domain is a zinc-finger motif with a Cys4-His-Cysg pattern, spanning SO­
SO aminoacids. It was originally wrongly identified as a Lim finger in two closely related 
plant homeodomain proteins, HAT3.1 and HOXIA, hence the origin of its name from Plant 
Homeo Domain. Its identification as a novel and distinct protein domain came from a 
systematic search for sequence similarities between proteins of the Trithorax and Polycomb
groups (Aasland et al., 1995). Subsequently, it became clear that this domain only appeared
in nuclear proteins acting in chromatin-mediated transcriptional regulation. Since then, the 
list of proteins featuring a PHD domain has grown substantially, and it now comprises more 
than 400 proteins. Still, in spite of this wealth of information and the persistence of its 
correlation with chromatin proteins, the function of the PHD domain has remained 
remarkably elusive. It is clearly distinct from two other similar zinc-finger motifs, namely 
the RING, characterised by a Cys3-His-Cys4 pattern, and the LIM, which has a Cys2-His- 
Cys5 pattern. By analogy to these two domains, it is thought to be a protein-protein 
interaction platform, rather than a more classical type of DNA-binding zinc-finger. It 
belongs to a repertoire of chromatin domains (Bromo domain, BAH domain,
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Chromodomain, Chromoshadow domain, RING finger, SET domain, SANT domain, SAND 
domain) which have been conserved in evolution, and shuffled in various combinations 
across different proteins and different species as modular interfaces for increasingly flexible 
regulation. More specifically, assortment of these domains in the trithorax and Polycomb 
groups, which act antagonistically to maintain the expression status of the genes of the Hox 
cluster, is suggestive. It may point to common mechanisms, by which these proteins could 
recognise their targets, although with a very different final transcriptional outcome.
Recently, structures of two PHD fingers have been solved (Capili et al., 2001; 
Pascual et al., 2000). The PHD finger present in the transcriptional corepressor KAP-1 
confirms predictions made from initial alignments (Aasland et al., 1995). The PHD finger 
appears to be an autonomously folding domain, which chelates two zinc atoms in a cross­
brace scheme. It is very similar to the RING finger, differing mainly in the hydrophobic 
core.
Provocative evidence for physiological interactions mediated by the PHD domain 
involve histone deacetylation as a common theme (Schultz et al., 2001; Zhang et al., 1998b). 
Mi2a and Mi2P, originally identified as the specific autoantigen of dermatomyositis, are 
members of the CHD family of proteins, which derives its name from the presence of three 
domains (Chromodomain, ATPase/helicase and DNA binding modules) (Delmas et al.,
1993; Woodage et al., 1997). The two polypeptides are 80% identical, and contain two PHD 
fingers, two chromo domains, and one SWI-SNF2 type ATPase/helicase domain. Mi2P (also 
called CHD4) was identified as an integral component of the nucleosome remodelling and 
histone deacetylase complex (NurD), in which it contributes the nucleosome remodelling
activity (Zhang et al., 1998b). The complex, purified by conventional chromatography, 
contains two histone deacetylases (HDACl and HDAC2) as well as the metastasis
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associated factor (MTA-1) and two histone binding proteins, RbAp46 and RbAp48. In vitro 
experiments showed that Mi2p binds HDACl directly, but neither RbAp46 nor RbAp48, 
and that the PHD finger is necessary for this interaction, thus establishing a first potential 
function for the PHD domain.
In another study of the KAP-1 corepressor, the PHD and the Bromo domains in the 
carboxyterminal half of the protein were shown to constitute together an interaction platform 
for in vivo recruitment of the M i2a polypeptide (Schultz et al., 2001). Interestingly, while
Mi2P was not associated with KAP-1, M i2a coimmunoprecipitated with HDACl and 
RbAp48, suggesting that the protein complex recruited through the PHD domain of KAP-1 
has a distinct NuRD-like composition. In these experiments, the PHD and the Bromo 
domains appeared to behave as a functional unit to mediate transcriptional repression. 
Accordingly, upon overexpression in 293 cells, the interaction between KAP-1 and M i2a 
was dependent on both the PHD and the Bromodomains. Interesting, albeit preliminary, data 
were obtained by assessing the repressive potential of chimeric proteins in which the PHD 
and the Bromo domains of various proteins were shuffled in different combinations. At 
most, these heterologous fusions achieved only partial levels of repression, suggesting that 
this was a specific property of the PHD and Bromo module within KAP-I. This observation 
has interesting counterparts in other studies trying to establish the function of chromatin 
domains, for example the methylase activity of the SET domain (see below), and may well 
have further implications for the future of chromatin research. It is becoming clear in fact 
that the presence of a domain may by itself not be enough to predict the specific function of 
this domain accurately within a particular protein. This is no great surprise, and could indeed 
be inferred from the great variability within most of these domain families, where key 
aminoacid residues provide a common scaffold, while the functional versatility lies in the
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details. Hence investigations of common domains from specific proteins constitute an 
invaluable reference framework, but a thorough understanding of chromatin regulation will 
require the characterisation of each and every protein complex involved. Interpretative 
shortcuts should be viewed with caution.
MLL has three canonical PHD fingers, clustered between residues 1433-1627, and 
downstream of them one so-called extended PHD finger (ePHD). The extended PHD differs 
from the canonical PHD finger by having an additional Cys2-His-Cys4 motif at its C- 
terminus. All reported leukemic MLL translocations interrupt the protein upstream of (most 
often) or immediately at the beginning of the triple PHD stretch. The resulting fusion protein 
is therefore almost invariably devoid of PHD fingers. Although they would be included in 
the reciprocal chimeric protein (along with the C-terminally located SET domain), the 
reciprocal fusion protein is not detected in all leukaemias, and its pathogenic relevance is 
therefore still debated. As truncation of MLL eliminates the PHD and the SET domains, a 
model was suggested whereby this truncation would itself constitute the first event on the 
road to malignant transformation (Yu et al., 1995). The second event would most likely 
come from the domains contributed by the fusion partner and/or by other unidentified 
genetic alterations. There is some evidence, also from experimental animal models (see 
below), to at least partially support this model. Alternatively, the truncated part of MLL in 
the various fusion proteins could act as a dominant negative with respect to the wild type 
(wt) MLL and its interacting proteins.
A further hint to the possible role played by loss of PHD function in the 
leukemogenic process comes from the characterisation of two MLL translocations which 
fuse MLL respectively to A PI0 or A PI7. Both genes have an N-terminally located PHD 
finger, followed by an extended PHD finger. Remarkably, all translocations examined to 
date interrupt these genes downstream of the extended PHD finger, with the result that the
75
ensuing MLL-AFIO and MLL-AF17 fusion proteins are completely devoid of PHD fingers. 
Lately, the ePHD finger of AFIO was shown to mediate homo-oligomerisation in vitro; 
interestingly, homo-oligomerization was required for the ability of the AT-hook domain
(also present in MLL) of AFIO to bind DNA (Linder et al., 2000). While awaiting a
confirmation of these results in vivo, it is intriguing to hypothesise a similar function for the 
MLL ePHD, which could mediate either homodimerisation or heterodimerisation with other 
ePHD containing proteins.
On the whole, the function of the MLL PHD fingers is unknown. From the evidence 
gathered for the PHDs of other proteins, in MLL this domain could recruit complexes 
containing either Mi2a (by analogy to KAP-1) and/or HDACl (by analogy to Mi2|3 within 
the NuRD complex). Interaction with repressive complexes, however, need to be reconciled 
with the activating functions of MLL and Drosophila Trx that have been genetically 
demonstrated by in vivo studies. One possibility would be for MLL to act as repressor of 
repressors, yielding a net activation function. Alternatively, MLL might oppose repressive 
complexes at specific target sites to quench their activities and thus enable local maintenace 
of gene expression.
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IV.3.2 The SET domain
The SET domain (for Su(var)3-9, Enhancer of zeste and Trithorax), evolutionarily 
conserved from yeast to man, consists of approximately 130 aminoacids, and is present in at 
least 140 proteins involved in chromatin regulation (Jenuwein et ah, 1998). Like the PHD
finger, the SET domain is found in very different classes of chromatin proteins, often 
displaying antagonistic functions in the regulation of gene expression. For example. 
Enhancer of Zeste (E[z]) belongs to the Pc-G group of proteins, which establish repressive 
chromatin domains, while trithorax (Trx) is the founding member of the trx-G group of 
proteins, which are required to maintain gene activity.
Multiple alignments between fifteen representative members of the SET 
domain family of proteins have identified within the SET domain the regions of highest 
sequence identity and hence presumptive functional significance (Jenuwein et al., 1998). The
first region, of about 20 residues, was found to be invariant among all members analysed, 
and was predicted to adopt an a-helical configuration by secondary structure predictive 
algorithms. The second region comprises about 50 aminoacids, with an inner core forming a 
predicted strand-loop-strand structure, and two to three conserved histidine/cysteine 
residues. The spacing between these histidine/cysteine residues, together with the overall 
alignment results, divides SET domain proteins into four different subgroups, which have 
been named after their founding members. Enhancer of zeste [E(z)], Trithorax (Trx), Absent 
small or homeotic (Ashl) and Suppressor of variegation 3-9 [SuVar(3-9)] (reviewed in 
Jenuwein et al., 1998).
Very recently, both the mammalian SUVAR3-9 and Clr4 proteins were shown to be 
histone methyltransferases which specifically methylate lysine 9 on the amino terminus of 
histone H3 in vitro (Rea et al., 2000). This first evidence for an enzymatic activity of the
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SET domain provides a starting point from which to investigate the functions of other SET 
domains as well. The catalytic site was mapped by mutational analysis to the motif 
H(j)(l)NHSC (where ({) represents a hydrophobic residue), corresponding to residues 320-326 
in the HUSUV3-9 protein. However, méthylation also depended on the C-terminal tail and 
the cysteine-rich region, which flank the SET domain. Deletions of these elements abrogated 
enzymatic activity. This may explain the finding that neither MLL nor EZH2 displayed any 
methylase activity in these experiments, as MLL lacks the cysteine-rich region N-terminal to 
the SET domain, and EZH2 lacks the carboxyterminal tail.
Méthylation at specific lysine residues, along with phosphorylation and acétylation on 
histone tails are pivotal in chromatin regulation. For example, specific modifications of the 
N-terminus of histone 3 at various positions have been linked to distinct chromatin 
functions: acétylation at lysine 14 with transcriptional activation, acétylation at lysine 9 with 
histone deposition and phosphorylation at serine 10 with chromosome condensation (Strahl
and Allis, 2000). On the molecular level, these modifications provide docking sites for the
appropriate chromatin modifiers. At least two more layers of regulation increase the 
flexibility and complexity of this histone information system. The first is the action of 
enzymes which catalyze opposing reactions in a highly specific and regulated fashion, 
among which histone deacetylases have been best characterised. Demethylases have been 
postulated but not yet identified. Second, it is becoming clear that individual modifications 
can affect each other. Thus, in the case of SUV39 methylase activity, it was shown that 
phosphorylation at serine 10 inhibited SUV3-9 mediated méthylation at the adjacent lysine 
9, and conversely, dimethylation at lysine 9 substantially decreased serine 10 
phosphorylation by Aurora kinase (Rea et al., 2000).
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Furthermore, as histones are not the only targets for histone acetyl transferases (HATs), it 
appears likely that méthylation might also not be restricted to histones. An example comes 
already from Pisum sativum, where a lysine methylase methylates the large subunit of a 
metabolic enzyme.
Within this framework then, it is possible to envision that different SET domains 
have specificities for different residues in histone tails and/or for other nuclear targets. While 
substantial variation occurs within the core of the SET domains identified so far, and could 
thus provide the molecular basis of differential target recognition, the basis for this 
specificity could also come from the adjacent N-terminal region, that is critical for 
SUVAR3-9 catalysis on histone tails. Interestingly, MLL and related proteins have a 
different conserved motif in this position. Furthermore, the potential catalytic site of MLL 
(R(|)(|)NHSC) matches the same region in Clr4. This suggests that MLL is a methylase and its 
substrate is different from the histone substrates used by Rea et al (2000).
An interesting alternative holds that some SET domains, including that of MLL, are 
truly devoid of methylase activity. Rather, they might counteract the function of active 
methylases by binding to the same targets. This would be an analogous role as that played by 
anti-phophatases, and appears particularly intriguing in the case of MLL since one of its 
potential protein partners (Sbf-1, see below) belongs to the anti-phosphatase family (Cui et
al., 1998) (see table 3). The MLL SET domain could thus conceivably counteract two 
enzymatic activities and their related pathways at the same time.
The relevance of this SET domain function is supported by recent experiments in 
which histone 3 méthylation at lysine 9, but not at lysine 4, created a binding site for the 
chromodomain of the heterochromatin protein HPl (Lachner et al., 2001).
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Of the protein interactions described for the MLL SET domain (summarised in table 
3), all were originally identified by yeast-two hybrid assays, and confirmed in heterologous 
cell systems with overexpression studies. Their specificity and significance await further 
confirmation.
IV.3.3 The ATAl and ATA2 domains
The initial comparison between MLL and Trx drew attention to additional, shorter
regions of shared homology (Stassen et al., 1995; Tillib et al., 1995). Two of them were
termed ATAl and ATA2. In both MLL and Trx, the ATAl domain is located downstream of 
the ePHD finger, while the ATA2 motif immediately precedes the SET domain.
Database searches indicate that the ATAl domain is found only in association with the 
ePHD in certain cases. It features several conserved hydrophobic residues and is predicted to 
contain four to five pstrands and one ahelix.
The ATA2 domain is estimated to be 107-148 residues long, and to contain two ahelices and 
several pstrands. This motif flanks the SET domain in all Trithorax homologs and occupies 
the immediately adjacent N-terminal position taken by the cysteine-rich region of Su(var)3-9 
members, which appears to be crucial for the methylase activity.
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Table 3: Putative protein-protein interactions of the SET domain of MLL, which is 
excluded from the leukemogenic fusion proteins:
Protein name Protein features 
and function
Reference 
describing the 
interaction
Sbf-1
(SET binding factor-1)
-homologous to myotubularin, a dual 
specificity phosphatase, but Sbf-1 lacks 
this activity.
Cui et al., 1998
INIl -member of the SWI/SNF complex
-Mutations of INIl have been linked to 
pediatric rhabdoid tumours and to 
lymphoid malignancies (Versteege et al., 
1998; Yuge et al., 2000)
Rozenblatt-Rosen 
et al., 1998
1
MLL SET domain -no function ahs yet been assigned to the 
MLL SET domain. In an in vitro assay 
for méthylation at lysine 9 of the histone 
H3 tails, the MLL SET domain, in 
contrast to the SET domains of the 
SUVAR3-9 and CLR4 proteins, did not 
show any activity (Rea et al., 2000)
Rozovskaia et al., 
2000
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IV.4 The MLL genomic locus: hot spots versus selection
The MLL gene in humans and mouse is greater than lOOkb, and has been shown to 
contain at least 37 exons, updating previous reports which had estimated only 21 exons 
(Nilson et al., 1996). The new nomenclature is used here. The breakpoint cluster region 
(BCR) has been completely sequenced; it is 8.3 kb long and covers the region from the 3' 
end of exon 8 to the 5' end of exon 14 (Gu et al., 1994; Marschalek et al., 1995). Except for
intron 8, which is of type 1 (ie. interrupting the codon after the first base), all introns within 
the BCR are of type "0" (ie. they interrupt the coding sequence between triplets) (figure 1). 
The same is true for the AF4 BCR (Nilson et al., 1997), providing the basis for the creation 
of in-frame fusion proteins following translocation. The narrowness of the MLL BCR, which 
contrasts with the much wider breakpoints observed in other translocations, is one of the 
most intriguing features of MLL translocations, and can be explained by two alternative 
possibilities. The first hypothesis predicts that rearrangements only occur within this region 
due to the presence of a "hot spot" sequence which promotes illegitimate recombination 
("hot spot" hypothesis); and potentially hot spots also occur in BCRs of the M LL  
translocation partners. The alternative view holds that only translocations occurring between 
certain introns produce in-frame fusions, whose specific combination of protein domains 
confers a selective growth advantage (selection hypothesis). According to this hypothesis, all 
combinations which have not been clinically reported probably occur with similar frequency, 
but result either in out-of-frame products or in in-frame fusions with negligible effects.
Intron phase maps of the MLL and AF4 genes are shown in figure 1. The BCR of 
AF4 spans at least 40 kb and involves three type "0" introns (3, 4 and more rarely 5). The 
involvement of intron 2, which is also of type "0", is uncertain, since most published studies 
used primer sets which only explore the region downstream of exon 3. However, at least one
82
study reported mapping of breakpoints which presumably occur upstream of exon 3 (Chen et 
ah, 1993).
The tight clustering of MLL breakpoints lends strong support to the selection model. It 
suggests that the aminoterminal domains of MLL (AT-hooks, nuclear localisation signals 
and methyltransferase homology domain) are necessary for the oncogenic function of the 
fusion proteins. Concomitant exclusion of the downstream domains (PHD fingers, ATAl, 
ATA2 and SET domains) could be equally relevant.
Following this hypothesis, the requirement for the MLL break to occur in this specific region 
of the protein directs the translocations to a patch of type "0" introns, many of which can be 
apparently used. Concomitantly, this directs fusions to type "0" introns of the translocation 
partners, including AF4. Interestingly, there is a single reported exception to the involvement 
of type "0" introns in the MLL BCR. In this case, the type "1" intron 8 is translocated to a 
presumptive type "1" intron of AFIO (Chaplin et al., 1995b). Since intron 8 of MLL is 
immediately adjacent to the type "0" introns of the MLL BCR, this maps the border of the 
required protein sequence for leukemogenesis by MLL fusion proteins to exon 8. No intron 
phase maps are available for other translocations partners, but the detection of in-frame 
fusions in all cases necessarily implies that the breakpoint regions of these genes occur in 
type "0" introns, except for the one case mentioned above.
If one considers the overall distribution of intron types in MLL and AF4, it is clear that many 
more possibile rearrangements exist which would also give rise to in-frame fusions, through 
other introns of the same type. The fact that essentially only those directed by the intron "0" 
phase of MLL have been observed is strong evidence for the selection model, which also 
predicts that the rearrangements are not detected because they do not result in a growth 
advantage.
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MLL-AFIO translocations provide an interesting case. MLL dinàAFlO have opposite 
telomere-centromere orientations with respect to the direction of transcription, and constitute 
the first example of oppositely oriented genes involved in translocations which yield in­
frame fusions. This is possible because they undergo complex rearrangements, sometimes 
involving even three chromosomes, in which one of the two genes is first inverted and then 
translocated (Beverloo et al., 1995; Chaplin et al., 2001; Tanabe et al., 1996). Two 
homologues of AFIO have been described in mammals, AF17 and BRI 40, and AF17 is also 
translocated to MLL (Chaplin et al., 1995a; Gregorini et al., 1996; Prasad et al., 1994). These 
proteins have a similar architecture consisting of PHD fingers located towards the N- 
terminus and leucine zippers positioned at the C-terminus. Notably, all breakpoints mapped 
to date for AFIO and AF17 occur between these two domains, suggesting that their 
respective exclusion from and retention in the MLL fusion proteins are essential for 
leukemogenesis (Chaplin et al., 1995b).
Although AFIO, AF17 and BRI40 are extremely similar (93% and 77% identity respectively 
in the PHD finger and the leucine zipper between AFIO and AF17, and 66% similarity 
between AFIO and BRI40 over a region of 150 residues), AF17 is much less frequently 
involved than AFIO, and BRI 40 has not been reported in MLL translocations, in spite of the 
fact that MLL-AFIO translocations require an additional chromosomal rearrangement to 
produce a fusion protein. This is very strong evidence for the selection hypothesis because it 
indicates that chromosomal rearrangements are not rate limiting. Rather, it suggests that in 
spite of the healthy homologies between AFIO, AF17 and BR I40, MLL-AFIO fusion 
proteins have the greater oncogenic potential.
The AF l0/A F l 7/BRl40 case sheds light on other cases of differential MLL translocation 
frequencies to homologous partners. They include translocations of M LL  to AF4 and 
AF5ofi\, CBP andp300, and AF9 and ENL. In all pairs, the more frequent partner is listed
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first. Since all translocations have been found in leukemias, the very different frequencies 
provoke the attractive possibility that the more frequent events are promoted by hot spots. 
This conclusion, however, assumes that the oncogenic potential of each pair is identical.
CBP and p300a are highly homologous transcription coactivators; however, while fusion 
with CBP has been found in several cases (Rowley et al., 1997; Satake et al., 1997; Sobulo 
et al., 1997; Taki et al., 1997), so far only one case has been reported of MLL-p300 
translocation (Ida et al., 1997). In MLL-CBP fusions, virtually whole of the CBP protein is 
retained, except for the nuclear hormone receptor interaction domain (NID). In contrast, in 
the MLL-p300 case, the breakpoint is further towards the C-terminus and the fusion product 
lacks both the cysteine-histidine rich region and the CREB binding domain located towards 
the N-terminus of p300. Thus, the strikingly different frequency with which CBP andp300 
are involved might simply mean that the observed MLL-p300 fusion (i) is the result of the 
only possible in-frame translocation (based on the distribution of intron types) and (ii) has a 
lower oncogenic capacity if compared to the MLL-CBP fusion. Alternatively, these two 
genes, which lie on different chromosomes, could be translocated to MLL with different 
frequencies, reflecting distinct features in the primary sequence or in the accessibility of 
their loci. However, the assumption that they are functionally identical has been disproved 
(Kawasaki et al., 1998).
Similarly, AF4 and AF5q31 are highly homologous proteins, and also in the case of the 
MLL-AF5q31 fusion, breakage occurs within the ALE domain (Nilson et al., 1997; Taki et 
al., 1999). However, while AF4 is the most frequent translocation partner of MLL, so far the 
MLL-AF5q31 translocation has been detected only in one case. The homology between 
and AF5q31 (57% in the transactivation domain) is lower than between CBP and p300, and 
therefore their different frequency of involvement might reflect genuine functional 
differences.
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AF9 and AF19 (also called ENL), which share 56% identity and 68% similarity with the 
highest homology at the amino- and the carboxitermini, are also translocated to MLL with 
different frequencies, accounting for, respectively, 27% and <12% of all MLL translocations 
in a recent cohort (Seeker-Walker, 1998; Swansbury et ah, 1998). Two BCRs have been 
defined in AF9, spanning respectively intron 4 and introns 7 and 8. A recent study identified 
in these introns both an in vivo topoll cleavage site and two scaffold attachment regions 
(SARs); as these elements are also present in the MLL breakpoint, it was suggested that they 
play a role in mediating MLL-AF9 translocation (Strissel et al., 2000).
Finally, a close homologue of MLL was recently identified in the Stewart lab (Angrand, P.O. 
et al. unpublished results) as well as in two other laboratories, and called MLL2 (FitzGerald 
and Diaz, 1999; Huntsman et al., 1999). MLL and MLL2 have the same domain architecture 
and are clearly the product of a gene duplication event (Angrand et al., unpublished 
observations). Although the overall identity is 25%, the PHD finger and the SET domain 
regions are 63% and 74% identical respectively. Though a much smaller gene (21 kb), MLL2 
also has 37 exons. Yet, so far M LL2 has not been detected in any chromosomal 
translocation, an intriguing observation which could point to a functional difference with 
MLL. On the other hand, it could simply mean that this locus has lost the "hot spots" which 
putatively drive MLL rearrangements.
Partial support to the selection hypothesis comes from the analysis of Alu elements in the 
MLL gene. These are repetitive elements of about 300 bp scattered throughout the human 
genome, and consist of two homologous tandem repeats separated by an AT-rich stretch. In 
the case of MLL, their presence has been invoked as the structural basis for chromosomal 
rearrangement through aberrant homologous recombination by unequal crossing-over during 
meiosis. Partial tandem duplication in MLL indicates at least in some cases improper
homologous recombination between Alu elements (Schichman et al., 1994a; Schichman et
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al., 1994b; S trout et al., 1998). This usually results in fusion of one of the BCR introns with
the intron downstream of exon 2. Yet, several other MLL introns contain Alu repeats, and 
recombination between some of them could produce in-frame fusions, which so far though 
have not been reported. The potential contribution of Alu repeats to MLL rearrangemenst 
was recently addressed in an analysis of 45 kb of sequence spanning the first three exons, 
which indicated that some MLL duplications cannot be explained by the presence of Alu 
repeats (Wiedemann et al., 1999), and therefore their role in MLL  interchromosomal 
translocations remains an open issue.
On the whole, the variety of MLL rearrangements all centered around a narrow breakpoint 
region presents a complex biological problem, and underscores the relevance of the 
aminoterminal MLL moieties in leukemogenesis. All available evidence can be most simply 
explained by the selection hypothesis, although features of genomic instability in the BCRs 
of MLL and its partner genes are likely to further restrict the range of possible aberrations.
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IV.5 Trithorax and Polycomb group genes in flies and mammals
The homology with Drosophila trithorax has contributed to the fundamental model 
for MLL function, both in normal development and leukemogenesis. Thus, MLL action has 
been interpreted within the experimental and conceptual framework of trithorax group (trxG) 
and Polycomb group (PcG) genes respectively maintaining stable states of gene activity or 
repression. Here some of the main features of these two families of genes are summarised, 
focusing on the data which are most relevant to MLL function.
In the fly, the identity of body segments is established early in development as a 
readout of the relative activities of homeotic (Hox) genes, which are clustered in Drosophila 
in two complexes, the Antennapedia (ANT-C) and the Bithorax (BX-C) complex (Duncan, 
1987; Kaufman et al., 1990; Kennison, 1995). Loss or gain of function of the appropriate
Hox genes in the cells of a specific segment results in the formation of structures 
characteristic of a different body segment, a phenotype usually referred to as homeotic 
transformation. The appropriate patterns of Hox expression are established early on through 
the activity of maternally encoded factors, the pair rule and the gap genes. However, some of 
these transcription factors are present only transiently during development, while the correct 
Hox expression profile is required throughout the life of the organism Therefore, other genes 
have evolved to maintain these expression patterns stably, the trxG and the PcG genes.
Starting in 1940, with the identification of the extra sex comb (esc) mutation, the 
founder of the Polycomb family, many genes have been identified whose loss of function 
causes a "polycomb-like phenotype", that is, alteration of segmental identities as a result of 
particular Hox genes derepression (Simon, 1995). However, although Hox genes have been 
the best studied example, also other genes are stably repressed by this family of proteins.
In 1981, the trithorax mutation was identified. It was characterised by inadequate 
expression of certain Hox genes, leading to transformations in segment identities and 
displaying a maternal effect (Ingham, 1981; Ingham, 1998). It was soon recognised that this 
mutation suppressed the polycomb phenotype, leading to the current paradigm that these two 
classes of proteins act in an antagonistic fashion to maintain a repressed (PcG) or an active 
(trxG) state of Hox gene expression. Since then, virtually all other trxG genes have been 
identified through genetic screens searching for suppressors of polycomb phenotypes 
(Kennison and Tamkun, 1988; Kennison and Tamkun, 1992). This experimental strategy is
worth emphasising, as it can account for one major difference in the general features of these 
two families of genes. Though extremely complex and varied, the PcG family shows 
substantial homogeneity, in that many members contain shared domains, have been found 
associated together in large multiprotein complexes, and virtually all appear to mediate 
transcriptional repression, albeit through a still poorly characterised mechanism (Kennison,
1995). In contrast, members of the Trithorax group appear to constitute a heterogeneous set 
of proteins. This is hardly surprising if one considers that affiliation to this group is granted 
solely upon a suppressive genetic interaction with any one of the many PcG genes identified. 
Hence, according to the above definition, interference at any level in the pathway mediating 
PcG action can uncover a trxG mutation.This in turn implies that the molecular mechanisms 
underlying the function of trxG proteins are likely to be significantly more diverse than for 
the Polycomb group.
The general relevance of this genetic paradigm in flies is emerging with the 
identification of mammalian homologues for many of trxG and PcG genes, of which MLL 
was one of the first examples. Importantly, for some of them, an analogous, reciprocal
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function in the regulation of subsets of Hox genes has been documented (Hanson et ah, 
1999; Yu et ah, 1995).
In terms of the molecular mechanisms of action, PcG proteins in Drosophila mediate 
gene repression through so called Polycomb response elements (PREs), which are complex 
and still partially characterised sequences, varying from hundreds of base pairs to a few 
kilobases (Paro et ah, 1998; Pirrotta, 1998). They were initially defined by their capacity to 
maintain repression of hox genes in transgenic flies and/or repress reporters in transgenes in 
a Polycomb dependent manner, that is, mutations in PcG genes affect the activity of these 
elements. On the basis of colocalisation on polytene chromosomes, it was initially suggested 
that most of these proteins would function within large multimeric complexes assembled at 
the relevant target sites. Recent biochemical data provide strong evidence for this model, and 
two bona fide Polycomb complexes have been characterised, both in flies and mammals 
(Alkema et ah, 1997; Ng et ah, 2000; Shao et ah, 1999; van Lohuizen et ah, 1998). It is 
thought that different Polycomb complexes bind to different regions within a single PRE, but 
it remains to be determined how they are recruited to these elements. In fact, until now, only 
one member of the family, Pleiohomeotic (Pho), has been directly shown to bind a PRE, but 
interestingly no other PcG members have been found to interact with it (Brock and van
Lohuizen, 2001; Brown et ah, 1998).
Trithorax response elements (TREs) have been also postulated. The overall evidence 
suggests that, if TREs exist, they are closely intermingled with PREs (Tillib et ah, 1999). For 
example, the GAGA factor, encoded by the trxG gene Trithorax-like (Trl), is bound in vivo 
to some PREs within the BX-C, though possibly in a different manner than PcG proteins 
(Parkas et ah, 1994). Reflecting the multifaceted nature of these complex regulatory regions.
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it was recently proposed that they be renamed maintenance elements (MEs), leaving the 
thorough characterisation of each of them to the task of identifying the respective binding 
sites for the Polycomb or Trithorax complexes (Brock and van Lohuizen, 2001).
These observations resonate with a variety of findings which have recently shown some 
potential weaknesses in the traditional, strictly antagonistic model of Polycomb versus 
Trithorax. Some Polycomb group proteins are needed to maintain activation, as in the case 
of Posterior sex combs (Psc), which is required for polyhomeotic (ph) expression 
(Fauvarque et al., 1995). Conversely,mutations in the trxG member GAGA factor cause 
derepression of the Fab-7 PRE, arguing that at least some trxG proteins can also mediate a 
repressive function (Hagstrom et al., 1997). More recently, the chromatin remodelling 
complex containing Osa and Brahma, two trxG members, was shown to be required for 
repression of wingless target genes (Collins and Treisman, 2000). Finally, the enhancer of
zeste (E(z)) gene, originally classified as a PcG gene, was shown to function also as a trxG 
gene (LaJeunesse and Shearn, 1996), and in a genetic screen aimed at identifying enhancers 
of the Trx phenotype, both TrxG and PcG mutations were identified, indicating that at least 
some members of these two families might have a dual role in regulation of gene expression
(Gildea et al., 2000).
How do these and similar observations relate to our understanding of MLL action? 
The Trx framework is obviously still very valid, and has gained important support from MLL 
knock-out studies which uncovered a role for MLL in maintaining transcription of at least 
some Hox genes, whose deregulation could also account for some oncogenic properties of 
MLL mutations, as various Hox genes have been directly implicated in leukemogenesis 
(Lawrence et al., 1996). However, the two domains consistently retained in all MLL fusions,
AT hooks and methyltranferase homology, are notably absent from Drosophila Trx, arguing
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that during evolution additional functions were conferred upon MLL which might not find 
an adequate parallel in the fly Trithorax paradigm. Furthermore, it is clear from the 
heterogeneity of the trx-G, and even more from the complexity inherent in 
Poly comb/trithorax functions, that the mere classification of MLL as a trxG member does not 
bring much informational content. Rather, as with all other trxG proteins, dedicated, in vivo 
studies of function and the interacting protein partners are needed to umavel its complex 
action, including the Trx aspects involved therein.
IV.6 Cell culture studies of MLL function
Several studies have addressed different aspects of MLL function in cell culture. They have 
mostly focused on one of two main topics: the potential role of MLL and some of its fusion 
proteins as transcriptional regulators, and its nuclear localisation.
Different regions of MLL were fused to the DNA binding domain of the yeast GAL- 
4 protein and assessed for the transcriptional regulation of a reporter gene harbouring GAL-4 
binding sites. The experiments were conducted in HeLa cells, NIH3T3 and CHO (Chinese 
hamster ovary) cells. The results from two independent studies are largely overlapping 
(Prasad et al., 1995; Zeleznik-Le et al., 1994). A transcriptional activation domain was 
originally identified between aminoacids 2339 and 3759; further characterisation identified a 
minimal transactivation domain spanning residues 2829 through 2883, which yielded 300- to 
500-fold activation of the reporter in this system. Mutational analysis identified a core 
sequence crucial for this activity: ILPSDIMDFVL, composed of two aspartate residues and 
seven hydrophobic aminoacids. Substitution of either the aspartic acid or the hydrophobic 
residues almost completely abolished the activity. This aminoacid array is reminiscent of 
similar motifs found in the activation domains of known transcriptional regulators, like
VP 16. One possible basis for the function of this transactivation domain comes from its
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recent identification in a yeast three-hybrid screen searching for interacting partners of the 
CBP coactivator protein (creb binding protein) (Ernst et ah, 2001). The screen was designed 
to isolate products which could interact with the unique interface formed by the CREB-CBP 
interaction. The interaction with the MLL transactivation domain was mapped to the CREB 
binding domain of CBP (also called KIX domain) and was confirmed by 
coimmunoprecipitation of the overexpressed epitope-tagged domains. Interestingly, in cell 
culture overexpression assays, increasing amounts of the El A12S protein (a virally encoded 
polypeptide which inhibits CBP-dependent activation by a variety of transcription factors) 
abolished the transactivation potential of the MLL fragment (aa 2829-2883 of MLL), 
strongly suggesting that its transactivation requires CBP. Mutational analysis identified 
several residues, within the core motif described above, which appear to be crucial for both 
CBP interaction and transactivation. If confirmed in vivo, these findings could provide an 
attractive mechanism for the role of MLL in enabling active states of gene expression. 
Furthermore, the MLL-CBP fusion proteins from t( ll;1 6 ) translocations could be 
constitutive, aberrant surrogates of the normal CBP-mediated MLL regulatory function.
Interestingly, a transcriptional repression domain was mapped to residues 1032 
through 1395, which include the region of homology to methyltransferase (1147 to 1240), 
which independently showed the highest repression (12-fold). This domain is retained in all 
MLL translocation products, as well as in the cases of tandem duplication.
Several studies showed that MLL has a punctate nuclear distribution pattern, 
consisting of small speckles distributed throughout the nucleoplasm; the protein appeared to 
be excluded from the core of the nucleolus. These observations were carried out in a variety 
of transformed cell lines (among which COS, HeLa, SV80, Jurkat, HL60, U937), including
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leukemic cell lines with llq23 rearrangements (ML2, RS4;11 and HB11;19), as well as in 
normal human tissues (Yano et ah, 1997).
To identify the specific motifs involved in nuclear localisation, multiple fusions were 
assessed in which parts of the MLL protein directed the localisation of the cytoplasmic 
enzyme PK (Yano et al., 1997). Two classes of elements were identified, responsible for 
nuclear localisation per se and/or for the specific dotted pattern, respectively. Overall, the 
820 aminoterminal residues exhibited nuclear targeting properties, clustered in three motifs: 
NTS-1, NTS-2 and NTS-3. The latter displays a classical nuclear localisation motif of 
RKRKRK sequences. Two elements identified in the N-terminal portion of the protein were 
responsible for the speckled nuclear distribution of MLL: SNL-1 and SNL-2, respectively 
spanning residues 388 to 432 and 1051 to 1089). They are located between the AT hooks 
and the CXXC domain. SNL-1 overlaps with NTS-2. Strikingly, these motifs are conserved 
between MLL and Drosophila Trx, arguing that specific subnuclear localisation of these 
chromatin regulators has been strictly conserved throughout evolution. Both these 
localisation elements are retained in the MLL translocation products. Although the N- 
terminal part of MLL contains additional subnuclear targeting motifs, in this assay no 
elements C-terminal of the translocation breakpoint were able to direct either nuclear 
localisation or distribution into speckles.
Another study extended the analysis to an N-terminal MLL truncation, which 
retained the AT hooks and most of the SNL-1 region (Caslini et al., 2000a; Caslini et al.,
2000b). This showed the same localisation pattern as the endogenous full length protein,
with a punctate nuclear distribution, which included regions adjacent to the nuclear envelope 
and the periphery of the nucleolus. Intriguingly, different imaging approaches (confocal laser
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scanning and immunoelectron microscopy) showed colocalisation of this truncated Mil 
protein with topoisomerasell in metaphase and telophase during mitosis.
Interestingly, for at least some of the fusion proteins (MLL-AF4, MLL-AF9 and 
MLL-AF17), the subnuclear distribution was not affected (Yano et al., 1997), lending to the 
suggestion that in the chimeric products, the aminoterminal MLL moieties target the 
domains of the translocation partners to the normal, physiological targets of MLL. This in 
turn is predicted to result in aberrant regulation of those targets.
These studies also indicate that, to be detected in bright dots by immunofluorescence, 
the Mil protein must be present in multiple copies at its target sites within the nucleus. This 
is, at least conceptually, in agreement with the long standing notion that MLL, like most trx- 
G members functions in large multimeric complexes. Furthermore, the observation that 
MLL nuclear dots do not overlap with nuclear subdomains defined by other oncoproteins, 
like PML (Promyelocytic leukemia) and TAL-1 could point to a novel and distinct nuclear 
subdomain where MLL exerts its action .
On the whole, several approaches have convincingly demonstrated the role of the N- 
terminal portion of MLL in directing speckled nuclear localisation of the wild type protein, 
as well as of several aminoterminal truncations and chimeric fusions. Some of the molecular 
details responsible for this pattern were initially defined through overexpression assays, and 
therefore warrant confirmation in more physiological systems. This appears particularly 
relevant, since overexpression of either MLL truncations or MLL fusions has resulted in a 
somewhat different pattern, with bigger clusters as well as small dots and nucleolar staining. 
These data also bring a word of caution when designing experiments to assess the function 
of MLL and/or its fusion proteins under non physiological conditions, as such staining 
artifacts could well have a confounding functional counterpart.
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IV.7 MLL function in the mouse
Two different Mil knock-out alleles have been generated.
In the first study (Yu et al., 1995), the function of MU was ablated by fusing the LacZ 
reporter gene in frame with exon 3 b, allowing simultaneous analysis of its expression 
pattern. In homozygous embryos this knock out design resulted in the absence of the full 
transcript, while a truncated transcript, coding for the N-terminus of the protein which 
includes the three AT hooks, was still detected.
Heterozygous mice displayed a complex phenotype, arguing that the MU gene is 
haploinsufficient. However, as the translation of the truncated protein was not investigated, 
the possibility remains that at least some aspects of the phenotype could be due to a 
dominant negative effect. The phenotype was characterised by smaller size at birth 
accompanied by growth retardation, anemia and mild thrombocytopenia. B-cell populations 
were also reported to be consistently reduced. In addition, several segmental abnormalities 
were detected, which included: second cervical vertebral and sternal malformations, anterior 
transformations of cervical vertebra C7 to C6 and thoracic vertebra T3 to T2, as well as 
posterior transformations of T13 to lumbar vertebra LI and L6 to sacral segment SI. Hence, 
one of the distinguishing characteristics of the MUM- phenotype, namely both anterior and 
posterior homeotic transformations, recapitulates the distinct homeotic phenotype of the first 
(hypomorphic) allele of trx identified in flies, namely bidirectional transformations of 
prothorax (Tl) and metathorax (T3) towards a mesothorax (3 X T2) identity. RNA in situ 
hybridisation on +/- day 10.5 embryos showed that the expression boundaries of Hoxa-7 and 
Hoxc-9 were shifted caudally in both mesodermal and neuronal derivatives.
Homozygous mutants were embryonic lethal. Mll-i- embryos were still recovered at
the expected Mendelian frequency between embryonic days (E) E9.0 and E l2.5; however,
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E l0.5 was the latest timepoint for embryo viability, as judged by the presence of cardiac 
contractions. At this time, expression of HoxaV and Hoxc9 was completely missing in 
homozygous embryos. However, in these embryos, the correct spatiotemporal expression 
pattern of those genes was properly initiated, at around E7.5-E8.5, but failed to be 
maintained beyond E9.0. This strongly supports the view that, in remarkable analogy with 
fly Trx, MLL also maintains, rather than establishes, Hox gene expression patterns during 
embryonic development.
As the appropriate pattern of Hox gene expression defines the segmental identity of 
cell types along the anteroposterior axis, a detailed analysis was performed on cranial
ganglia, spinal ganglia and somites (Yu et al., 1998). In good agreement with the
maintenance model, neural patterning appeared to procédé normally through the initial 
stages, but to then fail to establish the appropriate connections, especially as far as segmental 
patterning was concerned. As the segmental pattern of spinal ganglia is controlled by 
neighbouring somites, it came as no surprise that somites displayed disrupted architecture 
accompanied by widespread cell death.
In a further set of experiments, semiquantitative Reverse-Transcription (RT)-PCR 
was used to assess the expression of several Hox genes (from the Hoxa and the Hoxc cluster)
in MU-/- immortalised mouse embryonic fibroblasts (MEFs) from El 0.5 embryos (Hanson et 
al., 1999). Hoxa4 through HoxalO were either absent or markedly reduced in Mll-i- MEFs,
whereas Hoxa3 was less affected and Hoxal was normally expressed. Except for HoxcS, 
which showed reduced RNA expression, Hoxc genes 4 through 9 were completely absent 
from MU-/- MEFs. Caution should be taken in interpretation, since these cells were 
immortalised with the polyoma virus tumor antigen; however together these results strongly
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support the idea that MLL maintains the expression of at least some genes of the Hox 
clusters.
The analogy with Trx function in flies is reinforced by the analysis of mice lacking both MU 
and Bmi-1, the mammalian homologue of the Drosophila Polycomb group gene Suppressor 
o f Zeste 2 (Sz2) (Hanson et al., 1999). Some of the skeletal abnormalities noted in the 
respective single mutant phenotypes were corrected when the two mutations were combined, 
most notably the widened Cl and the C2—>C3 transformation accompanying Bmi-1 
deficiency. However, the abnormalities of the sternum and the thoracolumbar spine were not 
corrected, arguing that the balanced loss of both proteins restores identity specification only 
in some segments. At the molecular level, Hoxc^ and other, but not all, Hox genes were 
found to be reciprocally regulated by MLL and BMI-1, thus partially recapitulating the 
opposite actions of Trx and Pc in Drosophila.
A detailed analysis of yolk sac hematopoiesis was carried out on Mll-l- embryos
(Hess et al., 1997). In this knock-out model, in fact, death preceded the full onset of liver
hematopoiesis, which occurs at around E11.5-E12.5. Methylcellulose colony assays were 
performed on dissociated yolk sacs. Colony-forming-unit granulocyte, erythroid, 
macrophage, megakarycyte (CFU-GEMM), colony-forming unit macrophage (CFU-M), 
burst- forming unit-erythroid (BFU-E) and colony forming units-erythroid (CFU-E) were 
assayed. Except for CFU-E, which were normal or increased, in all other cases, a reduction 
in colony numbers, speed of growth and number of cells per colony was observed in Mll+I- 
embryos, which became more pronounced in Mll-i- embryos (60% decrease in the number of 
cells per colony). Importantly, mutant colonies did display the full range of differentiation 
seen in normal and heterozygous colonies, with a similar distribution of cell types, except for 
a striking reduction in monocytes and macrophages.
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The second MU knock-out experiment (Yagi et ah, 1998) overall confirmed the
hematopoietic disturbances described in the first study. In this case, Mll-l- embryos were 
reported to die between El 1.5 and E14.5. Death was preceded and/or accompanied by 
edema and purpura. The delayed time of death, when compared to the first experiment, could 
be due to the adoption of different experimental conditions or to the difference in the 
targeting construct, which replaced exons 12 through 14 with a PGK-Neo cassette. These 
exons correspond to the breakpoint cluster region in human leukemias (which spans exons 8 
through 14). A truncated transcript, encoded by the 5’ end of the gene, was detected in Mll-i- 
embryos, which comprises five additional exons if compared to the mutant transcript 
generated in the first study, including the methyltransferase homology domain. Therefore, it 
was suggested that this longer truncated MLL version could result in delayed lethality. 
However, it should be noted that neither of the two studies investigated the presence of the 
truncated protein.
The delayed time of death enabled assessment of the initial stages of fetal liver 
hematopoiesis in Mll-i- embryos. Both histological analysis and colony forming assays from 
fetal livers were performed. The results largely recapitulate the situation observed with yolk- 
sac hematopoiesis: marked reduction in hematopoietic cells and their precursors with an 
overall normal differentiation profile along the various lineages. Again, granulocyte- 
macrophage colonies were particularly affected.
Postulating a defect in the proliferation and/or survival potential of Mll-i-
hematopoietic precursors, an RT-PCR analysis was performed on several genes involved in
cell cycle regulation, including Rb, cyclinDl, cyclinD3, cdk2 and cdk4. No meaningful
difference between wt and mutant embryos was detected. An analogous strategy revealed
marked reduction in the expression of Hoxa7, HoxalO and Hoxc4, in agreement with the
previously reported results. On the whole, results on Mll-i- cells point to a pivotal function
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for MU in hematopoiesis; at the same time they also argue against a classical tumor- 
suppressor function for MU, which would have predicted growth deregulation upon 
disruption of both MU alleles.
IV.8 Mouse models of MU leukemogenesis 
IV.8.1 The Mll-A/9 model
To model the MU-AF9 leukemia in the mouse, Rabbitts and coworkers used a knock- 
in approach to fuse the 3’ terminal portion of the Af9 cDNA to exon 11 in the endogenous
MU locus (Corral et ah, 1996). Three other MU mutant alleles were also generated: the AT-
Lac allele in which the LacZ was fused in frame to MU exon 3 (analogous to the knock-out 
construct described above), the M/-myc-tag allele and the M /-exonll-LacZ allel, in which a 
myc tag or LacZ, instead of the Af9 cDNA, were fused in frame to MU exon 11 (Corral et al., 
1996; Dobson et al., 2000). Targeted ES cells for each mutant allele were injected into 
blastocysts. Chimeric mice, as well as heterozygous mice after germline transmission of the 
alleles, constituted the cohort in which leukemia development was assessed.
The great majority of both chimeric and heterozygous mice harbouring the Mll-Af9 fusion 
allele developed acute leukemia, starting at 4 months of age, with very few mice surviving 
beyond 12 months of age. The total observation period amounted to 18 months (about half of 
the normal mouse life-span). Mice developed predominantly acute myeloid leukemias, but 
acute lymphoid leukemias were observed rarely , in agreement with the spectrum of MLL- 
AF9 leukemias observed in humans. The disease bore a remarkable resemblance to the 
human condition, with bone marrow hypercellularity and extensive extramedullary 
hematopoiesis in spleen and liver. One of the most relevant findings was the pronounced 
expansion of the myeloid compartment observed prior to leukemia development in these
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mice (Dobson et al., 1999). This was assessed by bone marrow fluorescence-assisted cell
sorting (FACS) analysis at different ages using specific markers for the various 
hematopoietic lineages. Starting at birth, the Mll-Af9 allele was associated with a clear 
proliferative advantage of myeloid cells (assessed with the myeloid markers gr-1 and Mac- 
1), which by 12 weeks of age amounted on average to 82% of the total bone marrow 
population in heterozygous animals versus 52% in wild type mice. This suggests that the 
Mll-Af9 fusion ("the seed") is promoting the myeloid lineage ("the soil"), and that overt 
leukemia arises from an expanded myeloid pool as individual cells accumulate additional 
genetic lesions. This would also explain the relatively long latency of leukemia development 
in this mouse model, which had already suggested the need for secondary mutations in Mll- 
mediated tumorigenesis.
Importantly, the AT-Lac and the M//-myc allele did not result in either benign 
myéloprolifération or overt leukemia, while mice harbouring the M /-exonl 1-LacZ allele did 
develop acute leukemias. Interestingly, both the incidence and the latency of disease in this 
cohort were lower than for the Mll-Af9 experiment (only 35% of the animals developed 
leukemia, starting at around 8 months of age, versus the MU-Af9 cohort where all the mice 
developed the disease). The distribution of the leukemic phenotype recapitulated the Mll-Af9 
results, with the great majority of animals suffering from acute myeloid leukemia and only 
three cases of lymphoblastic disease (either ALL or lymphoblastic lymphoma). Several 
insights can be drawn from these experiments.
First, it is possible to recapitulate in the mouse many aspects of MU leukemogenesis,
establishing this organism as a powerful platform to model other MU translocations as well.
The knock-in approach is in this regard a very useful tool. However, it still lacks features
important for fully mimicking the human disease, the most important one being somatic
acquisition of the translocation in the context of normal hematopoiesis. For example, the
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extent of preleukemic myéloprolifération in Mll-Af9 mice could well reflect the starting 
number of cells harbouring the fusion protein. These limitations emphasise the need to 
develop more accurate, fully conditional translocation models which rely on the Cre-loxP 
technology.
Second, mere truncation of MU at either exon 3 or exon 11 does not seem to cause 
either leukemia or lineage expansion. On the contrary, in both AT-Lac (exon 3) and M/-myc 
(exon 11) chimeras, mutant ES cells were preferentially excluded from the hematopoietic 
lineage. This did not correlate with the overall chimerism (as judged by coat colour), arguing 
that hematopoietic development is exquisitely sensitive to the correct dosage of the MLL 
protein. This conclusion is also in good agreement with the analysis of Mll-I- knock-out 
mice (Yagi et al., 1998; Yu et al., 1995).
Third, at least in the case of the Mll-Af9 translocations, the fusion protein does indeed 
seem to direct lineage specification. In the light of these findings, the occurrence of 
lymphoid neoplasms with MLL-AF9 fusions, both in these experimental models and in 
patients, can be interpreted as the result of additional genetic lesions which override the 
lineage-specific expression prompted by the M LL-AF9  fusion. In addition, while the 
important role of MLL-fusion proteins in lineage determination is supported by animal 
models of the Mll-Enl translocation (see below), the M /-exonll-LacZ results suggest that 
the myeloid lineage might be the default pathway for MU tumorigenesis.
Possibly the most relevant observation from this set of experiments concerns the lack 
of leukemogenic potential displayed by the simple truncated MU alleles (AT-Lac and Mll- 
myc) as opposed to the transforming properties of the M /-exonl 1-lacZ allele. This has two 
immediate implications. The LacZ protein has been shown to assemble in a tetrameric 
complex (Jacobson et al., 1994), and it is therefore very likely that in this M /-LacZ fusion it
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provides an artificial homomerisation interface for the N-terminal half of MLL. Hence, in 
the spontaneously occurring diseases, homomerisation could be contributed by the different 
fusion proteins. At least two MLL translocation partners, AFIO onàA F ll, contain leucine 
zipper dimerization domains, making this hypothesis at least plausible. A compatible 
possibility is that the LacZ primarily acts to stabilise the truncated MLL protein, a function 
which would normally be carried out by the C-terminal half of the protein. In either of these 
two scenarios, the MLL-LacZ fusion could then act in a dominant negative fashion and 
interfere with the normal MLL pathway. This hypothesis would partially incorporate the 
notion that MLL tumorigenesis simultaneously includes a loss of function (truncation) as 
well as a gain of function (domains contributed by the fusion partners).
At the same time, the observation that a LacZ fusion to exon 3 (which includes the three AT 
hooks) does not result in leukemia, argues that the methyltransferase homology domain 
and/or flanking regions are essential for the aberrant function of that fusion protein.
IV.8.2 The Mll-Afl9 model
These and other related questions were explored in the other major mouse model of 
Mil leukemogenesis. In this study, the oncogenic potential of the Mll-fF19 translocation was 
investigated through transduction of hematopoietic progenitor cells with a retrovirus 
harbouring the Mll-Afl9 fusion cDNA (Lavau et al., 1997; Slany et al., 1998). As discussed
previously, among all MLL translocation partners, AF9 an d ^ F iP  (also called ENL) share,
together with ELL, some sequence similarity, and it is therefore particularly interesting to
compare models for these two related fusion proteins. In these experiments, the effect of the
fusion protein was monitored through methylcellulose colony forming assays. Infected cells
showed an increased ability to generate myeloid colonies, which could undergo successive
rounds of replating and finally established myelomonocytic cell lines. Upon transfer to both
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sub-lethally irradiated syngeneic and severe combined immunodeficiency (SCID) mice, 
these immortalised cells gave rise to acute myeloid leukemia in the majority of animals. 
Similar results were obtained by transferring freshly isolated hematopoietic progenitor cells 
infected with the same virus. Mutant constructs were tested in a parallel set of experiments, 
to investigate which component of the -MLL-AF19 fusion was responsible for the in vitro 
immortalisation. The AT hooks and the methyltransferase homology domains, which are 
consistently present in all MLL fusion proteins, were both found to be necessary. 
Interestingly, the methyltransferase homology domain was shown to bind DNA through a 
south-western blotting assay using salmon sperm DNA and poly(dl-dC), which, like the AT 
hooks, may indicate a non-specific DNA binding property.
The AF19 component was also necessary for immortalisation (Slany et al., 1998).
While expression of only the N-terminal half of MLL did not cause transformation, deletion 
analysis identified the 84 carboxy-terminal residues of AF19 as both necessary and sufficient 
for transformation when they were fused to MLL. This region has been predicted to contain 
two alpha-helices, and disruption of either one of them abrogated the oncogenic potential of 
the fusion protein. The region also corresponds to the segment of homology with Af9, and it 
is intriguing that in at least one documented case of MLL-AF9 leukemia, only the carboxy- 
terminal 91 residues were retained in the fusion protein, which was therefore very similar to 
the minimal oncogenic fusion detected in these experiments. Therefore, Mll-Af9 and Mll- 
A fl 9 mediated leukemogenesis might procédé along common pathways, which would be 
reflected in their preferential association with a myelomonocytic phenotype.
On the whole, these studies demonstrate the crucial role of a translocation partner for
MU leukemogenesis. They exclude the possibility that truncation may be the sole mechanism
leading to tumorigenesis. While caution should be taken, since the deletion was analysed
only by in vitro methylcellulose colony forming assays, the results demonstrating the role of
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the AT hooks and the CXXC domain in immortalisation will help in the interpretation and 
design of further experiments.
Another interesting observation concerns the levels of expression of the fusion 
protein achieved in these studies. Only RT-PCR managed to detect expression of the fusion 
cDNA, while both northern and western blotting failed. Similarly to what has been reported 
for PML-RARa, the M ll-Afl9  cDNA also could not be expressed under the control of a 
constitutive promoter in a variety of cell lines. This indicates that only limited levels of the 
fusion protein can be tolerated in most cell types, and that this might turn out to be a more 
general feature of many translocation products. It also has far reaching implications for the 
design of translocation models, where alterations in the apparently low levels of expression 
required for transformation, as with standard transgenesis approaches, could dramatically 
affect the phenotype.
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VAF4
V .l Introductory remarks
The AF4  gene was originally identified through cloning of the translocation 
breakpoint in t(4;ll)(q21;q23) cell lines (Corral et al., 1993; Djabali et al., 1992; Domer et
al., 1993). At the time of its discovery, no other known genes showed any region of 
homology with AF4. Subsequently, three genes, which share high similarity with AF4, LAF- 
4, FMR2 andAF5q31, were identified in mammals, (Gecz et al., 1996; Gu et al., 1996; Ma
and Staudt, 1996; Taki et al., 1999), AF5q31 being isolated because it is also translocated to
MLL. They have been grouped in a new protein family of putative transcription regulators, 
termed ALT after the name of the most conserved domain shared among the members (from 
the initials of the three founder genes AF4, LAF-4 and FMR-2). Very recently, a Drosophila
homologue has been identified (Tang et al., 2001; Wittwer et al., 2001).
AF4  codes for a nuclear protein of 140KDa with a wide, possibly ubiquitous 
expression pattern (Chen et al., 1993). A diagram of the AF4 protein is shown in figure 2. It 
is particularly rich in serine and proline (26% of all residues), a feature interestingly shared 
by ENL, another of the MLL translocation partners. In addition, both proteins share a
consensus GTP-binding site (GXXXXGK located at residues 946 to 952) (Morrissey et al.,
1993; Morrissey et al., 1997). The main cDNA observed in most tissues is about 12.5 kb 
long, due to an unusually long 3' untranslated region. Alternative splicings have been 
detected in many tissues, as has the alternative use of two first exons (see below) (Morrissey
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et al., 1993). This combinatorial potential produces proteins of different sizes (Li et al., 
1998).
As for the other members of the family, their function is still largely unknown. LAF4 
was originally isolated from a Raji Burkitt's lymphoma cDNA library that was subtracted 
with K562 (erythroleukemia) cDNA to identify lymphoid specific genes (Ma and Staudt,
1996). It was found to be expressed in B cells, with the highest peak in pre-B cells and
complete downregulation in plasma cells. It is a nuclear protein, with nonspecific DNA 
binding capacity, and two transactivation domains, one of which is conserved in AF4.
FMR2 is the gene associated with FRAXE mental retardation. FRAXE, located on 
Xq28, is one of at least five folate-sensitive fragile sites on the X chromosome, which are 
associated with various forms of X-linked mental retardation. Positional cloning of the 
FRAXE locus identified the causative mutation, for the majority of cases, as amplification of 
a CCG repeat immediately adjacent to the promoter of the FMR2 gene, in analogy to the 
mechanism described for FRAXA and FMRl. The expanded CCG repeat is methylated 
leading to silencing of FMR2 expression. An alternative mutational mechanism is found in 
some families that have been characterised, where microdeletions lead to severely truncated 
forms of the protein. Depending on the degree of CCG amplification, a range of premutation 
or full mutation alleles have been described, where full mutation correlates with the presence 
of mild non specific mental retardation (MR).
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V.2 Protein domains present in AF4
Functional domains have been postulated in AF4, mostly on the basis of homology 
between the members of the family. A diagram of the AF4 protein and its domains is 
presented in figure 2. Expectedly, they are also the regions of highest homology between the 
mouse and the human protein (which have an overall homology of 64%). Two studies have 
reported such alignments, with largely overlapping results (Nilson et al., 1997) (Isnard et al.,
1998). The differences, likely arising from the respective use of the human and mouse 
sequence of AF4, mainly concern the portion of the protein which contains the putative 
transactivation domain (Prasad et al., 1995). Whereas in the first report, aligning only the
human sequences (Nilson et al., 1997), a single homology domain was proposed for this
region (the ALF domain, see below), in the second study, which compared the mouse AF4
with the human AF4, FMR2 and LAF4 proteins (Isnard et al., 1998), two seemingly distinct
domains of homology were identified, located respectively upstream and downstream of the 
BCR, with the downstream one including the transactivation domain. This last alignment is 
summarised here.
The first putative domain is located N-terminally (and is therefore called NHD), 
spanning 66 residues (position 6-72 in the mouse sequence) with 91% human/mouse 
homology. This region shares 53.8% homology with FMR-2 and 60% homology with LAF- 
4.
The second is located at positions 258-321 (mouse sequence), and displays 89%
homology to the human counterpart. Homology to FMR-2 and LAF-4 is respectively 51%
and 56%. These first two homology regions are located upstream of the translocation
breakpoint, and are therefore not present in the MLL-AF4 fusion protein. The reciprocal
fusion protein, which would harbour these two domains at the N terminus, has been detected
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in most t(4;ll)(q21;q23) leukemias, although its relevance to the leukemogenic process is 
completely unknown.
The third domain has attracted considerable interest, since it includes the putative 
transactivation domain identified through GAL4 fusion assays (Morrissey et al., 1997;
Prasad et al., 1995). It comprises 105 residues (positions 405-510 in the mouse sequence)
with 86% human/mouse conservation, including the serine/proline rich region. The degree of 
homology with FMR-2 and LAF-4 is 51% and 48% respectively. In LAF-4, it corresponds to 
one of the two strong transcriptional activation domains identified (Ma and Staudt, 1996).
This domain is consistently retained in MLL-AF4 fusion proteins, and has therefore been 
postulated to aberrantly regulate putative MLL target genes. It is comprised in the ALF 
domain recognised by Nilson et al (1997).
The fourth region of homology is a short stretch of about 30 residues (positions 753 
to 780 in the mouse sequence) with 86% similarity between human and mouse. Homology to 
FMR-2 and LAF-4 is 57% and 64%.
Finally, the fifth region of homology, located at the carboxyterminus (and hence 
called CHD for carboxyterminal homology domain), includes amino acids 968-1126, with 
80% human/mouse homology and 48% and 52% similarity with FMR-2 and LAF-4 
respectively.
In all other regions, homology between the different members of the family is below 40%. 
The homology between AF4 and AF5q31 is restricted to the first, third and fifth region, with 
homology values of respectively 62%, 57% and 48% (Taki et al., 1999). Of note, as with 
AF4, in the MLL-AF5 leukemia also the breakpoint is in the third region, upstream of the 
transactivation domain, and the phenotype is remarkably similar to the MLL-AF4 leukemias.
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Up to six putative nuclear localisation signals have been identified in the AF4 
sequence, in good agreement with immunodetection of the protein in the nucleus (see 
below).
V.3 Organisation of the AF4 genomic locus
All the information concerning the genomic organisation of this locus comes from the 
analysis of the human XFV gene, both in normal and in t(4;l I)(q21;q23) leukemic cell lines.
The gene is more than 100 kb long and contains at least 21 exons (Nilson et al., 1997) 
(figure 1). Two alternative exons have been described (exonla and exon lb), based on the 
isolation of distinct cDNAs differing at their 5' ends (Morrissey et al., 1997). For neither 
exon has the transcription start site been defined. The two exons are used respectively by the 
two major AF4 transcripts identified to date, FelA and FelB (from the original name of the 
gene Fel). In addition, a third transcript has also been detected (termed FelC), which 
terminates about 1500 nucleotides into intron 3 due to a cryptic poly adénylation site (Nilson
et al., 1997). Its presence has only been detected by RT-PCR, and the corresponding band 
was not visible by northern hybridisation, possibly indicating the very low efficiency with 
which this transcript is produced. Interestingly, though, similar truncated transcripts, coding 
for only the NHD and the ALF domain, have been reported for other members of the family 
(LAF-4A for LAF-4 and 0X19 for FMR-2) (Chakrabarti et al., 1998; Ma and Staudt, 1996).
The corresponding truncated proteins, which should however be cytoplasmic due to the lack 
of a nuclear localisation signal, remain to be identified before their functional relevance can 
be assessed.
The 5' part of the locus is characterised by the presence of large introns. Thus, exons
la  and lb are at least 19 kb apart, and intron Ib is  also larger than 10 kb. Intron 3 represents
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the greatest portion of the breakpoint cluster region in t(4 ;ll)  leukemias, and has been 
estimated to be approximately 30 kb long. Less frequently, the breakage occurs in intron 4 or
intron 5 (Nilson et al., 1997). All available data indicate that the genomic architecture of 
AF4, FMR2 and LAF4 is the same (Gecz et al., 1997). The similarity is particularly 
intriguing in the case o f FMR2, which also features two very large introns, of about ISOkb, 
at its 5' end (intron 1 and intron 3). The two patients from whom the gene was originally 
isolated actually had a submicroscopic deletion in intron 3, and two other cases of 
developmental delay are known, where the deletion was entirely within this intron (Gecz et
al., 1996). Thus, it is intriguing to envision that this intron (and possibly the whole 5' region
of the gene), both in AF 4  and in FMR2, contains unstable sequences which promote 
chromosomal aberrations, deletions in the case of FMR2 and translocations in the case of 
AF4.
The significance of the AF4 intron phase map (figure 1) for MLL-AF4 translocations 
has been discussed in chapter IV. 1.
V.4 Cell culture studies of AF4 function
The function of AF4 has been explored in cell lines by fusing different portions of 
the protein to the DNA binding domain of the yeast coactivator GAL4, and assessing
transcriptional regulation of a reporter gene (Morrissey et al., 1997; Prasad et al., 1995). This
analysis identified a putative transactivation domain which maps respectively to residues 
480-560 and 365-572 in the two studies, and which is consistently retained in MLL-AF4 
fusion proteins, hence the suggestion that they may contribute to leukemogenesis through
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aberrant regulation of potential MLL target genes. As with MLL, this putative 
transactivation function displays both promoter and cell line dependency.
V.5 Expression pattern of AF4
The expression pattern of AF4 throughout development and in adult life has been 
studied by northern blot analysis, western blot hybridisation and RNA in situ hybridisation. 
Combining the results of several different studies, a picture emerges of widespread 
expression.
These studies have also shown the presence of multiple transcripts and/or protein isoforms, 
resulting from alternative splicing and alternative use of at least the two first exons.
By northern blot hybridisation, human AF4 RNA was detected in heart, kidney, skeletal 
muscle, placenta, pancreas, and a large variety of both hematopoietic and nonhematopoietic 
cell lines. In all cases, two transcripts were detected, of 10.5 and 12 kb.
Two studies in the mouse confirmed the nearly ubiquitous transcription of the gene 
(Baskaran et al., 1997; Isnard et al., 1998). In the adult mouse Af4 RNA was present in all
tissues examined. Thymus, lymphnodes and kidney expressed particularly high levels. 
Weaker signals were detected in spleen, bone marrow, heart, muscle, lung and liver, and the 
transcript levels were still weaker in testis and brain. However, there appears to be some 
discrepancy between the two studies in the relative levels of expression in liver, lung and 
brain, possibly reflecting the different probes used. All organs showed a band of 9.8-10 kb, 
in agreement with the human AF4 size. A shorter band (4.6 kb) was also detected with 
longer exposures in all organs, probably representing an alternatively spliced transcript that 
is less abundant or is present in only a minority of cells in that organ. In addition, the kidney 
displayed unique transcripts.
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These results were supplemented by RNA in situ hybridisation using a 300 bp probe from 
near the 3' end of the open reading frame of Af4, in a region not homologous to either LAF-4
or FMR-2 (Baskaran et al., 1997).
With this probe, Af4 appeared to have a distinct and specific pattern of expression in situ. In 
the heart, myocardium was negative, while the endocardium tested positive. Af4 transcripts 
were abundant in hepatocytes, and rarer in the endothelial lining of the hepatic sinusoids. In 
the kidney, despite the strong northern hybridisation signal, transcripts were only found in 
epithelial cells of the medullary tubules and in cortical arteries. Glomeruli, including 
endothelial cells, were negative. In the pancreas, the gene was expressed in acinar cells, 
whereas both ducts and the Langherans islets were negative. In the gastrointestinal tract, 
both the smooth muscle and the lymphocytes of the lamina propria were positive, while 
epithelial cells were negative. Finally, the spleen, rich in extramedullary hematopoiesis, 
showed abundant Af4 RNA in the myeloid, erythroid and megakaryocytic compartments 
within the red pulp. The white pulp, where mature B lymphocytes accumulate, had less 
RNA. Consistent with this, transcriptional downregulation was observed in the B-cell 
compartment as cells proceeded from the mantle zone to the marginal zone in their 
maturation pathway. This observation has an interesting counterpart in the analysis of Af4 
transcription during thymic development. Starting from E l5.5, the expression of Af4 in the 
developing thymus was assessed by northern blot analysis. On day E l6.5, additional 
transcripts appeared, a longer one (12.kb), presumably corresponding to the one observed in 
other studies, and a 2.5 kb transcript, which has also been detected in some human cell lines. 
Curiously, the longer transcript was no longer detectable in the thymus of adult 6 weeks old 
mice. Cell lines in culture which corresponded to various stages of thymocyte development 
(from CD4-/CD8- to CD4+/CD8+ thymphocytes) were also positive for Af4 RNA.
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In development, a general pattern emerged of transcriptional downregulation o f Af4 during 
early embryonic differentiation. Embryos were analysed from E7.5 to E l7.5. At E7.5, Af4 
RNA is detected across all germ layers, with lower levels in the neurectoderm and 
ectoplacental cone, and high levels in the mesoderm, visceral and parietal endoderm. The 
invading trophoblast is also positive at this stage. RNA levels increase up to day E9.5. Of 
note, Af4 RNA is present in the yolk sac, which contains hematopoietic and endothelial cells 
at this time, as well as in the paraaortic splanchnic mesoderm, from where intraembryonic 
hematopoietic precursors are thought to originate.
At around day E l0.5, transcriptional downregulation starts in some compartments, and is 
followed by further downregulation in other tissues as well, with the exception of the central 
nervous system, where RNA expression is widespread and sustained throughout 
development.
In almost every organ analysed, different cell types thereafter display different patterns of 
RNA expression, suggesting elements of tissue specific regulation. Thus, cardiomyocytes 
strongly express Af4  RNA until day El 1.5, but then stop transcribing it, while the 
endothelial lining of both the heart and great vessels continue to present Af4 RNA. In the 
skin, Af4 RNA is first expressed throughout all layers, then becomes restricted to the basal 
layer. In the gastrointestinal tract, both epithelia, lamina propria and smooth muscle express 
Af4 initially, but eventually only the smooth muscle retains expression. Expression in 
skeletal muscle remains strong throughout development. In the lung, there is progressive 
transcriptional downregulation in the bronchiolar epithelium, and the transcript eventually 
disappears in the epithelia of the airways as well as in the endothelium of pulmonary vessels. 
Cartilage development follows a similar pattern, with high levels of expression in the 
perichondral cells and the chondrocytes of the primordial vertebral bodies, followed by 
marked downregulation in mature chondrocytes.
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V.6 Af4 function in the mouse
The function of Af4 in vivo was recently explored through a knock-out approach in the
mouse (Isnard et ah, 2000). The targeting vector was designed to delete the 3' end of exon 11
and the 5' end of intron 11. Homozygous mutant mice were bom at the expected Mendelian 
frequency, indicating that the deletion was compatible with embryonal survival.
On the whole the phenotype observed was very mild and displayed low penetrance. Among 
homozygous mice on a mixed 129/BALB/c background, 20% were significantly smaller 
than wild type and heterozygous controls. The size retardation abated by 6 weeks of age, 
except when it was particularly severe and eventually led to death of the animal. The growth 
retarded mice also showed a twofold reduction in thymic cellularity. The spleen and the bone 
marrow were less affected. Flow cytometry analysis demonstrated that the deletion most 
likely affected immature CD4+ CD8+ double positive thymocytes undergoing positive 
selection, which were reduced by more than twofold. The levels of CD4 expression were 
halved in a fraction of both single (CD4+/CD8- or CD4-/CD8+) and double positive 
(CD4+/CD8+) cells. In vivo reconstitution of the single and double positive thymocyte 
compartments was assessed after glucocorticoid treatment, which selectively eliminates 
double positive cells by apoptosis. In the affected animals, thymocyte precursors (double 
negative) managed to repopulate the mature single positive cell compartment, though more 
slowly than wt and only reaching half the normal number of cells.
Analysis of the bone marrow revealed a threefold reduction in the size of the B-cell 
compartment, which mainly affected both preB cells (B220+, CD43- or B220+ IgMlow) and 
the more mature bone marrow B cells (B220+, IgMhigh). This suggests that the pre-B-cell 
receptor dependent expansion phase is impaired by this mutation, without a concomitant 
block of differentiation.
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The effects of this Af4 mutation support a potential role in both T and B cell development. 
The low penetrance of the phenotype could be due to the targeting strategy, as partially 
functional proteins could be produced by alternative splicing which skips exon 11. Hence, 
this exon 11 deletion allele is probably a hypomorph rather than a true knock-out. 
Alternatively, if protein function was completely abolished by the exon 11 deletion, the low 
penetrance indicates substantial redundancy in the physiological pathways in which Af4 is 
involved. Combinatorial ablations of the Af4 family members as well, or analysis of an 
unquestionable knock-out, will clarify these issues.
V.7 An AF4 related gene in Drosophila
Very recently, three studies identified a gene in Drosophila which shares some
regions of homology with the AF4 family members (Tang et al., 2001; Wittwer et al., 2001).
The gene, called Lilliputian (Lilli), is implicated in the control of cell size and also in the 
establishment of proper segmentation in the Drosophila embryo.
The predicted open reading frame of Lilliputian codes for a protein of 1673 amino acids. At 
the carboxyterminus, it features the CHD domain shared with members of the AF4 family. 
The degree of identity when compared with different ALF family members varies between 
31 and 37% over a region of 250 residues. Interestingly, the intron/exon boundaries of 
Lilliput in this region are conserved with genes of the AF4 family, pointing to a common 
evolutionary origin for these exons.
Like AF4, FMR2, LAF4 and XFJq21, Lilli has serine and proline rich regions, and the 
serines are concentrated at the same relative position as in the other family members. 
Whereas Lilliput and AF4 share serine stretch and the CHD domain, both the NHD and the 
ALF domain homologies are missing in Lilliputian.
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In addition, Lilli has two nuclear localisation signals, an AT hook domain, and a sequence 
homologous to a portion of a putative transactivation domain from the POU class of 
transcription factors.
Interesting functions have emerged for this gene from mutational analysis. Embryos lacking 
maternal Lilli have cellularization defects and display a pair-rule segmentation phenotype, 
thus establishing Lilli as a maternally active pair-rule gene. This effect probably results from 
its role in regulating expression of a distinct subset of early patterning zygotic genes, which 
include fushi tarazu (ftz), huckebein (hkb) and serendipity alpha (sry a). In contrast to 
zygotic pair-rule genes (which are expressed in seven stripes in the embryo), Lilli is not 
expressed in a segmented fashion, and probably does not function through the major gap 
genes knirps (kni), kruppel (Kr) or giant (gt), since the striped pattern of the primary pair- 
rule genes even-skipped (eve), hairy (h) and runt (run) do not appear to be affected. 
Furthemore, Lilli mutations phenocopy the sry a  phenotype, where disruption of the 
appropriate cytoskeleton rearrangements leads to a defect in cellularization of the embryo. 
The other major conclusion emerging from these studies is the role of Lilli in cell size 
determination. In the photoreceptor cell system, Lilli mutations result in a cell autonomous 
decrease in cell size. Similarly, ablating Lilli function in the eye and in the head by the ey- 
Flp system resulted in flies with reduced eye and head sizes. Two pathways are known to 
regulate cell size in Drosophila, the PI3K/PKB and the Ras/MAPK pathways. The Lilli 
mutant phenotype is similar to that observed for many components of both these pathways, 
but shows some distinctive features. Most notably, while overexpression of any of the 
molecules of these two pathways increases cell size, overexpressing Lilli results in reduced 
cell size, just like loss of function mutations. Moreover, mutations in the PI3K pathway 
result in a concomitant reduction in growth rate and proliferation, which is not observed for 
Lilli, and the Lilli mediated decrease in cell size affects only adult cells. Another hint to the
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complex interaction of Lilli with the PI3K pathway comes from the genetic interaction with 
mutations in PTEN, a homologue of a tumor suppressor gene known to act as a negative 
regulator of the PI3K/PKB pathway; whereas tissues mutant for PTEN display both 
hyperplastic and hypertrophic growth, concomitant loss of Lilli partially restores normal cell 
size. The observation that the two mutations do not completely eliminate each other, though, 
argues that Lilli is not a simple downstream effector of the PTEN pathway, but rather that 
these two molecules might interact in more complex ways to regulate cell size.
In parallel, Lilli also exerts a partially redundant function in the Ras/MAPK pathway, where 
it seems to regulate the efficiency of signal transduction downstream of Raf. Analysis of 
different mutations indicate that the C-terminal domain of Lilli is crucial for its function 
downstream of R a f, but is less critical for its effects on cell size, thus possibly uncoupling 
the two functions. Remarkably, one of the mutants responsible for this "Raf phenotype" has 
a tyrosine to alanine mutation at a position in which the tyrosine is invariably conserved 
among all members of the AF4 family.
Further characterisation of these Lilli mutants also is likely to shed more light on the 
function of the domain shared with AF4. It is intriguing to speculate that two of the major 
pathways regulating cell size and growth could both involve the C-terminal domain of AF4, 
and thus be decisively affected by the MLL-AF4 fusion protein. The essential function of 
Lilli for increased activity of the Ras pathway is in this regard particularly thought- 
provoking. Mutations which constitutively activate Ras are frequent in lymphomas, but 
absent in leukemias with MLL rearrangements implying that the aberrant function of the 
MLL-AF4 protein might partially circumvent the need for constitutive Ras activation 
(Mahgoub et al., 1998). Alternatively, the absence of Ras mutations in MLL leukemias might 
simply be one more example for the known, and poorly understood absence, or infrequency 
of this type of point mutation in leukemias.
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VI
Advanced genome engineering: 
new approaches and techniques
VI. 1 Introductory remarks
The completion of large scale sequencing projects is radically changing the 
conceptual paradigms of molecular biology and medicine. The challenge ahead is to make 
sense of this unprecedented amount of information, a task which is usually referred to as 
functional genomics. This can be broadly shaped into two main areas of development.
On the one side, it is becoming increasingly possible to design strategies where the full 
biological output of a given experimental variable can be assessed at the same time. DNA 
microarrays are the most prominent example, enabling the documentation of entire genomic 
(for example in the case of single nucleotide polymorphisms) or transcriptomic (in the case 
of cDNAs) profiles for a specific set of biological conditions. Protein microarrays promise to 
constitute the next leap forward in this direction.
On the other side, mutational analysis is a prerequisite to explore biological function. It can 
be phenotype or genotype-driven. In the first case, the phenotypic effect of random 
mutations has to be traced back to the affected locus. In the second, prior knowledge of a 
gene is used to introduce desired mutations in order to alter the phenotype. In both cases, the 
newly available sequence information presents new opportunities and challenges for more 
efficient methods to manipulate genomes.
Improvements in our mutational capabilities together with the global dimension of current 
analytical tools are expected to greatly increase our understanding of biological phenomena, 
both in health and disease.
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In terms of genotype-driven mutational analysis in higher organisms, one of the main 
problems is the complexity of the genomes, both in terms of the size of many individual 
genes, and of the long range interactions which have been shown to play a crucial role in 
gene regulation. Indeed, in many cases it may be worth asking what exactly is a gene, when 
some of the regulatory regions which influence its activity may lie very far away and even 
overlap with other loci. Rather than the conventional string-like representation of letters, it 
may be more faithful to visualise such genes as ordered nets connecting a centrum (the 
coding sequence) to its multiple regulatory elements at their various positions.
A prerequisite for mutational analysis, and at the same time a cornerstone of 
molecular biology, is precise methods to engineer and propagate cloned DNA for further 
analysis and/or use. However, the size of many eukaryotic genes constituted a formidable 
challenge, addressed in part by the development of several cloning vectors of large capacity, 
such as bacterial artificial chromosomes (BACs) (Shizuya et al., 1992), PI vectors 
(Sternberg, 1992) and PI artificial chromosomes (PACs) (loannou et al., 1994). These can 
carry sufficient DNA to include, in the majority of cases, whole eukaryotic genes and even 
gene clusters with the full set of regulatory regions. Although this solves the problem of 
cloning and propagation in E. coli, it would be of little use without adequate methods to 
efficiently and precisely manipulate the large DNA inserts. Traditionally, precise assembly 
of DNA molecules relied on restriction enzymes and DNA ligases, which are still in the 
mainstream of recombinant DNA technology. However, these techniques are limited to 
molecules of considerably smaller size, due to the frequent occurrence of cleavage sites. 
Furthermore, the necessity to utilise preexisiting restriction sites substantially narrows the 
range of modifications which can be introduced into a given molecule.
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Polymerase Chain reaction (PGR) has obviated some of these problems and has 
greatly increased cloning flexibility. However, the size limitation and the mutagenicity 
inherent to any PGR approach seriously limit its application, when large portions of DNA 
need to be reliably and precisely manipulated.
A valid alternative to engineer DNA is presented by homologous recombination in 
vivo in E. coli.
VL2 DNA engineering via homologous recombination
In homologous recombination, exchange of DNA occurs through regions which 
share sequence homology to yield a new recombined DNA molecule. It is a precise, faithful 
and specific reaction, which make it an ideal tool for DNA modification. This “technological 
power” has been long recognised, and two pivotal applications have been the introduction of 
desired foreign sequences at predetermined sites in the yeast and the mouse genome (Orr- 
Weaver and Szostak, 1983; Shashikant et al., 1998; Thomas and Gapecchi, 1986; Thomas 
and Gapecchi, 1987). The striking difference in the length of homology required in these two 
organisms for useful frequencies of homologous recombination (50 nucleotides versus more 
than 1 kb) points to the diversity of the pathways involved.
In the last few years, exploitation of homologous recombination in E. coli has 
advanced so that now the modification of any DNA molecule is possible. For cloning 
vectors like BAGs, P is and PAG this has meant a revolution in the ability to manipulate 
their large inserts in a precise, fast and predictable manner.
In any system (even yeast), homologous recombination is intrinsically a relatively 
rare event, which therefore requires an appropriate selection strategy to identify successful 
recombinants. The incorporation of a selectable marker (most commonly a drug resistance
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gene) in the targeted DNA, however, is sometimes problematic. In order to remove it, 
several approaches can be considered:
1) The selectable marker can be flanked by recognition sites for site specific 
recombinases (SSRTs), so that, upon expression of the relevant site specific 
recombinase either in E. coli or in the final host of the construct, the intervening 
marker can be deleted. This is a commonly used procedure, and recently, the 
repertoire of recombinases available (traditionally Cre and Flp) has been augmented 
by the addition of Tnpl (see chapter X.2.5) A potential drawback of this approach is 
that it leaves behind one 34 bp SSRT, which might be a problem if for example the 
coding region of a gene is being targeted.
2) The selectable marker can be flanked by restriction sites, so that it can be 
conveniently excised fi'om the recombined molecule with the appropriate restriction 
enzyme. This strategy also leaves behind an obligatory stretch of sequence (though 
normally shorter and more flexible than a SSRT). As it relies on restriction enzyme 
digestion, it can only be applied to relatively small molecules.
3) A two step homologous recombination strategy can be implemented. In the first 
round, both a selectable marker as well as a counterselectable marker are targeted to 
the desired position of a DNA molecule. Selection of the first-round recombinants 
relies on the selectable marker. In the second round, both markers are eliminated by 
homologous recombination with a new linear DNA molecule which only carries the 
appropriate segments of homology. Selection of the second-round recombinants 
relies on the counterselectable marker. This is the cleanest strategy, as it yields a 
seamless product modified only in the intended way. However, the efficiency of the 
second round is much lower, since any mutation which ablates function of the 
counterselectable marker will score as positive.
122
Two methods for recombinogenic engineering in E. coli will be described, one based 
on recA and the other on ET recombination.
VI.2.1 RecA mediated homologous recombination
In E.coli, the major homologous recombination pathway involves the RecA protein 
(a strand invasion protein) and the RecBCD complex, which is the major cellular 
exonuclease amongst other activities pertinent to recombination. Despite the preeminence of 
E. coli as both a model organism and the cloning host of choice, homologous recombination 
has proven to be a difficult process to harness for DNA engineering. This is partly due to the 
fact that RecBCD plays a major role in distinguishing self DNA from foreign through 
recognition of an 8 nucleotide sequence, called Chi (%), from double strand breaks. DNA 
without chi sequences is destroyed at the amazing rate of 1000 nucleotides/second. 
Consequently, it is not possible to introduce foreign DNA in linear form. However, double 
strand breaks greatly promote the initiation, and hence efficiency, of homologous 
recombination. There have been three solutions to this conundrum.
First, linear DNA is not employed (Hamilton et al., 1989; Yang et al., 1997). Rather,
for every DNA engineering exercise, a dedicated targeting plasmid must be assembled which
contains: the recA protein (to complement the usual absence of recA in cloning hosts);
extensive regions of homology to the target molecule (usually around 1 kb); a selectable as
well as a counterselectable marker; and finally a temperature sensitive (ts) origin of
replication. In the first round of homologous recombination, carried out at a non permissive
temperature for the plasmid origin, this whole plasmid is integrated into the target DNA
molecule through the regions of homology. Selection of the recombinants relies on the
selectable marker. The result is a cointegrate, which can be resolved by shifting to the
permissive temperature. Under these conditions, resolution can occur through either one of
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the regions of homology, resulting respectively in either the original, unrecombined or the 
intended recombined target molecule. Selection for this second step relies on loss of the 
counterselectable marker. This method has been successfully applied to the modifications of
both regular plasmids, large vectors (BACs) (Yang et al., 1997) as well as to the E.coli
chromosome (Hamilton et al., 1989). However, it requires the presence of large regions of 
homology, and hence the construction of a dedicated plasmid in a difficult, temperature 
sensitive backbone for each engineering step. This is obviously a great disadvantage if one 
wants to subject the same molecule (for example a BAC) to multiple rounds of 
modifications.
Second, Smith and coworkers reasoned that inclusion of chi sites next to double 
strand breaks would permit the use of linear, foreign DNA (lessen et al., 1998). This strategy 
works but not with the anticipated efficiencies and the published reports indicate difficulties. 
Furthermore, this method, like all recA approaches, needs homology regions greater than 
500 bp to accomplish workable efficiencies.
Third, Messerle found that the sbcBC host, which is recA+, recBCD-, did permit use 
of linear, foreign DNA. Since the sbcBC mutation activates the recA-dependent RecF 
pathway, this approach also requires long homology regions (Messerle et al., 1997).
Overall, all recA approaches also appear to deliver low ratios of homologous to non- 
homologous recombination. This may be due to the other activities of recA which include 
DNA repair and non-homologous end joining.
VI.2.2 ET mediated recombination
The alternative to recA based methods is ET recombination (Zhang et al., 1998a). 
Homologous recombination is initiated by either one of two protein pairs: RecE/RecT from
124
the Rac phage (after which the system is named), and Reda/RedP from the X phage 
(Muyrers et ah, 1999; Zhang et ah, 1998a). These two pairs have been shown to be 
functionally equivalent; RecE and Reda are 5’-3’ exonucleases, while RecT and Red|3 are 
DNA annealing proteins (Kolodner et ah, 1994; Muyrers et ah, 2000b). They not only serve 
to circumvent RecA, but also RecBCD. Consequently, E. coli hosts that are recBCD- can be 
used. Alternatively, RecBCD can be inhibited by expression of the X phage Redy protein. In 
fact, an unexpected outcome of the work that started with the discovery of ET 
recombination, is that this mechanism is the purpose of X's operon (ocpy). Since RecBCD is 
removed, use of linearised DNA is possible.
In the fundamental reaction, a linear DNA molecule carrying a selectable marker 
flanked by regions of sequence identity is integrated at the desired location into a circular 
DNA molecule. The most important difference with the RecA method is that ET 
recombination requires only very short stretches of homology (in the range of 40-60 
nucleotides), which can be easily incorporated into oligonucleotides. Indeed, ET 
recombination appears similar to homologous recombination in S. cerevisiae in several 
ways, with perhaps the most useful being the high ratio of homologous to non-homologous 
recombination. In the simplest case, the recombinogenic, linear DNA molecule can be 
generated by a PCR reaction to amplify the desired selectable marker with oligonucleotides 
consisting of two parts: a 3’ PCR primer and a 5’ part consisting of the 40-60 nucleotides of 
sequence identity with the chosen site in the target molecule. No dedicated plasmid need be 
assembled, rendering the whole engineering exercise much more fluid.
ET recombination has been successfully applied to regular plasmids, large cloning 
vectors (like BACs) and the E. coli chromosome. It shows consistently high efficiencies in 
all these applications. Usually more than 80% of recombination events are homologous.
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A remarkable development of this methodology has recently been its application to direct
cloning and subcloning (Zhang et ah, 2000). In this set up, the linear, recombinogenic DNA
molecule is a PCR generated plasmid backbone, carrying a selectable marker and an 
appropriate origin of replication. As for any ET experiment, the PCR oligos include regions 
of sequence identity which precisely delimit the boundaries of the DNA molecule to be 
cloned or subcloned. Upon homologous recombination, the desired portion of the target 
DNA molecule is faithfully copied into the plasmid backbone. This method has been applied 
to subclone desired segments from regular plasmids, BACs and even the E. coli 
chromosome. It presents several interesting uses. First, in a variety of cloning exercises, it 
can conveniently transfer a desired DNA region from large cloning vectors to higher copy, 
easier to handle cloning vectors. Second, it can be combined with conventional cloning 
methodologies, by inserting appropriate restriction sites in the homology arms, which will 
now flank the selected segment for subsequent cloning steps. Specifically, the subcloning 
from a BAC of the whole third intron of the mouse Af4  gene presented in this thesis 
pioneered the use of this technology and demonstrated that it can be used to precisely 
subclone very large DNA segments (28 kb in this case). This presents two chief adavantages 
over PCR (which has been used to achieve similar goals), namely the wider size range over 
which it can be applied, and the very high fidelity of the reaction. In fact, recombination 
occurs in vivo in E. coli, and is therefore subjected to the physiological proof-reading 
properties of E. coli DNA replication machinery, limiting drastically the occurrence of 
mutations.
Remarkably, the same principle has been successfully applied to the direct cloning of a
desired DNA molecule from a complex mixture such as genomic DNA preparations from
E.Coli, yeast and mouse. The frequencies at which the correct products were obtained in
these three cases were respectively 100%, 33% and 17%, broadly relating to the increased
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complexity of the starting population of DNA fragments. In this set up, ET recombination is 
conceptually analogous to PCR, in that it enables the amplification of a desired DNA region 
from a complex mixture. Optimizations in several reaction parameters are likely to further 
increase the efficiency, unfolding new possibilities to directly clone pieces of the genome 
without the need of library screening. The availability of complete genome sequences will 
soon eliminate the problem posed by the requirement for prior knowledge of the sequences 
flanking the target region.
In this thesis, three basic ET cloning variations are presented to assemble complex, 
versatile targeting constructs and BAC transgenes to be used in mouse functional genomics. 
They are schematised in figure 3.
Panel A shows the basic ET reaction in which a PCR product is inserted at a desired 
location in the target molecule. Importantly, this strategy works independent of the distance 
intervening between the homologous regions on the target molecule. This means that it can 
be used either to insert a foreign sequence between adjacent nucleotides, or, at the other 
extreme, to delete very large portions of intervening, undesired sequence; in this last case, 
the PCR product replaces the selected region resulting in a net loss of genetic material. This 
strategy was applied to the characterisation of the MU BAC (see chapter VII) and to the 
assembly of the final BAC based MU targeting construct.
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Figure 3 Schematic illustration of the three main variations of the ET recombination 
technology applied to the generation of the targeting constructs described in this thesis 
Panel A illustrates the most basic setting, in which a PCR product carrying arms o f 
homology is precisely integrated at the desired location in the target molecule.
Panel B depicts the use o f the same methodology to precisely subclone a 
fragment o f interest from a donor plasmid (or a BAC) into a more convenient acceptor 
vector. The acceptor vector is amplified by PCR including the appropriate arms o f 
homology, in analogy to the strategy depicted in panel A.
Panel C illustrates a variation o f the strategy o f panel A, in which the homology arms 
are not incorporated via PCR, but rather cloned by conventional methods into a pre­
existing targeting cassette, to yield the final linear DNA molecule used in the ET reaction. 
This strategy avoids the problem o f mutations generated during the PCR reaction.
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In panel B, the basic aspects of ET subcloning are depicted. This technique was 
instrumental to the characterisation of the mouse Af4 BCR through subcloning intron 3 from 
a BAC, and subsequent subcloning from the BAC the chosen portion of the Af4 gene for the 
Af4 targeting construct.
Panel C shows a variation of the basic ET cloning strategy depicted in figure 3a, 
which circumvents the mutational risk inherent to PCR amplification (Angrand et al., 1999). 
This is an important consideration when, most typically in the assembly of mouse targeting 
constructs, several functional elements (selectable markers, protein tags, reporter genes, 
splice acceptor and 1RES elements) need to be incorporated in the linear DNA molecule. 
While deleterious mutations for some of these (double selectable markers for use in both E. 
coli and eukaryotic systems) can be easily identified, for most the functional test would have 
to await the mammalian experiment, and this constitutes an unacceptable risk. Therefore, to 
avoid PCR, the desired targeting cassette is first assembled in a regular plasmid through 
conventional and/or ET cloning, and suitable restriction sites are placed at both of its ends. 
Homology arms for ET recombination are then cloned by conventional ligation at the two 
sides of the cassette, which thus does not undergo any round of PCR. Prior to the ET 
reaction, the recombinogenic DNA fragment is excised from the plasmid by restriction 
digest. This necessarily results in the presence of non homologous sequence at the ends, 
minimally the restriction sites. However, this does not interfere with the method, since, as 
expected, homologous recombination eliminates these spurious overhangs upon integration 
into the target loci. This strategy was applied to generate all selectable marker cassettes 
described in this thesis, which were then targeted by ET recombination to the three BACs 
encoding respectively the Af4, Mil and Ikaros gene.
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RESULTS AND DISCUSSION 
VII
The objective of this thesis
The objective of this thesis was to develop and apply novel genome engineering 
strategies for the assembly of complex targeting vectors to model in the mouse the acute 
leukemia associated with the t(4;ll)(q21;23) translocation. The chosen approach based on 
the Cre-loxP technology (Figure 4) requires that the two genes have the same centromere- 
telomere orientation, otherwise, upon Cre recombination, an acentric and a dicentric 
chromosome would be generated and impair cellular viability. The still very limited amount 
of sequence information available for the mouse genome (1.3% of the whole genome as 
finished sequence and 10.3% as draft sequence) does not allow yet to determine the 
orientation of the MU and Af4 genes in the mouse with bioinformatics tools. I relied on the 
following genetic mapping data to conclude that the likelihood that the two genes had the 
same orientation was sound enough to warrant a Cre-loxP based approach.
The MU gene was mapped to mouse chromosome 9 by interspecific backcross 
analysis (Ma et al., 1993) at 26.0 centimorgan (cM) from the centromere, tightly linked to 
the Cd3d locus (< 2.9 cM apart). This was in agreement with the human location, as a probe 
for the human homologue of Cd3 was originally used to identify by positional cloning the 
human MLL gene (Cimino et al., 1991; Cimino et al., 1992; Ziemin-van der Poel et al., 
1991). The Af4  gene was mapped to the central region of mouse chromosome 5 by 
interspecific backcross analysis, at 56 cM from the centromere in a region of conserved 
sinteny with the human 4q21 region (Baskaran et al., 1997). It is linked to the Albl, fgfS and 
Adrbk2 loci, and based on the backcross results, the most likely gene order is: centromere-
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Alb 1-FgfS-4/4-Adrbk2. Location of a gene in a conserved region of sinteny between 
genomes is in itself not a guarantee that the genes have maintained the same order. 
Comparison of the human genome with the genome of the pufferfish Fugu rubripes has in 
fact revealed that whereas some regions of conserved sinteny display a striking conservation 
of gene order(Miles et al., 1998), others do not(Gilley and Fried, 1999). However, the 
overall evidence from the backcross analyses reported argues that both genes have the same 
centromere-telomere orientation. Importantly, this assumption has been strengthened in the 
case of MU by the study reporting the Cre induced Mll-Af9 translocation (Collins et al.,
2000), which constituted an indirect evidence that the two genes, both of which had been
mapped to regions of conserved mouse/human sinteny, had maintained the same orientation
in the mouse.
Complex alleles were then generated for the MU and Af4 genes, which allow them to 
be used for Cre-driven interchromosomal translocation, as well as to study the function of 
these genes in the mouse. In order to drive the Mll-Af4 interchromosomal translocation, a 
transgenic mouse line was established in which Cre is expressed under the control of the 
Ikaros gene. The strategy employed should allow both regulated as well as constitutive Cre 
activity.
The following sections describe the results obtained for each line (4/4, MU and 
Ikaros-CxQ), and discuss the experimental strategies adopted and their perspectives for 
advanced genome engineering.
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Figure 4 Diagram of the Cre-loxP approach to model the t(4;ll)(q21;q23) leukemia 
in the mouse.
At least three mouse lines need to be established, two harbouring a loxP site in the relevant intron 
o f the Af4 and MU genes respectively, and the third driving the expression o f Cre recombinase. 
Various Cre-expressing mouse lines can be used, to assess the time and/or tissue dependence o f  the 
oncogenic activity o f the fusion protein. LoxP sites are indicated by black arrowheads. The Af4 and 
MU genes are depicted respectively in green and yellow.
Af4-\oxP m o u se  line
X
MllAoxP m o u se  line
% :io x p }
Cre de le te r m o u se  line
0
Mll-Af4 tran sloca tion
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VIII
Engineering of a multifunctional Af4 mouse line 
VIII. 1 Overview of the strategy
The Af4 targeting construct was engineered from a bacterial artificial chromosome 
(BAC). BACs offer many advantages for performing complex DNA engineering exercises, 
the two main ones being the large size of the cloned insert (up to 150kb) and the 
convenience of handling BACs compared with other large cloning vectors like yeast 
artificial chromosomes (YACs). In the case of the Af4 gene, it was known that human AF4 is 
a long gene (about lOOkb), and that the breakpoint cluster region involved in the 
t(4;ll)(q21;q23) translocation has been mapped in the majority of cases to the third intron, 
which in humans has an estimated size of 30 kb (Nilson et ah, 1997). It was therefore 
desirable to obtain as large a clone of the murine homolog as possible, which would span at 
least the whole of intron 3, in order to characterise the appropriate region for the mouse 
targeting experiment.
In assembling the targeting construct for A f4 ,\  aimed at a versatile, multifunctional 
cassette, which could provide multiple entry points to analyse the function of this gene.
The primary goal was to introduce a loxP site into the third intron of the Af4 gene for 
Cre-mediated interchromosomal translocation in the mouse. This single step could in 
principle be achieved by targeting the relevant region of this intron with a relatively simple 
cassette, featuring a selectable marker, most commonly the neomycin resistance gene, 
flanked by two loxP sites. Upon Cre recombination either in ES cells or directly in the 
mouse, the selectable marker would be deleted, leaving behind one single loxP site in the 
chosen site of intron 3. However, this targeting strategy would only enable the study o f Af4 
function as an MU partner in MLL-AF4 associated leukemias. In spite of the fact that the
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MLL-AF4 translocation is the most frequent MLL associated translocation, very little is 
known about the function of AF4 per se. The homology between AF4, LAF-4 and FMR2 (see 
chapter IV) has identified a potentially new family of genes, but other than the conserved 
domains shared by all three members, no regions of similarity to other known proteins have 
been found. The observation that MLL-A/4 leukemias almost invariably have an early 
lymphoid, most often Pre-B phenotype suggests a function for A f4 'm  lymphopoiesis. 
According to the prevailing hypothesis the AF4 moieties present in the MLL-Af4 fusion 
protein direct a cell in which the translocation has occurred towards lymphoid 
differentiation.
Thus, it appeared useful to combine the requirements of placing a loxP site in the
third intron of the gene with a multi-purpose knock-out strategy. Towards this end, the
targeting cassette included a fusion of the lacZ to the neomycin resistance gene ((3Geok),
behind a splice-acceptor site and an internal ribosomal entry site (1RES) element, followed
by the strong SV40 late polyadenylation signal. The pOeok cassette used was based on the
pGeo construct published by Smith and coworkers (Mountford et al., 1994). PGeo
comprised intronic sequences and a splice acceptor site from engrailed 2 (en-2) and the
encephalomyocarditis virus (EMCV) internal ribosomal entry site (1RES) fused to a lacZ-
neomycin resistance fusion gene. Previous work in the Stewart lab altered the pGeo cassette
to create pGeok, by (i) changing the 50 aa. linker region between the end of lacZ and start of
neo to include, whilst keeping the open reading frame, an E. coli promoter and ribosome
binding site (rbs). The purpose of this change was to permit expression of the neomycin
resistance gene in E. coli so that the pGeok cassette would deliver kanamycin resistance.
Consequently, integration of the cassette by ET recombination could be selected by
kanamycin resistance in E. coli and then used for G418 selection in ES cells, (ii) The
polyadenylation signal of PGeo was replaced with that of SV40 late. The SV40 late
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polyadenylation region, comprising more than 200 bp, is probably the strongest 
polyadenylation element described. Earlier work in the Stewart lab confirmed that it is the 
most reliable polyadenylation element for complete processing of the nascent transcript in 
many contexts. Hence, SV40 late polyadenylation can be inserted at the 5' end of a gene to 
create a knock-out allele through RNA processing without the need to delete segments of the 
gene in question. In different experimental settings, the PGeok cassette has proven efficient 
in yielding ES cell and mouse lines. PGeok simultaneously achieves, in one targeting event, 
monitoring of the expression pattern of the gene being studied through pgalactosidase 
activity and a gene knock-out. For the Af4 translocation allele, the PGeok cassette was 
flanked by loxP sites. A further modification of the loxP-pGeok-loxP cassette was made for 
the following reason. The pGeok cassette can only be used for homologous recombination in 
active genes in ES cells because selection for neomycin resistance relies on an 1RES. 
Consequently, I examined Af4 expression in ES by RT-PCR and Northerns. Although Af4 
mRNA was detected in ES cells by RT-PCR, Northern analysis failed to detect any ES cell 
Af4 transcript. Therefore, a hygromycin resistance gene, expressed from the SV40 promoter 
was included between the SV40 late polyadenylation region and the 3' loxP site, so that 
targeting into the potentially inactive Af4 gene in ES cells could be selected by hygromycin 
resistance. Ironically, I subsequently found that this precaution was unnecessary, since the 
Af4  gene in ES cells expresses sufficient mRNA for neomycin selection from the 
homologously integrated pGeok cassette.
After subcloning and sequence characterisation of the Af4 BCR (see next section), a 
target site for homologous recombination in intron 3 was chosen. Since the loxP-PGeok- 
SV40hygro-loxP cassette was too large to be reliably amplified by PCR, the short homology 
arms for ET recombination with A f4 intron 3 subclone were added by conventional
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ligation of Af4 intron 3 PCR products at either side of the loxP sites (strategy depicted in 
figure 3, panel c).
A mouse line carrying the loxP-pGeok-SV40hygro-loxP cassette inserted into the 
Af4 gene will incorporate four functions (figure 5)
1) Prior to Cre recombination, the sA-IRES-pGeok-pA cassette permits convenient display 
of the transcription of the gene by staining for P-galactosidase activity.
2) Prior to Cre recombination, the sA-IRES-pCeok-pA cassette can result in partial or total 
ablation of protein function through complete polyadenylation of the nascent transcript.
3) Following Cre recombination, the Af4 allele will be but the loxP in intron 3 can be 
used for interchromosomal translocation with the M/-loxP allele.
4) The loxP-flanked sA-IRES-PGeok-pA cassette is amenable to lineage specific gene repair 
strategies using mouse lines expressing Cre recombinase in a tissue specific fashion.
The experimental steps involved in generating this targeting construct are 
summarised below:
1. Isolation of a mouse Af4 BAC.
2. Characterisation of the relevant regions of the BAC through:
2.1 Restriction mapping Southern hybridisation
2.2 Direct BAC sequencing
3. Assembly of the Af4 ES targeting construct by ET recombination:
3.1 Assembly of the ET targeting cassette bw-sA-IRES-PGeok-pA-hygro-SV40-aw
3.1.1. Generation of PUX4-sA-IRES-PGeok-pA-hygro-SV40, a universal 
knock-in targeting vector which is independent of the expression of the target 
gene in mouse ES cells.
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3.1.2. Assembly of the final Af4 ES targeting vector PUX4-bw-sA- IRES- 
PGeok-pA-hygro-SV40-aw
3.2 Subcloning of the targeting backbone from the Af4 BAC (4/^sub)
3.3 Insertion of selectable marker cassette bw-sA-IRES-pGeok-pA-hygro-SV40-aw 
into the desired region of the targeting backbone from the Af4 BAC (4/^sub).
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Figure 5 Potentials of the Af4 recombinant allele
The targeting eonstruct for the Af4 gene ineorporates four functions.
Prior to Cre recombination, it can report expression o f the gene through X-gal 
staining, and can potentially result in a loss-Ot-function phenotype, which 
would be amenable to conditional gene repair strategies.
Following Cre recombination, it results in a translocation prone allele.
Azure arrows indicate flanking genomic sequences.
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VIII.2 Assembly of the Af4 targeting construct
VIII.2.1 Isolation of the mouse A // genomic clone from a high density BAC library
High density mouse BAC filters (Research Genetics, Inc.) were screened with a 
probe specific for the mouse Af4 gene. The probe was a 600 bp fragment of exon 3 derived 
by PCR from mouse genomic DNA. The sequence of exon 3 for primer design was derived 
from the Genebank entry of mouse Af4. Primer 4/^ex3F has the following 5-3' sequence: 
CTTTATCGATTGGGTGACTATGAGGAGATGAA.
Primer 4/^ex3R has the following 5'-3' sequence: 
TATCTCTAGAAGGGGAGAGGAGGGGGTGGAAA.
Hybridisation of this probe (Af4ex3) to the high density BAC filters yielded two independent 
positive signals (Figure 6). Both clones, n.l89o7 and 183cl4, were screened by PCR and 
Southern hybridisation and found to contain the third exon of the mouse Af4 gene (Figure 7) 
The correct identity of both 4 /^  BAC clones was further determined by directly sequencing 
the two BACs with a primer annealing to exon 3 and reading in the direction of intron 3. 
After confirmation of the correct identity of the two BACs, one BAC (n.l89o4) was chosen 
for further characterisation.
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Figure 6 Isolation of the Af4 BAC from a high density BAC library
Hybridisation of high density mouse BAC filters with an A ft probe (ex3) spanning approximately 
600 bp in exon 3. Each BAC clone is spotted twice to distinguish true signals (a double spot) from 
possible false positives. The filter was simultaneously hybridised with a control probe which 
highlights the reference marks on the four sides of the membrane to unequivocally identify the 
clone of interest.
Positive signals are circled in red.
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Figure 7 Mouse Af4 genomic and BAC blot
Southern blot hybridisation of genomic DNA and BAC DNA with the 
A ft exon 3 probe to verify the correct identity of the BAC 189o7 isolated 
from the screening of the mouse BAC library.
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VIII.2.2 Restriction mapping and Southern hybridisation
Two probes were used to generate a restriction map of the region of the Af4 BAC 
spanning intron 1 through intron3. The first probe was the same Af4ox3 probe used to isolate 
the BAC clone (see above). The second probe (g51) spanned 624 residues of intron 3, 2349 
bp from the end of exon 3. The sequence information necessary to amplify this probe by 
PCR was derived from the sequencing strategy outlined in the next section.
DNA from BAC 189o7 was digested with a battery of restriction enzymes. Single restriction 
results were complemented by double restriction digests with Nhel as a reference enzyme. 
Figure 8 shows the Southern hybridisation results from a representative set of digests. These 
data were then assembled in a restriction map of this region of the BAC (figure 9)
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Figure 8 Southern hybridisation restriction mapping of the Af4 BAC
Representative single (A) and double (B) digests of the Af4 BAC 189o7 used 
to map the region corresponding to the breakpoint cluster region (BCR) in human 
leukemias. This was instrumental to develop an appropriate strategy to target the 
loxP flanked pOeok cassette, and to screen for homologous recombinants in mouse 
ES cells. The figure represents two blots hybridised with the ex3 probe, which 
spans about 600 bp in the third exon of the Aft gene.
The size of the marker bands is expressed in Kb.
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VIII.2.3 Sequencing the region of Af4 covering the intron 1 through intron 3 interval. 
VIII.2.3.1 Direct BAC sequencing
Direct sequencing was performed on the Af4  BAC around exon 2 and 3 by the 
EMBL sequencing facility, yielding complete sequence from intron 1 well into intron 3. This 
information was needed for two reasons: to complement the restriction map required for the 
design of an adequate Southern strategy to screen ES cells for homologous recombination 
and to place the loxP flanked selectable marker cassette sA-IRES-PGeok-pA-hygro-SV40 
into intron 3.
The following regions were sequenced:
1) 3526 residues upstream of exon 2.
2) The complete sequence of intron 2, encompassing 409 bp.
3) 1145 residues downstream of exon 3. At this site, a region was encountered which proved 
resistant to any sequencing attempt, because of an extremely high GC content. The only 
sequencing option would have involved “walking” with sequencing primers from the other 
side (ie. exon 4), but the inferred length of AF4 intron 3 in humans (approximately 30 kb) 
suggested that such an approach would be practically not feasible. This problem highlights 
two main features of contemporary genomic engineering in higher organisms.
First, despite remarkable progress, the mouse genomic sequence is currently 
unavailable for easy and direct use in genetic engineering. Furthermore, although DNA 
sequencing has become a straightforward and high-throughput technique, this example 
shows that some regions of the genome can be a remarkable hurdle, even with the use of 
advanced sequencing methods.
Second, current approaches to genome manipulation in higher organisms are 
progressively moving from traditional cDNA transgenesis techniques (whereby usually 
simple cDNAs are integrated in the genome randomly), to more precise alterations in the
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endogenous locus of a particular gene, which often require working with large inserts of 
genomic DNA. Hence, large cloning vectors (like BACs) are becoming the tool of choice for 
higher genomic manipulation. Precise changes in such large genomic fragments require 
substantial sequence information, and the case of intron 3 of Af4 was a typical example of a 
situation in which sequence information was required and not available for a region whose 
distance from the closest anchor point of known sequence (more than 25 kb to the beginning 
of exon 4) made any attempt at sequencing by a “primer-walking” method unrealistic.
A variety of approaches can address this kind of problem, including long-range PCR 
and random subcloning of the BAC with subsequent identification of the positive colonies 
harbouring the region of interest. Long-range PCR was repeatedly tried in this case without 
success, indicating that the length and/or the GC content of this locus were beyond the 
current limits of the technique. I therefore decided to apply a variation of the ET cloning 
methodology to subclone in one step almost the whole intron 3 from the BAC into a high- 
copy plasmid . Having this whole region cloned in a conventional plasmid was expected to 
facilitate direct sequencing and random subcloning of the relevant region. This experiment 
also established, as a proof of principle, the applicability of ET subcloning to large regions 
of BACs, which offers obvious advantages in many analogous experimental settings.
VIII.2.3.2 ET recombination can be successfully used to directly subclone large 
fragments of BACs: applieation to the third intron of the A //  gene.
Oligos Af4di and 4 /%  were designed, each containing two regions. The 5’ region was 
identical to the sequence in the BAC immediately flanking the region to be subcloned, and 
thereby mediated homologous recombination in E. coli upon expression of the relevant 
recombinogenic proteins. The 3’ end was a stretch of 40 nucleotides annealing to the 
plasmid amplified by PCR in whose backbone the target region would be subcloned. EcoRI
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and BamHI sites were included in the oligos between the 5’ and the 3’ ends to facilitate 
subsequent cloning steps.
Oligo Af4h has the following 5-3' sequence:
TCTCAAAGCTTTGCTGACCATAGTCCTCCAGTGGCAGCTTCAGCTCGGGGG
ACTCACTGGGAACCTGATCCTGACCGTCCATGGGACGGACATATGCCGTGG
ACTTCGG^rCCTTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTA 
Residues 1 through 107 (in bold) constitute the arm of homology to the Af4 BAC (positions 
684-790 m Af4  exon3). A BamHI site (in italics) was inserted at positions 108-113. Residues 
114-153 (underlined) constitute the portion of the oligo which anneals to the PCR template 
pACYC177 at the 3' end of the kanamycin resistance gene.
Oligo Af4di has the 5'-3' sequence:
AGCTGAGCCCAGGGGCAAGGCTGCTTTGTACCAGCCTGCTGTCTGCGGGG
GCATCACCTGATGTGGCACTTGCTGTGTGTACAAGGGCTCGCGAGTGACAC
AG G T^rrCTTAATAAGATGATCTTCTTGAGATCGTTTTGGTCTGCGCG 
Residues 1 through 103 (in bold) constitute the arm of homology to the third intron of Af4 
1105 bp upstream of the start of exon 4. An EcoRI site (in italics) was inserted at positions 
111-116. Residues 117-156 (underlined) constitute the portion of the oligo which anneals to 
the PCR template pACYC177 5' of the replication origin.
As diagramatically shown in figure 10a, the resulting PCR product (4/^intronsub) features at 
its ends the two regions of homology to the Af4 BAC (donor DNA molecule).
HS996 E. coli cells harbouring the Af4 BAC 189o7 were made competent for heat shock 
transformation by the Rubidium Chloride method (see Materials and Methods), and were 
then transformed with the recombinogenic plasmid pBAD-otPy-Amp, which expresses the 
recombinogenic proteins Reda and Redp under the control of an arabinose-inducible 
promoter. From correct transformants, electrocompetent cells were prepared (see Materials
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and Methods) and electroporated with the PCR product 4/^intronsub, and incubated on 
kanamycin (25 pg/ml) containing plates. About 160 colonies/plate were observed and 15 of 
18 analysed showed an identical EcoRI digestion pattern (figure 10b), consistent with 
subcloning of a region spanning at least 24 kb (as estimated by electrophoresis).
The correct identity of recombinant clones was confirmed by Southern hybridisation with an 
oligonucleotide probe spanning 113 bp of sequence located 1144 downstream of the end of 
exon 3. All candidate colonies displayed the correct hybridisation band, demonstrating that 
they all contained the desired insert from 4/^  intron 3 (Figure 10b).
5 of the EcoRI restriction fragments were then subcloned in pBluescript vector and 
completely sequenced. This assembled a sequence region from the third intron spanning 
10097 residues downstream of exon 3. Importantly, this approach readily yielded sequence 
from the region that had proved resistant to all previous sequencing attempts, probably due 
to the presence of a stretch of 19 Cs.
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Figure 10 ET mediated subcloning of the third intron of Af4
A. Schematic representation of the ET mediated subcloning of the third intron of Af4. pBADocpy 
expresses the recombinogenic proteins Reda Redp from an Arabinose inducible promoter. The 
third intron of Af4 was subcloned into a pl5A origin plasmid carrying the kanamycin resistance gene. 
Green blocks represent the arms of homology.
B. 9 independent colonies showed the same restriction pattern, compatible with the length of the 
subcloned intron as inferred from the human gene. Correct identity of each subclone was confirmed 
by southern hybridisation with an intron 3 probe.
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VIII.2.4 Assembly of the targeting cassette bw-sA-IRES-pGeok-pA-hygro-SV40-aw 
VIII.2.4.1 Generation of a universal knock-in targeting vector which is independent of 
the expression of the target gene in mouse ES cells.
As described above (section VIII. 1) I was uncertain about the expression status of 
Af4 in mouse ES cells. Hence the pOeok cassette was potentially unsuitable since its ability 
to deliver G418 resistance relies on placement within an actively transcribed gene. 
Therefore, I modified this cassette to add the hygromycin phosphotransferase gene, carrying 
its own promoter (cloned opposite to the direction of transcription of the gene, in order to 
minimize the risk of possible promoter interference) downstream of the sA-IRES-pOeok-pA 
component. An outline of the cloning strategy used in the assembly of this cassette is 
depicted in figures 11 and 12.
To facilitate the introduction of the SV40-hygro cassette into pOeok, I combined an ET
cloning based approach with traditional cloning techniques. The SV40-hygro cassette was
first subcloned into a recipient plasmid using ET subcloning. Flanking restriction sites,
chosen for simplicity of subcloning into pOeok, were included at this step. The SV40-hygro
cassette was then subcloned into sA-IRES-pGeok-pA by traditional methodology.
Figure 11 shows the commercially available plasmid pcDNAS. 1 -hygro, which served as the
donor plasmid for the hygromycin phosphotransferase gene. The hygromycin
phosphotransferase gene is located under the control of the SV40 promoter. The recipient
plasmid was pACYC184, also shown in figure 11, carrying the chloramphenicol resistance
gene. To subclone the hygromycin phosphotransferase gene from pcDNA3.1-hygro into
pACYC184, a PGR reaction was performed with oligos ShygroFl and ShygroR, each of
which, as in any ET cloning experiment, is composed of two parts, one annealing to the
template (in this case pACYC184), the other consisting of around 50 nucleotides of
homology to the donor plasmid (in this case pcDNA3.1-hygro ) immediately flanking the
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target region to be subcloned (in this case the hygromycin phosphotransferase gene). Oligo 
ShygroFl has the 5'-3' sequence:
TCGCCGATAGTGGAAACCGACGCCCCAGCACTCGTCCGAGGGCAAAGGAA
t a g g t ™ ^ ^ ct t a a t a a g a t g a t c t t c t t g a g a t c g .
Residues 1 through 53 (in bold) are identical to the region of pcDNA3.1 hygro which covers 
the 3’ end of the hygromycin phosphotransferase gene.
A Pmel site (position 54-61, italics) was inserted to enable the subsequent cloning into 
PUX4- sA-IRES-PGeok-pA
The 3’ end portion (62-87, underlined) anneals in the PGR reaction to pAGYG184 template 
at residues 728-753.
Oligo ShygroR has the 5'-3' sequence:
TCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCT
GCCTGGGCCCjGCCTTCACCGGTGTGCCCGGGCGCGGCCGCTTACGCCCCGCCCT
GGGAGTGATGGG.
Residues 1 through 57 (in bold) are identical to the region of pcDNA3.1-hygro which covers 
the start of the SV40 promoter.
A polylinker (position 58-92, italics) of unique restriction enzyme sites (Fsel, SgrAI, Srfl 
and Not!) enables both the subsequent cloning into PUX4-sA-IRES-PGeok-pA, and the 
further insertion of one of the two homology arms for the final ET cloning step into the Af4 
BAG.
The 3’ end portion (93-118, underlined) anneals in the PGR reaction to the pAGYG184 
template.
As depicted in figure 11, the PGR product features at its ends the two regions of homology 
to the hygromycin phosphotransferase gene. The PGR product was first digested with Dpnl, 
an enzyme which cleaves only when its restriction site (GATG) is methylated, and thereby
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serves after the PCR to eliminate the template (in this case pACYC184), which could 
otherwise contribute a serious source of background in the ET cloning reaction. Following 
purification of the Dpnl digest, the PCR product (300 nanograms) was coelectroporated 
together with the donor plasmid (pcDNA3.1-hygro) in the E.Coli strain JC8679, which 
constitutively expresses the recombinogenic proteins RecE and RecT. Cells were then plated 
on chloramphenicol selection. Eight out of nine colonies displayed the correct restriction 
pattern consisting of two bands of 2129 and 1133 bp respectively. Subsequently (figure 12), 
the flanking Pmel and Notl sites were used to subclone into sA-IRES-POeok-pA, yielding 
the final plasmid PUX4-sA-IRES-pGeok-pA-hygro-SV40.
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Figure 11 ET mediated subcloning of the hygromycin resistance gene
The hygromycin resistance cassette was subcloned from the pcDNA3.1-hygro plasmid 
into the pACYC184 vector. Convenient restriction sites were incorporated in the ET 
homology arms to enable subsequent cloning steps.
See text for a full description of the cloning strategy.
Abbreviations: (Cm) chloramphenicol resistance gene; (Amp) piactamase gene; (ColEl) 
ColEl origin of replication; (p i5A) p i5A origin of replication; (pA) polyadenylation 
signal; (SV40) simian virus 40.
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Figure 12 Generation of a universal promoter trap targeting vector.
Schematic illustration of the cloning strategy to generate a universal promoter trap 
targeting vector based on the |3Geok fusion (PUX4-sA-IRES-PGeok-pA-hygro-SV40) 
and the hygromycin phosphotransferase gene. It can be used to target genes in ES cells, 
regardless of their expression status, for the generation of mouse lines where the loss of 
function and the expression of the gene can be studied simultaneously.
The names of the DNA molecules (constructs and PCR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter.
Abbreviations: (Amp) piactamase gene; (ECMV 1RES) encephalomyocarditis virus 
internal rybosomal entry site; (LacZ-neo) fusion of the P-galactosidase and the neomycin 
genes (pA) polyadenylation signal; (SV40) simian virus 40.
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VIII.2.4.2 Assembly of the final ET targeting cassette bw-loxP-sA-IRES-PGeok-pA- 
hygro-SV40-loxP-aw
As already described, ET cloning normally utilises a PCR reaction to incorporate at 
the two ends of a given donor DNA molecule the two regions of homology which will direct 
its incorporation at the desired site into the acceptor DNA molecule. Given the possibilities 
offered by current long-range PCR protocols, this approach could also be considered in this 
case, am plifying the newly generated sA-IRES-|3Geok-pA-hygro-SV40 with 
oligonucleotides which add the homology arms for ET recombination. However, the inherent 
risk of mutations generated during the PCR reaction over long distances discourages this 
approach. Hence, a combination of ET cloning and conventional cloning techniques 
represented the best solution to this problem. In the first step, short homology arms were 
made by PCR and placed by conventional cloning at the two ends of the targeting vector, 
using unique restriction sites incorporated in the early steps of the cloning plan. This assured 
that the core of the targeting construct was never subjected to PCR amplification. The 
homology arms could have been directly synthethized as oligonucleotides and added by 
ligation, however the cheaper alternative of PCR generation was preferred.
The Af4 BAC 189o7 was used as a template to generate the 5' and 3' homology arms, called 
bw and aw respectively (diagram in Figure 13). The region to be targeted in intron 3 was 
chosen after an analysis of the sequence available. First, current literature and the Genebank 
database were searched for the AF4 genomic breakpoint sequences in human patients. 
Unfortunately, little sequence information is available. It would have been interesting to 
compare such sequences with the mouse intron 3 sequences. Even in the absence of 
significant homology (a rather likely outcome for intronic sequences), it would have been 
valuable to place the loxP site in the mouse intron at roughly the same distance from exon 3 
or 4 as in the human cases. Unfortunately, even for MLL-AF4 leukemia cases analysed by
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Figure 13 Generation of the ET targeting cassette for the Af4 BAC
The figure shows the cloning steps involved in the generation of the ET targeting 
construct PUX4-bw-sA-IRES-pGeok-pA-hygro-SV40-aw.
See text for a full description of the cloning strategy.
The names of the DNA molecules (constructs and PCR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter.
Abbreviations: (Amp) piactamase gene; (ECMV 1RES) encephalomyocarditis virus 
internal rybosomal entry site; (LacZ-neo) fusion of the P-galactosidase and the neomycin 
genes (pA) polyadenylation signal; (SV40) simian virus 40; (bw) 5' ET homology arm; 
(aw) 3' ET homology arm.
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PCR or Southern blotting, the actual intronic breakpoints had not been sequenced at the time 
of these experiments.
Second, on the basis of the sequence available and the mapping information, the disposition 
of Nhel sites presented a good Southern strategy to screen the ES cell clones for homologous 
recombination. Two Nhel sites in the 5’ end of intron 3 were identified, whose replacement 
by the targeting construct generates bands of different sizes in the wild type and 
homologously recombined alleles. The two Nhel sites flank the stretch of 19 Cs, which 
confounded the sequence characterisation of the BAC, and a B1 repeat. B1 repeats are the 
most abundant type of repeats in the mouse genome, and they have so far not been 
associated with any function. Hence, it was decided to design the ET cloning homology arms 
in such a way that the loxP-sA-IRES-pGeok-pA-hygro-SV40-loxP targeting vector would, 
upon homologous recombination in the Af4 BAC, replace the 700 bp region between the two 
Nhel sites, including the 19 Cs and the B1 repeat. The 5’ homology arm was amplified by 
PCR from BAC DNA using the oligos Nq/^bwF and Nq/¥bwR. Forward oligo Nq/^bwF has 
the 5-3' sequence:
TTACATTGGCGCGCCTAATTATCCTGAACCCTCCCACCTC.
At position 8-15, an AscI (italics) site was incorporated for further cloning, while the 
annealing portion includes residues 16 to 40. Reverse oligo Nq/^bwR has the 5'-3' sequence: 
CACGGTGCCm^rrA4ATAACTTCGTATAGCATACATTATACGAAGTTATAGG 
Ct t t c t CACACGCAATACAGGT.
At position 10-17, a P ad  site (italics) was incorporated for futher cloning; the loxP site (in 
bold) is located at position 18-51, while the annealing portion (underlined) includes residues 
52-76. The resulting PCR product (bw) is 403 nucleotides long and contains 336 nucleotides 
of sequence identity with the region of the BAC to be targeted.
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The 3’ homology arm was amplified from Af4 BAC DNA using the oligos No/^awF2 and 
Nq/?awR. Forward oligo Nq/¥awF2 has the 5'-3' sequence:
TTACCATTCAGGCCGGCCATAACTTCGTATAATGTATGCTATACGAAGTTATG
AGGGAGAGCCAATCAGAAGA.
An Fsel site (position 11-18, italic) was incorporated for further cloning. The loxP site (in 
bold) is located at position 19-52, while the annealing portion includes residues 53-73 
(underlined). Reverse oligo Nq/^awR has the 5'-3' sequence: 
CTAATGGTAACTCCGGrGGCTACCAAGACTGACAAACCAAG.
An SgrAI site (position 11-18, italic) was inserted for further cloning. The annealing portion 
(underlined) includes residues 19-41. The resulting PCR product (aw) is 336 base pairs long 
and contains 265 residues of sequence identity with the region of the BAC to be targeted.
The final product was the bw-loxP-sA-IRES-PGeok-pA-hygro-SV40-loxP-aw cassette, 
ready to be placed by ET recombination into the backbone for the targeting construct 
subcloned from the BAC.
VIII.2.5 ET-mediated subcloning of the A f4  target region from the 4 /^  BAC into the 
vector pACYC-177
To assemble the final Af4 targeting construct for homologous recombination in 
mouse ES cells, two sequential steps of ET recombination were applied. The first step is 
described here, and the second in section VIII.2.6.
A subclone from the BAC was made, by ET recombination, to establish the 
backbone of the targeting vector including the 5' and 3' homology arms for use in ES cells. 
These homology arms were chosen by design so that the boundaries of the final ES targeting 
vector suited a convenient Southern strategy. The Af4 targeting construct described below 
exemplifies the merits of this strategy based on Nhel, since it could be used to screen for
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homologous integration at both the 5’ and the 3’ ends. Furthermore, the finite amount of 
DNA available for each ES clone is an important consideration for any Southern strategy, 
limiting the number of digests which can be performed. Use of a single digest, and hence a 
single blot, renders the screening strategy easier, faster, and less prone to errors in ordering 
samples and interpreting the results.
Another advantage of using ET recombination to establish the ES cell targeting 
vector backbone exploited in this Af4 example, involves the easy placement of a chosen, 
unique restriction site flanking the subclone. Subsequent cleavage of these flanking sites 
yields the linear fragment for targeting in ES cells.
To subclone the Af4 targeting backbone from the Af4 BAC into pACYC177 (Figure 
14), a PCR reaction was performed with oligos Af45En& and Nq/?3End, each of which, as in 
any ET cloning experiment, is composed of two parts: the PCR primer annealing to the 
template (in this case pACYC177), and the homology arm to the donor plasmid (in this case 
the Af4 BAC) that defines the target region to be subcloned. Forward oligo Af45Ervà. has the 
following 5'-3' sequence:
ACAGGCATTTGTCAACTACACCCACCGGGCAGGCTCCAAGTTCACTCACTA
CAAATCTGTAGTAGCTGAAGTGTTCTTGGCGGCCGCTCACGAGGCAGACCTC
AGCGCTAGCGG.
Residues 1-79 constitute the 5’ ET homology arm. A Notl site was incorporated (position 
80-87) to release the insert from the targeting vector prior to ES cell electroporation. The 
annealing part to the pACYC177 template includes residues 88 to 114. Reverse oligo 
Nq/^3End has the following 5-3' sequence:
GCCCTAGGAGCTAGTTCTCAGTGAATGTATGTTACACAAGTATAGTTCCTGT
AACCCCTGCATAGGGCATGGGGATGCGGCCGCTGAAGACGAAAGGGCCTCGT
GATACGCC.
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Residues 1-76 constitue the 3’ ET homology arm. Also in this oligo, a second Notl site was 
incorporated (position77-84) to release the insert from the targeting vector prior to ES cell 
electroporation. The annealing part to the pACYC177 template includes residues 85 to 112. 
As shown in figure 14 the PCR product (pACYC1774/^) features at its ends the two regions 
of homology to the Af4 BAC.
E. coli cells harbouring the A f4  BAC 189o7 were transformed with the 
recombinogenic plasmid R6K-aPy-Tet, which expresses the recombinogenic proteins Reda 
and Redp under the control of an arabinose-inducible promoter. The R6K origin of 
replication allows this plasmid to coexist in the same cell with ColEl origin plasmids, like 
pACYC177, a prerequisite for this kind of experiment where the presence of two plasmids is 
necessary. Electrocompetent cells were electroporated with the PCR product 
pAC YC lllA f4 ., and spread on ampicillin (100 pg/ml) plates. On each plate, approximately 
250 colonies arose and twelve colonies were picked from different plates. In 4/12 colonies 
the expected pattern was detected (3 bands of respectively 6815, 4544 and 623 base pairs) 
(Figure 15). Since this result was less efficient than the previous subcloning of a larger 
section of the same region from the same BAC, positive candidates were then digested with 
the following battery of restriction enzymes (Seal, Notl, Kpnl, Apal, Nhel, and Sad) to 
further confirm that they contained the correct fragment (figure 16). The expected patterns 
were observed (for Seal Three bands of 5478, 3584 and 2929 base pairs; for Notl, two bands 
of 9924 and 2067; for Kpnl, two bands of 9729 and 2262 base pairs; for Apal, a single band 
of 11991 base pairs, corresponding to the linearised plasmid; for Nhel three bands of 6815, 
4544 and 623 base pairs; and for Sad, four bands of 4608, 3287, 3224 and 872 base pairs). 
Colony n.2 (Af4suh2) was then linearised with Apal, since it was shown that the ET cloning 
reaction is more efficient with a linearised than a supercoiled DNA target. In this case, the 
Apal site (position 6927-6932 of the Af4Suh construct) was chosen since it is located within
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the region of Af4 to be replaced by the bw-loxP-sA-IRES-(3Geok-pA-hygro-SV40-loxP-aw 
cassette.
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Figure 14 ET mediated subcloning of the 4 /4  target region from the Af4 BAC 
into the vector pACYC177
The relevant region for the ES targeting construct was subcloned via ET recombination 
from the Af4 BAC into the middle-copy vector pACYC177.
See text for a full description of the cloning strategy.
The names of the DNA molecules (constructs and PCR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter. Due to the size 
of the Af4 BAC molecule, the dashed line region of the Af4 BAC construct represents a 
region greater than 100 Kb.
Abbreviations: (Cm) chloramphenicol resistance gene; (pi 5A) pl5A  origin of replication; 
(pA) polyadenylation signal; (SV40) simian virus 40.
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Figure 15 FT mediated subcloning of the Af4 targeting backbone
Nhel digests of 12 colonies resulting from the subcloning of 
a fragment of the Af4 BAC into the vector pACYC177 to yield the 
backbone for the assembly of the knock-in targeting construct. 
Colonies 2, 3, 8 and 11 show the correct restriction pattern.
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Figure 16 Restriction analysis of the Af4 subclone
Restriction digest of the fragment of the Af4 BAC 
subcloned into the pACYC177 vector (Af4Sub) as a starting 
backbone for the assembly of the knock-in targeting construct. 
Af4Sub colonies n.2 and n.3 were digested with Seal, Notl, Kpnl, 
Apal, Nhel and Sad to check for the correct restriction pattern.
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VIII.2.6 Insertion of the bw-IoxP-sA-IRES-PGeok-pA-hygro-SV40-loxP-aw cassette 
into the 4 /^  subclone
In the final step to assemble the Af4 ES cell targeting construct (4/^-loxP-PGeok), 
the bw-loxP-sA-IRES-PGeo-pA-hygro-SV40-loxP-aw cassette was cloned into the Af4 
target backbone, 4/^Sub, by ET recombination (Figure 17).
PUX4-bw-loxP-sA-IRES-PGeo-pA-hygro-SV40-loxP-aw was digested with Notl and AscI, 
to release the recombinogenic bw-loxP-sA-IRES-pGeo-pA-hygro-SV40-loxP-aw insert. 
The released insert was gel purified and cotransformed with the Apal linearised 4/^Sub into 
two different E. coli strains; DHIOP which had been transformed with the recombinogenic 
plasmid R6KaPy; and JC8679, which constitutively express the recombinogenic proteins 
RecE and RecT. Successful ET recombinants were identified by growth on double selection 
plates (kanamycin 50 pg/ml and ampicillin 100 pg/ml). A total of 20 colonies, 16 from the 
DHlOp strain, and 4 from the JC8679, were analysed by Seal digestion (figure 18a). All 20 
colonies showed the correct pattern (4 bands of 7594, 5478, 3584 and 3042 base pairs.) 
Colony 2 was chosen for a more detailed restriction analysis in order to confirm that the ET 
cloning reaction had indeed generated the correct plasmid (figure 18b).
165
Figure 17 ET mediated targeting of the loxP-PGeok-hygro cassette to the Af4 
subclone
The bw-loxP-sA-IRES-PGeok-pA-hygro-SV40-loxP-aw cassette was targeted by ET 
mediated homologous recombination to the Af4 targeting backbone, which had been 
previously subcloned into the pACYClT? vector (Af4Sub).
The names of the DNA molecules (constructs and PCR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter.
A bbreviations: (Cm) chloram phenicol resistance gene; (ECMV 1RES)
encephalomyocarditis virus internal rybosomal entry site; (LacZ-neo) fusion of the p- 
galactosidase and the neomycin genes (pA) polyadenylation signal; (sA) splice acceptor; 
(SV40) simian virus 40; (bw) 5' ET homology arm; (aw) 3' ET homology arm.
See text for a full description of the cloning strategy.
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Figure 18 ET mediated targeting of the loxP-pGeok-hygro cassette to the Af4 subclone 
(restriction analysis)
The loxP-flanked pGeok-hygro cassette was targeted to the third intron of the Af4 gene 
previously subcloned in pACYC177.
A. All colonies show the correct pattern upon Seal digestion
B. Colony n. 2 (Af4-koxP-pOeok) is checked with a battery of restriction enzymes, which 
yield the expected digestion patterns
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VIII.3 ES cell targeting with the Af4 construct
Mouse E l4 ES cells (from the line originated in K. Rajewski's lab) were used for the 
targeting experiment. They were grown on confluent layers of inactivated mouse embryonic 
fibroblasts (MEFs). The construct Zl/^-loxP-pGeok colony n.2 (40 |Xg) was digested with 
Notl to release the targeting construct from the pACYC177 vector. The digested DNA was 
precipitated and resuspended in 50 p-1 PBS. On the day of the electroporation, 10 X 10  ^ES 
cells were trypsinized, resuspended in 700 |li1 PBS and electroporated with the 40 \ig of 
construct at 240 Volts. After electroporation, cells were plated at low-middle density onto 8 
10 cm dishes.
As discussed above, the expression status of the Af4 gene in mouse ES cells was 
unclear. Therefore, it was decided to divide the 8 dishes into two sets, one which would be 
selected with G418, and the other with hygromycin. G418 resistance is conferred by the neo 
part of the PGeok fusion protein, and, in the configuration of the of 4/^-loxP-pG eok 
construct, it relies upon the endogenous expression of the targeted gene. In contrast, 
hygromycin resistance is autonomous since it is expressed from the SV40 promoter. Since 
expression of G418 resistance relies on a promoter trap, it seemed likely that selection with 
G418 would result in much less colonies than with hygromycin. Moreover, if Af4 was 
expressed in ES cells, one would predict a much higher frequency of homologously targeted 
colonies among the G418 than the hygromycin selected ones, since only in the former 
selection scheme would the promoter trap nature of the construct have been advantageously 
exploited.
Selection was started 1 day, in the case of G418, and 2 days, in the case of 
hygromycin, after electroporation, with the following drug concentrations in the cell culture 
medium; G418 (250]jLg/ml) and hygromycin (200 }Xg/ml). Selective medium was then
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changed daily. G418 resistant and hygromycin resistant MEFs were used during selection. 
Nine days after the start of selection, massive cell death had occurred in all plates treated, 
and surviving ES cells had formed fully grown colonies, which were then picked and 
transferred into drug resistant MEF coated 48-well plates. Unexpectedly there were 
comparable number of colonies in either selection scheme. In total, 96 hygromycin resistant 
and 48 G418 resistant colonies were picked. After four days, each 48-well plate was 
trypsinised and replica plated into two 24-well plates and two additional 48-well plates. 
Colonies in the 24-well plates were grown to confluence for DNA extraction. Of the two 
additional 48-well plates, one was frozen for future reference, while the other one was grown 
to confluence and stained with X-Gal to assess the expression of Pgalactosidase. All plates 
were scored to assess the percentage of colonies effectively surviving after picking, as well 
as the morphology of the colonies as a partial indicator of their undifferentiated state.
Figure 19 shows the X-Gal stained replica plates of 48 hygromycin resistant and 48 
G418 resistant colonies. There were many more blue colonies among the G418 resistant than 
among the hygromycin resistant ones, hardly a surprise since G418 resistance and P- 
galactosidase activity are linked in the same fusion protein Pgeo. However, it is known that 
the sensitivity of detection of both activities (G418 resistance and X-gal staining) can vary, 
and that cells which are clearly resistant to G418 may not necessarily show detectable X-Gal 
staining. From the staining of figure 19, this appears to be clearly the case for the following 
colonies: 10, 18, 21, 41 and 44. On the contrary, lack of staining in the wells 2, 11, 13, 36, 
37, 40 and 48 reflects the absence of colonies or an exceedingly low number of cells in these 
wells. It has been estimated that promoter-trap vectors provide a 100-fold enrichment for 
homologously targeted versus randomly integrated clones. Moreover, though ideal for genes 
expressed at high levels in ES cells, promoter trap selection schemes have also been 
successfully applied to poorly expressed genes.
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Figure 19 LacZ staining of ES cells targeted with the Af4 construct
The majority o f clones selected with G418 versus only few o f those selected with 
hygromycin are positive for LacZ staining, reflecting the architecture o f the targeting 
construct in which the hygromycin resistance gene is expressed from its own promoter, 
while the pGeok fusion is a promoter trap.
See text for details.
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VIII.3.1 Southern blot analysis of G418 resistant colonies
Genomic DNA was extracted from the 48 G418 and 96 hygromycin resistant ES cell 
colonies and digested with Nhel for analysis by Southern blotting with the probes indicated 
in figure 20.
To screen for homologously recombined colonies on the 5’ side of the Af4 locus, a 
probe was used (Probe-ex3) which spans 617 nucleotides oîA f4  exon 3. On a genomic Nhel 
digest blot, it hybridises to a wild type band of 5546 bp, resulting from Nhel cleavage at 
positions 508 and 6054 of the wild type Af4  allele (4/^BAC'wt). In the case of correct 
integration of the the 4/^-loxP-pGeok construct in the endogenous Af4 locus, the Nhel site at 
position 6054 would be lost, since it had already been deleted during the ET cloning of the 
selectable marker cassette bw-loxP-sA-IRES-|3Geok-pA-hygro-SV40-loxP-aw into the Af4 
fragment subcloned into pACYC177 (4/^Sub). However, the cassette bw-loxP-sA-IRES- 
PGeok-pA-hygro-SV40-loxP-aw contains three Nhel sites , and therefore, upon Nhel digest, 
correctly targeted colonies would show a new band of 6744 bp, resulting from Nhel cleavage 
at positions 508 and 7252 of the correctly targeted 4 /^  allele.
To screen for homologous recombined colonies on the 3’ side of the Af4 locus, a 
probe was used (neo), which is an EcoRI fragment of the PUX4-PGeok plasmid. In the case 
of correct integration of the 4/^-loxP-pGeok construct in the endogenous Af4 locus, upon 
Nhel digestion, the “neo” probe hybridises to a band of 12312 bp, resulting from Nhel 
cleavage at positions 7577 and 19889 of the correctly targeted Af4 allele. An advantage of 
using at least one probe internal to the targeting construct is the ability to distinguish single­
copy from multiple-copy ES cell clones, since multiple integrant ES clones cannot be used 
to produce mouse chimeras. The same blot was hybridised sequentially with the two probes 
(neo and exon3), and the results showed that 14/35 G418 colonies analysed displayed the
correct integration pattern on both sides, amounting to
171
A. B. 0)
CÔ
1 2  3 [4 ]5  6 7 8 9 10 11 12 13141516 17 18
Nhel (203)
wt Af4 locus
Nhel (5749) Nhel (6381)
1 2 0 0
5’ border of the 
Af4-loxP-Betageok 
targeting construct
wt band 
5 ’ probe (5.5 Kb)
5 probe loxP
Gx 2 ex 3
GC rich 
s t r e t c h
wt band 
3 ’ probe (5.5 Kb)
3’ border of the 
Af4-loxP-Betageok 
targeting construct
homologous recombination 
in ES cells
A f4 - lo x P -B e ta a e o k  
targeting construct
Nhel (5716)
Nhel (5858) SV40 pA
ex 2 ex 3
Nhel (11877)
1200 
I-------1
SV40 promoter
lo x P
ECMV 1RES
5’ homology arm of 
targeting construct
4.39 Kb
Hyg ro
3’ homology arm of 
targeting construct 
4.75 Kb
targeted Af4 locus
Nhel (6947)
1200
loxP Nhel 19421
Hygro
ECMV 1RES
Nhel (203) 5 ’ probe 1
y  ^  \ /  Nhel (7272)
targeted band 
5’ probe (6.7 kb)
targeted band 
3 ’ probe (12.3 Kb)
12 Kb.
11 K b ^  
10 K b ^
9 Kb ►
8 K b - - ^
7 K b ^  
6 K b /
^Targeted band 3 ’ probe 
Targeted band 5 ’ probe
wt band
ICÔ
20 21 22 23 24 25 26 27^8 29 30 31 32 34 35 36 37 38
Targeted band 3’ probe 
Targeted band 5’ probe
wt band
Figure 20 Af4 Targeting in mouse ES cells (Southern hybridization)
A. Graphical representation of the wild type Af4 locus, the Af4-loxP-Pgeok targeting construct, and the targeted 
Af4 allele after homologous recombination in ES cells.
The names are indieated in bold and underlined. The azure arrows on both sides of the wt Af4 locus and the 
targeted Af4 allele indicate the flanking genomic regions. The 5’ probe is represented by a green rectangle within 
the third exon of the gene. The wt bands identified by the 5’ and 3’ probes are represented by green lines.
The targeted bands identified by the 5’ and 3’ probes are represented by a red and a purple line, respectively.
The purple thin boxes represent the 5’ and the 3’ border of the Af4-loxP-pgeok targeting construct. The positions 
of the Nhel sites are indicated, on which the Southern strategy is based.
The scale (1200) indicates the number of nucleotides/centimeter.
Abbreviations: (sA) splice acceptor; (pA) polyadenylation element; (ECMV 1RES) eneephalomyiocarditis 
virus internal ribosomal entry site; (LaeZ-neo) fusion of the pgalactosidase and the neomycin genes; (Hygro) 
hygromycin phosphotransferase gene; (SV40) simian virus 40.
B. Southern blot of Nhel digests from the DNA of G4I8 resistant ES cell clones.
The filters were sequentially hybridized with the 5’ and the 3’ probe, since
both are compatible with an Nhel based Southern strategy. 14 out of 35 colonies analyzed 
showed the correct pattern, amounting to a 40% frequency of homologous recombination.
(positive colonies are marked in red). Colonies n. 4 and n.33 (red squares) were used for 
the generation of chimeric mice.
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an extremely high homologous recombination frequency of 40%. This great 
efficiency is compatible with a promoter trap selection, and clearly argues that Af4  is 
expressed in mouse ES cells. In agreement with this prediction, there was good 
correspondence between the X-gal staining pattern of the G418 selected 48-well plate and 
the Southern blot results. In fact, most homologously recombined colonies expressed lacZ at 
approximately the same level (colonies n. 1,4, 15, 22, 26, 28, 32, 33 and 35 in figure 19) 
Colonies n. 8, 20, 27, 29 and 34, on the other hand, showed a lower level of B-galactosidase 
expression. However, it should be noted that X-gal staining is a very qualitative type of 
assay. Furthermore, there is definitely an element of stochastic variability when one 
examines the activity of a promoter (in this case the promoter of the Af4 gene) within the 
context of the genome packaged into chromatin. For example, the two alleles of a gene 
might lie, at a given time, in slightly different chromatin environments, so that their 
respective expression levels might indeed not always be equal. As a consequence, the 
expression of a selectable marker would vaiy according to which allele had been targeted. In 
a population of cells, the weight of stochastic variations in chromatin accessibility and 
localised availability of appropriate transcription factors is likely to be even greater. It is 
therefore not surprising to observe, even among the supposedly homogeneous population of 
G418 resistant correctly targeted clones, a significant degree of variability in the X-gal 
staining.
On the basis of the above results, clones 4 and 33 were injected into mouse
blastocysts (from strain C57B1/6J) to generate 4/^LacZ chimeras.
From clone 4, the following chimeras were obtained with level of chimerism, as judged by 
coat colour, indicated in parentheses:
1 male (100%); 2 males (90%); 3 males (80%); 2 males (60%); 2 males (50%); 1 male
(40%); 1 male (30%); 1 female (90%) and 1 female (50%).
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The three males with 100% and 90% chimerism were bred to C57B1/6J females to transmit 
the allele through the germline.
From clone 33, the following chimeras were obtained:
2 males (100%); 3 males (90%); 2 males (80%); 1 male (70%); 2 males (40%); 1 female 
(80%); 1 female (70%); 1 female (60%) and 2 females (20%).
Two males with 100% chimerism, one male with 90% chimerism and one male with 80% 
chimerism were bred to C57B1/6J females to transmit the allele through the germline,
VIII.4 Transmission of the ^4/V-IoxP PGeok allele through the mouse 
germline.
In order to transmit the 4/^-loxP-PGeok allele through the mouse germline, high percentage 
chimeras from both ES clones 4 and 33 were crossed with wild type mice of the strain 
C57BF6J. Both clones transmitted the allele through the germline, demonstrating that the ES 
cells had retained their totipotency during the targeting experiment.
Two schemes of breeding were then established to exploit the multiple functions of 
the v^-loxP-POeok allele.
FI mice carrying one copy of the recombined allele were intercrossed to obtain 
homozygously mutant mice, which could then be used to characterise the degree to which 
the sA-IRES-pOeok cassette in intron 3 interferes with Af4 gene activity and the ensuing 
phenotype.
DNA from mouse tails was analysed by Southern blot hybridisation with the probe ex3 (see 
above). As shown in figure 21, homozygous mutant mice were born at the expected 
Mendelian frequency (25%). This shows that the possible impairment caused by the sA- 
IRES-PGeok cassette did not result in embryonic lethality. This was expected, based on the
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results of a previous study, where loss of function of the Af4 gene was compatible with life 
(Isnard et ah, 2000).
In the second breeding scheme, both 4/^-loxP-PGeok chimeras and 4/4-loxP-PGeok 
heterozygotes were crossed to either one of two Cre expressing mouse lines, to delete the 
pGeok cassette leaving a single loxP site in the third intron of the gene. The two Cre 
expressing mouse lines were the X-linked Cre-deleter line (Schwenk et al., 1995) and the 
PGK-Cre line (Lallemand et ah, 1998). Crosses with both lines were successful in Cre 
mediated deletion of the intervening cassette. Figure 22 shows the results from a 
representative litter. This proved in vivo that a loxP site placed in the Af4 locus is accessible 
to Cre mediated recombination, a prerequisite for inducing later the interchromosomal 
translocation.
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Figure 21 Af4-/- mice are born at the expected Mendelian rate
Southern blot hybridisation on mouse tails from a representative 
offspring of two heterozygous Af4-loxP-pGeok mice (ID 510639 and 
510646). The Probe-ex3 was used, which detects a wild type 
band of 5546 bps (green arrow) and a recombined band of 6744 
bps (red arrow).
Homozygous Af4-loxP-pGeok mice were born at the expected mendelian 
frequency (3/12=25%). 25% of the mice were wild type, and 50% 
were heterozygous.
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re 22 Cre deletion of the mutant Af4 allele
■aphical representation of the targeted Af4 locus before and after Cre recombination, 
tames are indicated in bold and underlined. The azure arrows on both sides of the Af4 locus indicate 
lanking genomic regions. The 5’ probe (ex3) is represented by a green rectangle within the third exon 
; gene. The targeted band before Cre recombination identified by the 5’ probe is represented by a red line, 
argeted band after Cre recombination identified by the 5’ probe is represented by an orange line, 
turple thin boxes represent the 5’ and the 3’ border of the Af4-loxP-pgeok targeting construct, 
lositions of the Nhel sites are indicated, on which the Southern strategy is based, 
cale (1200) indicates the number of nucleotides/centimeter.
sviations: (sA) splice acceptor; (pA) polyadenylation element; (ECMV 1RES) eneephalomyiocarditis 
internal ribosomal entry site; (LacZ-neo) fusion of the pgalactosidase and the neomycin genes; (Hygro) 
imycin phosphotransferase gene; (SV40) simian virus 40.
îpresentative Southern hybridization analysis of a litter from an Af4-loxP~Pgeok X Cre-deleter mouse 
ross. Analogous results were obtained with the PGK-Cre mouse line. The 5’ probe (ex3) was used to 
t the band (orange arrow) resulting from Cre deletion of the loxP-flanked pGeok-hygro cassette on an 
digest of mouse tail genomic DNA. The red arrow points to the targeted band, prior to Cre recombination, 
ted with the same exon 3 probe. The green arrow points to the wild type band, detected with the same exon 
be.
177
VIII.4.1 Mice homozygous for the 4/^-loxP-pGeok allele do not express the full Af4 
transcript
To determine whether the loxP flanked PGeok cassette in intron 3 does actually 
interfere with transcription of the Af4 gene, an RT-PCR strategy was designed. RNA was 
extracted from both wild type and 4/^-loxP-pGeok homozygous mice, and cDNA was 
synthethised. Three primers were used to explore different regions of the Af4 transcript, 
together with two primers to amplify Pactin as a positive control for the quality of the RNA 
and the efficiency of the RT-PCR conditions used. Primer A/4qxA¥ and primer 4/^exl IR 
amplify the Af4 transcript from exon 3 to exon 11, yielding a band of 1430 nucleotides. 
Primer 4/^ex3F has the following 5'-3' sequence: 
CTTTATCGATTGGGTGACTATGAGGAGATGAA 
Primer 4/^exl IR has the following 5'-3' sequence:
CTGCCCTCAGCGACACCCTTACTT
The P-actin primers have the following 5'-3' sequences:
P-actinF (GGCCCAGAGCAAGAGAGGTATCC)
P-actinR (ACGCACGATTTCCCTCTCAGC). They yield a band of 439 nucleotides. Since 
the pGeok cassette is placed in intron 3, the 4/^ex3F-q/^exl IR primer pair allows to check 
whether this configuration prevents full transcription of the Af4 gene. As expected, no 
transcript is detected in the v^-loxP-pGeok homozygous animals, while the P-actin band is 
readily detected in both wild type and homozygous mice (figure 23). In case that some 
nascent transcripts would escape processing by the SV40 late polyadenylation signal of the 
knock-out cassette, aberrant mRNAs could be produced by cryptic donor sites in the PGeok 
cassette splicing to exon 4. Due to their length, these transcripts would most probably not be
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detected by the RT-PCR assay described above. However, even if such mRNAs were 
produced, they would still result in a prematurely truncated protein after exon 3.
To check whether the pOeok cassette also results in the absence of any downstream Af4 
transcript, the same primer Af4Qx\ IR was used in combination with primer 4/^ex4F, which 
anneals in the fourth exon oïAf4, and has the following 5-3' sequence: 
GAAGTCCATTGCGTTGAAGAGATT
Surprisingly, a band of the expected size was detected in both wild type and 4/^-PGeok 
homozygous animals. A suggestive explanation for this result is the presence of an 
alternative promoter located downstream of the pGeok cassette. At present, it is not known 
whether in homozygous mice this 5' terminal truncated transcript is actually translated in the 
corresponding aminoterminally truncated protein. Even if this were the case, these animals 
would still lack the full AF4 protein lacking both the NHD (N-terminal homology domain) 
and the first half of the ALF domain, as defined in (Nilson et al., 1997). As discussed in 
chapter 6, both these domains are highly conserved between all members of the AF4 family, 
suggesting that such a truncated protein would be very likely impaired in its function. 
Furthermore, it could also behave as a dominant negative.
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Figure 23 RT-PCR analysis of/l//-loxP-PGeok homozygous mice
An RT-PCR analysis was performed on several organs from mice homozygous 
for the 4/4-loxP-pGeok allele.
A. RT-PCR with primers Af4ex3F, Af4exllR, PactinF and pactinR. Primers Af4ex3F 
and Af4exllR amplify the Af4 transcript (red arrow) only in wild type mice, while the 
pactin band (green arrow) is readily detectable in both wild type and homozygous mice. 
This indicates that no full transcript is produced in the 4/^-loxP-pGeok homozygous 
animals.
B. RT-PCR with primers Af4ex4F and Af4exl IR. This experiment explores the presence 
of the Af4 transcript downstream of the PGeok cassette inserted in the third intron of 4/4. 
The presence of the band in both wild type and 4/4-pGeok homozygous animals argues 
for the presence of an alternative promoter located most likely in intron 3 downstream 
of the knock-in cassette.
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IX
Engineering of a multifunctional Mil allele
IX. 1 Overview of the strategy
Gene targeting in the mouse has been extensively employed to analyse in vivo the 
function of many genes through the generation of knock-out, knock-in and hypomorphic 
alleles. As the technique has been progressively streamlined, it is becoming increasingly 
possible to address questions in the context of the v^hole organism.
One of the main assets of mutational analysis is the ability to assess the role that 
single domains, sometimes even single residues, play in the function of genes and proteins in 
vivo. In the context of modern mouse genetics, this is usually achieved by generating 
different targeting vectors for any desired mutation, a very time consuming process. Indeed, 
besides the logistics of suitable animal facilities, one of the main impediments to generating 
an allelic series of desired mutations in a gene of interest is the time involved in the 
assembly of the relevant targeting vectors. Furthermore, the option to combine two or more 
mutations in cis for assessment of the combination is currently very limited For large genes, 
where the sites to be mutated are too far apart to be included in the same targeting vector, 
again individual targeting constructs need to be generated for each desired mutation. To 
target two mutagenic cassettes to the same locus, mouse ES cells must be subjected to 
several rounds of electroporation and drug selection, a procedure which can result in loss of 
totipotency and subsequent inability to colonise the mouse germline. Additionally, upon 
retargeting a given locus at a new position with a second cassette, only 50% of the 
homologously recombined clones will have the two targeting cassettes on the same allele, 
and only these will be useful for propagating the desired mutations together through the 
mouse germline. Particularly for genes which display low homologous recombination
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efficiencies, the impact of a 50% reduction in the amount of successfully targeted ES clones 
cannot be overemphasised.
Furthermore dual mutational combinations need not be only changes in amino acid or 
cis element sequence. Introduction of a reporter gene (like p-galactosidase or GFP) or of a 
protein purification tag are both examples of useful mutations for gene function analysis in 
vivo. Targeting of many genes with GFP and/or p-galactosidase is now a widespread 
approach to characterising, at the organismal level, expression patterns throughout 
development and intracellular localisations. To apply these tools to the study of the effect of 
specific mutations on expression patterns and/or the intracellular localisations, the fluent 
introduction of combinations on the same allele of a deleterious mutation and a reporter 
gene, presents new options for mutational analyses.
This approach can also encompass biochemical analysis using protein-puriflcation 
tags fused in frame to the protein of interest. Systematic characterisation of biochemical 
complexes is an ambitious goal of modern large scale biology, commonly referred to as 
proteomics, and a prerequisite to understanding physiological and pathological processes in 
molecular detail. A variety of protein tags have been applied to characterise multicomponent 
complexes using reliable, generic purification protocols. The use of protein tags in knock-in 
experiments presents another use of directed mutagenesis in the mouse and a further 
example for combinatorial two-site mutagenic applications.
Ideally, for any given gene, a full battery of targeting constructs can be envisioned, 
each combining a protein-tag fusion to facilitate in vivo localisation studies or purification of 
protein complexes with the wt or specific mutations which explore the relevance of different 
domains or residues.
It is evident that realisation of the potential inherent in dually mutagenised alleles lies 
with the ability to rapidly establish ES cell lines harbouring the combinatorial allele for the
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gene of interest. The strategy outlined in this chapter for the MU gene presents a novel 
approach to a dual engineering task and an experimental platform to test its feasibility.
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IX.2 Establishment of an MU allele mutated at two sites 60 kb apart
The primary goal was to insert a loxP site in the MU gene at an equivalent position to 
the BCR for translocation with the 4/4-loxP allele. For many of the same reasons discussed 
above for Af4, I chose not to position only a loxP site but also to create a multi-purpose 
allele. Hence, the same pOeok cassette (sA-IRES-pOal-neo-pA) was used after placement 
between loxP sites. As for Af4, the M/-pGeok allele serves two purposes before Cre 
recombination. First, P-galactosidase activity can be used to report MU promoter activity in 
situ. Second, the SV40 polyadenylation signal should truncate the primary transcript to 
produce, possibly, an interesting hypomorphic allele. If expressed and stable, the truncated 
MLL protein will correspond to the leukemogenic MLL part of MLL fusion proteins without 
a fusion partner. However, in contrast to the Af4 work, the possibilities presented by the Mll- 
pGeok allele are partially redundant to previous work on MU (Dobson et al., 2000; Yagi et 
al., 1998). Nevertheless, we felt that inclusion of the pGeok strategy here had sufficient 
merit. Also, other work in the Stewart lab had shown that PGeok was the most reliable 
cassette at hand for the primary goal anyway.
The secondary goal in creation of this MU allele was the addition of a protein tag 
(TAP-tag see below) to the very N-terminus. Thereby I hope to utilise the protein tag for 
biochemical purifications and/or immunoprécipitations of MLL in various ways. They are 
summarised here and illustrated in figure 24.
1) Before Flp recombination, the TAP-tag is not fused to MLL and serves as a good control 
for biochemistry. This allele (TAP-M//-hygro-IRES-LacZ) is predicted to result in a 
complete loss of function. The hygromycin cassette stops translation of the protein after the 
end of the ATG-TAP-FRT fusion. Even assuming the presence of a downstream promoter, 
the trap cassette in intron 11 should be sufficient to impede generation of a full length
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Figure 24 Four MU alleles generated from a single targeting construct
Schematic representation of the four alleles which can be generated from the single MU targeting 
construct using Cre and Flp recombinases. The allele depicted in panel A should ablate expression 
of the gene. The alleles in panels B, C and D are expected to allow biochemical characterisation 
of the truncated, wild-type and translocated MLL proteins, respectively.
See text for a full description of the potential uses of these alleles.
Abbreviations; CBD (calmodulin binding domain); sA (splice acceptor element); 1RES (internal 
ribosomal entry site); polyA (polyadenylation signal); TAP (tandem affinity purification)
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transcript. In fact, in a previous study, deletion of exons 12 through 14 resulted in a complete 
loss of function (Yagi et al., 1998).
2) After Flp recombination and before Cre recombination, the TAP-tag should be fused to 
the N-terminal half of MLL without the C-terminal half (TAP-M/-lRES-LacZ allele). This 
should in principle allow characterisation of the protein complex assembled around the N- 
terminal domains of MLL from a variety of tissues and organs. This could yield precious 
insights into MLL leukemogenic potential, as the truncated protein contains the domains 
which are consistently retained in the MLL fusion proteins (the three AT hooks, the 
subnuclear localisation signals and the CXXC domain). Furthermore, with this allele Lac-Z 
staining could be used to analyse the expression pattern of MU throughout embryonal 
development and adult life.
3) After Flp and Cre recombination, the TAP-tag is fused to full length MLL (TAP-M// 
allele). This should allow characterisation of the wild-type protein complex(es) in which the 
MLL protein exerts its function. Comparison of this protein complex with the TAP-M//- 
IRES-LacZ complex could help delineate which protein interactions are centered around the 
N-terminal (leukemogenic) half of the protein as opposed to the C-terminal.
4) After Flp and Cre recombination, followed by Cre mediated translocation to Af4, the 
TAP-tag is fused to the MLL-AF4 leukemogenic protein. If leukemias arise, it may be 
possible to obtain these cells in sufficient quantities for biochemistry. Furthermore, this 
mouse line could also be used to address one of the most puzzling issues regarding MLL 
oncogenic potential. In spite of widespread MLL expression throughout development and 
adult life, so far MLL translocations have been observed only in leukemias. As discussed 
previously, there could be several reasons for this, which can be grouped into either a pre- 
recombinational or a post-recombinational bias. Driving interchromosomal translocations in 
a variety of compartments other than the blood lineages could be very informative. If no
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other tumors arise in spite of the translocation, western blotting could be used to probe the 
translocation positive cells for the presence of partner proteins identified in the 
leukemogenic complex. Their possible absence would help to understand why in these cases 
the fusion protein has a neutral function.
In cases (2), (3) and (4), the tagged proteins will be heterozygotic to the wt protein, 
potentially permitting to address questions of multimerisation in protein complexes. In case 
(3), homozygosity of the tagged protein can be used to evaluate the phenotypic impact of the 
tag. Furthermore, the TAP-tagged alleles should facilitate biochemical investigations during 
development and in different tissues. In particular, it will be interesting to compare 
associated proteins in ES cells, representing the totipotent, stem cell condition, to 
differentiated tissues.
Finally, the various configurations of the MU allele potentially create an allelic series of three 
from knock-out to neutral. Together with heterozygotic combinations of the three 
configurations, a spectrum of graded phenotypic severity may also be obtained.
IX.2.1 The tandem affinity purification (TAP) system
The tandem affinity purification (TAP) protein tag was chosen because biochemical 
purification of proteins expressed at their native levels poses a greater challenge than 
approaches relying on overexpression (Rigaut et al., 1999). The TAP was shown in yeast to 
enable accurate purification of protein complexes present at relatively low levels. It consists 
of a fusion of the IgG-binding unit of protein A of Staphylococcus aureus (ProtA) with the 
calmodulin binding domain (CBD). A TEV protease cleavage site is present between the two 
moieties. The first affinity purification step utilises IgG coated beads which bind to the 
ProtA element. Following TEV cleavage to free the protein complex, a second round of 
purification is carried out using calmodulin coated beads. Importantly, all steps enable
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specific release from affinity columns under native conditions, one of the strongest aspects 
of this system.
IX.2.2 Construction of the doubly mutated M il allele
In order to select for integration into the MU locus, both in an E.Coli BAG and in the 
ES cell genome, the TAP module was linked to a hygromycin resistance cassette, flanked by 
FRT sites, so that upon Flp mediated recombination, the hygromycin resistance gene is 
deleted. In this configuration, after the first methionine coded by the starting ATG of the MU 
gene follows translation of the TAP tag in frame with the FRT left after Flp recombination; 
immediately downstream of the FRT, translation of the MLL protein, from the second 
amino-acid onward, resumes.
The second mutagenic cassette is a loxP-flanked sA-IRES-PGeok-pA module 
inserted in the intron 11 of the MU gene. This intron is one of the most frequently disrupted 
in MU translocations. As already discussed, insertion of this cassette in an intron has been 
shown to result in truncation of the normal mRNA of the gene (which may or may not be 
translated) and expression of the PGeok protein under the regulatory control of the targeted 
gene. Upon Cre mediated recombination, this whole cassette is deleted, leaving one single 
loxP site in intron 11. Importantly, this can be then used to drive interchromosomal 
translocation with the 4/^loxP mouse line.
The experimental steps involved in generating this targeting construct are summarised 
below:
1. Isolation of a mouse MU BAG.
2. Characterisation of the relevant regions of the BAG through:
2.1 ET mediated isolation of the promoter region
2.2 Direct BAG sequencing
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3. Assembly of the MU ES targeting construct by ET recombination:
3.1 ET mediated engineering of the B AC-based backbone for the targeting construct.
3.1.1. ET mediated deletion of the 5' side of the MU BAG
3.1.2. ET mediated deletion of the 3' side of the MU BAG
3.2 Assembly of the knock-in cassette M//Hom5-TAP-FRT-pA-hygro-PGK-FRT- 
M/Hom3
3.3 Assembly of the knock-in cassette inti 1-loxP-sA-IRES-PGeok-pA-loxP-intl 1
3.4 ET mediated insertion of the inti 1-loxP-sA-IRES-PGeok-pA-loxP-intl 1 cassette 
into the BAG-based construct backbone.
3.5 ET mediated insertion of the M/Hom5-TAP-FRT-pA-hygro-PGK-FRT- 
M/Hom3 cassette into the BAG-based construct backbone.
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IX.3 Assem bly o f the Mil targeting construct
IX.3.1 Isolation of the mouse M il genomic clone from a high density BAG library
High density mouse BAG filters (Research Genetics, Inc.) were screened with a 
mouse MU specific probe (pS2). The probe was a cDNA fragment corresponding to the first 
three PHD fingers of the MLL protein (PH-A, PHD-B and PHD-G) which span exons 11 
through 16.
Hybridisation of this probe to the high density BAG filters yielded 5 independent positive 
signals (Figure 25). 3 clones, n.l46D23, 145K16 and 145L16, screened by PGR and 
Southern hybridisation, were found to contain bands of the expected size. (Figure 26)
A combination of both direct sequencing, PGR amplification and Southern blot hybridisation 
was used to check for the presence, within the same BAG, of both the first exon of the gene 
(as a substrate for targeting the TAP cassette) and intron 11 (as a substrate for targeting the 
loxP-pGeok cassette).
The probe used for Southern hybridisation was an oligonucleotide probe (mM /exl) with the 
following 5'-3' sequence:
GGGGGGGGGTGGTGGGGGTGGGGGGGGGGTTGGAGGGGGGGGTGGAGGTGTGGG
GGGGGATGGGGAGGAAGGTGGGGGGGTTGGGGGGAGTGTTTGGGGAGAGGGGGG
GGGGAGGGGGGAGGGGAGAG
BAG 145L16 was found to contain both regions of the MU gene needed for targeting and 
was therefore selected for the further steps.
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Figure 25 Isolation of Mil BAC clones
Hybridisation of high density mouse BAG membranes with an Mil probe (pS2) spanning the 
exons coding for the three PHD fingers (PHD-A, PHD-B and PHD-C). Each BAG clone is 
spotted twice to distinguish true signals (a double spot) from false positives.The filter was 
simultaneously hybridised with a control probe which highlights the reference marks on the 
four sides of the membrane to unequivocally identify the clone of interest.
Positive clones are circled in red.
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Figure 26 Southern blot hybridisation of candidate Mil BACs
8 candidate Mil BACs isolated from a BAG library screening were tested with the Mil probe 
pS2. BAG clones n. 146D23, 145K16 and 145L16 display the correct signal. BAG 145L16 
was chosen for further characterisation.
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IX.3.2 ET mediated cloning of the 5’ region upstream of Mil exon 1
Once both sequence analysis and Southern blot hybridisation had confirmed the 
presence of MU exon 1 in the BAG 145L16, it became important to derive more sequence 
information on the region immediately upstream of the initiating ATG of MU exon 1 so that 
a Southern blot strategy which would discriminate between random integration and 
homologous recombination events could be developed. Also, the substantial length of extra 
5’ homology present in the BAG would make it impossible to devise a suitable Southern 
strategy and hence needed to be eliminated. Therefore, sequence information was also 
needed to devise a strategy which would shave the BAG from one end of the BAG vector up 
to about 5 kb upstream of the initiating ATG. In this step a rare cutting restriction enzyme 
site was concomitantly introduced so that the final targeting construct could be easily 
severed from the BAG vector prior to ES cell electroporation. In order to perform this ET 
cloning mediated deletion ("BAG shaving"), it was necessary to obtain sequence information 
from the region around 5 kb upstream of the ATG.
While the 5’ region of the human MLL gene has recently been sequenced, the 
corresponding region in the mouse was completely unknown. A primer-walking sequencing 
approach would have been very time consuming. Plus, for BAGs to become the tools of 
choice in contemporary genome engineering, techniques must be developed which improve 
their ease of manipulation, including the ability to rapidly isolate a region of choice from a 
BAG. Therefore, I decided to apply a further variation of the ET methodology to subclone 
this region from the BAG. In this variation (figure 27) a region of choice is deleted from the 
target DNA molecule and replaced with a selectable marker. Here, all of the MU BAG 
downstream of exon 1 to the BAG vector was deleted. This placed a selectable marker 
immediately adjacent to the unknown region to be subcloned on one side, and the knovm 
sequence region of the BAG vector on the other. Upon digestion of this deleted BAG with
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Figure 27 ET mediated BAC deletion to subclone the promoter region of MU
An ET recombination approach was chosen to delete from the MU BAG the whole region 
spanning exon 1 to exon 25, by replacing it with the kanamycin resistance gene. The MU 
promoter region was then easily isolated by random BAG subcloning into the vector 
pBluescriptll KS applying kanamycin selection.
The names of the DNA molecules (constructs and PGR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter. The region to 
be deleted is shown in light blue. The subcloned region is shown in orange. The 
homology arms and target regions mediating ET recombination are shown in red. 
Segments of the constructs accompanied by arrows indicate open reading frames 
Abbreviations: (Gm) chloramphenicol resistance gene; (Amp) piactamase gene;
See text for a full description of the cloning strategy.
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appropriate enzymes chosen for suitability from the known sequences and ligation to 
a standard plasmid, the positive colonies harbouring the region of interest could be very 
easily identified by doubly selecting for both the plasmid marker and the selectable marker 
positioned in the BAG.
End sequencing from the BAG vector revealed that up to intron 26 of MU was 
present and also established the orientation. With this information, the following oligos were 
designed: M/ET5 and BAGET2.
Oligo M/ET5 has the following sequence 5-3':
TGCTCCGGGTGGGCCCGGGCTTCGACGCGGCGCTGCAGGTCTCGGCCGCC 
ATCGGCACCAACCTGCGCCGGTTCCGGGCAGTGTrZ4vfrrA4AGGAGGTAGGT 
T GGAGT GGGGTT AG AT GGGG. Residues 1-86 (in bold) constitute the MU homology arm 
starting from near the 5' edge of known sequence, 301 base pairs upstream from the 
initiating ATG of MU. The PGR primer part of this oligo (residues 93-123, underlined) was 
used to amplify the kanamycin resistance selectable marker. A P ad  site was introduced in 
the oligo as a possible anchor point in subsequent cloning steps (positions 85-92, italic). 
Oligo BAGET2 has the following 5'-3' sequence:
TCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCA
CTATAGGGCGAATTCGAGCTCGGTACCCGGGGATTET4T7Mv4TGGAAGGGGAG
AGTGGGGGTGAGAAGAAGTGG.
Residues 1-85 (in bold) constitute the homology arm to the BAG vector. The PGR primer 
part of this oligo includes residues 94 to 125 (underlined). Also in this case, a P ad  site was 
introduced in the oligo as a possible anchor point in subsequent cloning steps (positions 86- 
93, italic). The resulting PGR product (PGRMLLET2) is 1205 base pairs long.
For the ET cloning reaction, HS996 cells, harbouring the MU BAG, were transformed 
with the recombinogenic plasmid pBAD-aPy, and made competent as described (see
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materials and methods). After electroporation with the PCR product, cells were plated under 
double selection (chloramphenicol 25|xg/ml and kanamycin 25 |Ltg/ml).
Among all colonies analysed, two closely related restriction patterns were observed. 
Both showed substantial and almost identical deletions. To analyse in more detail the two 
types of deletions, colonies G and T were chosen for further analysis. Maxiprep DNA 
preparations were made of both colonies and digested with either EcoRI or BamHI. Figure 
28 shows the analysis of these digests by electrophoresis. By comparing the patterns of lanes 
1 and 2 (EcoRI digests of wt BAG 145L16 and the deleted BAG-G, respectively), and the 
patterns of lanes 3 and 4 (BamHI digests of the wt BAG 145L16 and the deleted BAG-G 
respectively), it was possible to estimate the extent of the deletion as being greater than 50 
kb. By comparing lanes 2 with 7 (where BAG-G in lane 2 shows a higher band than BAG-T 
in lane 7), and lanes 4 with 8 (where BAG-G in lane 4 shows a higher band than BAG-T in 
lane 8), it also became clear that BAG-G was longer than BAG-T by approximately 3 kb 
(Figure 28).
To further characterise the deletion, pulsed-field-gel electrophoresis was performed 
on BamHI digests of the wt BAG and the deleted BAG-G. (Figure 29)
Finally, to subclone and characterise the region 5’ of the ATG, DNA preparations of 
both colonies G and T were digested with either EcoRI or Sad. These two enzymes were 
chosen because they only cut the known DNA in the BAG vector near the inserted 
kanamycin resistance cassette. After ligation to pBluescriptll and analysis, it was found that 
subclones from both G and T deleted BAGs were the same. The reason for the occurrence of 
two slightly different patterns of deletion was therefore not further investigated, since it did 
not constitute the main objective of this experiment.
Final sequencing of EcoRI and Sad subclones delivered approximately 5.5 kb of 
unknown upstream sequence.
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Figure 28 ET mediated BAC deletion to subclone the promoter region of 
Ml! (restriction analysis)
The region from exon 1 to intron 26 was replaced with the kanamycin resistance 
gene by ET recombination. The extent of the deletion was estimated by electrophoresis 
of EcoRI and BamHI digests. O an indicate the bands of the wt Mil BAG 
which are missing from two independent "ET deleted" colonies. Mil BAC-G and 
MU BAG-T. More than 50 kb were deleted.
MU BAG-G and Mll-BAG-T differ only by about 3 Kb, as indicated by the bands 
circled in yellow and azure from EcoRI and BamHI digests respectively.
HMW= high molecular weight DNA marker (Gibco, BRL)
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Figure 29 Pulsed field gel electrophoresis of wt and ”ET deleted" Mil BACs
The wt Mil BAC, as well the "ET deleted" Mil BAC-G were analysed by pulsed 
field gel electrophoresis. Red arrows indicat the bands of the wt Mil BAG which 
missing from the deleted Mil BAC-G
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IX.3.3 ET mediated engineering of the MU BAC to yield the backbone for the 
MU targeting vector.
Having obtained sufficient sequence information for the regions 5’ of the initiating 
ATG and 3’ of intron 11, a strategy to shave the MU BAC on both sides (figure 30) to yield 
the backbone for the final targeting construct was undertaken.
HS996 cells harboring the vyt MU BAC 145L16 were transformed with the 
recombinogenic plasmid R6Kapy- Two colonies, n. 3 and n. 8, were used to prepare batches 
of competent cells.
In the first step of the deletion strategy, a PCR product was designed to replace the 5’ 
end of the MU BAC from the BAC vector to approximately 5 kb upstream of the initiating 
ATG. To this end oligos M//DellF and MU DellR were used to amplify the P-lactamase 
gene.
Primer M/Del IF has the following 5'-3' sequence:
TTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTATTTAGGTGACACT
ATAGAATACTTAATTAATGAAGACGAAAGGGCCTCGTGATACGCC.
Residues 1-63 constitute the arm of homology to the BAC backbone. A P ad  site was 
included at positions 64-71 to facilitate subsequent recognition of correctly targeted BACs. 
The portion of this oligo annealing to the p-lactamase gene (from plasmid pACYC177) 
comprises residues 72 to 99.
Primer M /D ellR  has the following 5'-3' sequence:
GCAGGTACCTAGCCATATGCCTGTTTCCTCATTTGCAAACATAAGAATATTAATA
GCAACTCCTGCCATTTCATTACCTCTTTCTCCGCACCCGACATAGATATCAATCT
AAAGTATATATGAGTAAACTTG.
Residues 1-63 constitute the arm of homology to the MU region 5031 bp upstream from the 
initiating ATG of the gene. Residues 64-102 constitute a site for the extremely rare cutting
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Figure 30 Sequential "shaving" of the MU BAC
Schematic representation of the sequential "BAC shaving" strategy to obtain a suitable 
BAC based backbone for the insertion of knock-out or knock-in cassettes. The case of the 
Mil BAC is illustrated here. ET recombination was used to replace the irrelevant portions 
of the BAC with two selectable markers. Rare restriction sites (in this case Pi-Scel) were 
introduced into the ET homology arms, to enable release of the targeting construct from 
the BAC vector prior to ES cell transfection.
The region to be deleted in the first round is shown in light blue. The selectable marker 
used in the first round was the P-lactamase gene (Amp), also shown in light blue. The 
homology arms and target regions mediating ET recombination in the first round are 
shown in blue.
The region to be deleted in the second round is shown in orange. The selectable marker 
used in the second round was the gentamycin resistance gene (Gent), also shown in 
orange. The homology arms and target regions mediating ET recombination in the second 
round are shown in blue.
MU exons 1,11, 12 and 25 are represented by thin pink boxes. Intron 11, where the loxP- 
sA-IRES-Pgeok-pA-loxP was targeted, is indicated by a lila bar.
The scale bar indicates the number of nucleotides/centimeter.
Segments of the constructs accompanied by arrows indicate open reading frames. 
Abbreviations: (Cm) chloramphenicol resistance gene; (Amp) piactamase gene;
See text for a full description of the cloning strategy.
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enzyme Pl-Scel (also called VDE). This site was included to cleave the final targeting 
construct from the BAC backbone. The portion of this oligo annealing to the P-lactamase 
gene (from plasmid pACYC177) comprises residues 103 to 132.
The PCR product (PCRM//DellF-M//DellR) was then electroporated into competent BAC 
cells from both batches n.3 and n.8, and cells were plated under double selection 
(chloramphenicol 12,5 pg/ml and ampicillin 50 pg/ml).
Fourteen colonies were analysed with BamHI. As shown in figure 31, all 14 colonies 
showed the intended deletion. However, colonies 1,3 and 10 also showed wild type bands, 
indicating that they were mixed colonies in which only a subset of cells had undergone ET 
deletion, conferring ampicillin resistance to the whole colony.
Two restriction patterns emerged from this first round of ET mediated deletion (colonies 1- 
11 versus colonies 12-14), differing by one band (a band of 9 kb is present in colonies 1 to 
11 but absent from colonies 12 to 14, while a band of around 10 kb is present in colonies 12 
to 14 but absent in colonies 1 to 11). Interestingly, colonies 1-11 had all originated from 
competent cells of batch n.3, while colonies 12-14 had originated from competent cells of 
batch n.8. This suggests that the intramolecular undesired recombination event had happened 
prior to the electroporation of the recombinogenic PCR product, either in the wild type strain 
HS996 as a result of intrinsic instability of this particular BAC, or during preparation of 
competent cells, when the induced expression of the recombinogenic proteins might have 
promoted intramolecular recombination between homologous regions of the BAC. To 
distinguish between these possibilities, and to exclude the possibility that the two patterns 
reflected two distinct deletion reactions mediated by the same PCR product (PCRM/DellF- 
M//DellR) due to multiple regions of homology, the following experiment was devised. A 
new PCR product was designed, whose homology arms to the MU BAC lay just adjacent to 
the previous ones (employed for the PCR product PCRM/DellF-M/DellR).
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Figure 31 First round of Mil BAC shaving (restriction analysis)
First round of ET mediated deletion ("BAC shaving") on the 
Mil BAC 145L16 with the PCR product PCRMllDELl conferring 
Ampicillin resistance. The light blue arrows indicate two of the bands 
which have been deleted from the wt BAC. The upper band (pink arrow) 
points to a new band which results from the deletion. Colonies 1, 2, 3 and 
10 constitute mixed colonies which harbour both the wt and the deleted BAC.
The pattern of colonies 4-11 and 12-14 differ for a single band (yellow arrowheads), 
which correlates with the original batch of competent cells utilised (see text and 
figures 31 and 32).
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The assumption was that, if one of the patterns were resulting from inappropriate 
recombination with a region in the BAC other than the target one, after changing both 
homology arms, one should not observe this pattern again. In fact, the chances that both new 
homology arms would also have significant degrees of homology to the alternative spurious 
target regions were expected to be rather low. Plus, designing the new homology arms right 
next to the previous ones made it possible to directly compare the results of the two 
experiments, since the expected deletion pattern would not be affected by shifting the 
homology arms such a short distance. In order to completely exclude the role of sequences 
from the previous PCR product (PCRM/DellF-M/DellR) in the spurious deletion reaction, 
the selectable marker was also changed. The kanamycin resistance gene from the plasmid 
pACYC177 was chosen and amplified with the following oligonucleotides: oligo 
NM /DellF and oligo NM/DellR.
Oligo NM /DellF has the following5'-3' sequence:
CCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCG
GATAACAATTTAATTAATCTCTGATGTTACATTGCACAAGA.
Residues 1-64 constitute the arm of homology to the BAC backbone, in a position adjacent 
to the homology arm of oligo M//DellF. A P ad  site was included at positions 65-72 to 
facilitate subsequent recognition of correctly targeted BACs. The portion of this oligo 
annealing to the kanamycin resistance gene (from plasmid pACYC177) comprises residues 
73 to 96.
Oligo NM /DellR has the following 5'-3' sequence:
CACTGCAAATCAGTATCATGGTGTGACTAACATGGGTTCAGAGCCACCAGCCTA
GGCTTGATTTGCCCGGGCCCAGTGTTACAACCAATTAACCAATTC.
Residues 1-64 constitute the arm of homology to the MU region 4968 bp upstream from the 
initiating ATG of the gene, adjacent to the homology arm of oligo M//DellR. Residues 65-
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72 constitute a site for the rare cutting enzyme Srfi. The portion of this oligo annealing to the 
kanamycin resistance gene (from plasmid pACYC177) comprises residues 73 to 99. The 
resulting PCR product (PCRNM/DellF-NM//DEllR) was electroporated into the same 
batches of MU BAC-containing competent cells (n.3 and n.8). BamHI digestion of the 
resulting colonies once again showed (figure 32) two distinct patterns, respectively 
associated with the batch of competent cells. In terms of efficiency, 5/6 colonies originating 
from batch n. 3 showed the correct deletion pattern (A,B,C,E and F). Colony n. D was an 
unrecombined colony which managed to survive selection. 3/6 colonies originating from 
batch n. 8 showed the correct deletion pattern (K, M and O). Colonies L, N and P were 
unrecombined colonies which also survived selection. The repeated occurrence of the same 
two patterns of deletion upon electroporation with two recombinogenic PCR products of 
completely unrelated sequence strongly suggest that the two patterns were preexisting, and 
were not the result of inappropriate recombination between the PCR product and spurious 
homologous regions in the BAC. Furthermore, comparison of colonies E, L, N and P (ie. 
unrecombined colonies respectively from batches n.3 and n.8) with the original wild type 
MU 145L16 digest run alongside on the same gel as standard reference shows that batch n. 3 
preserved the correct restriction pattern, while cells from batch n.8 did not. To confirm this, 
both batches n.3 and n.8 were streaked and individual colonies picked and digested with 
BamHI. In parallel, cells from the original glycerol stock of wt BAC 145L16 were also 
streaked, individual colonies picked and digested with BamHI. All three sets of digests were 
run alongside on a 0.4% agarose gel.
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Figure 32 First round of Mil BAC "shaving" (control experiment)
ET mediated deletion o f the Mil BAC with the PCR product 
N M llDell which confers kanamycin resistance and is unrelated 
to the PCR product M llDell used in the previous experiment (Figure 30) 
Results show that independent o f the recombinogenic PCR product 
used, colonies originating from batch 3 and 8 o f competent cells show 
consistently a single band difference in the restriction pattern 
(indicated by the yellow arrowheads). Colonies E, L, N and P 
represent unrecombined colonies which survived selection.
The two bands indicated by pink arrows originate from the recombinogenic 
plasmid R6Ka(3y which in this experiment was not lost from the cells after 
recombination.
205
The patterns (shown in figure 33) establish that all cells from batch n.3 are correct, while all 
cells from batch n.8 have undergone an intramolecular recombination event. The fact that all 
colonies from the original wt BAC show the same pattern (and none of them shows the 
pattern of batch n.8) supports the notion that the intramolecular recombination event 
probably occurred during preparation of competent cells upon expression of the 
recombinogenic proteins. This in turn probably resulted from the presence of significant 
homologous regions within the BAC.
In the second step of the deletion strategy, a PCR product was designed which would 
replace the 3’ side of the MU BAC from the BAC vector to a region approximately 5 kb 
downstream of the location in intron 11 that had been chosen for targeting the loxP flanked 
sA-IRES-Pgeok-pA cassette. To this end PCR oligos M//Del2F and M//Del2R were 
synthethized to amplify the gentamycin resistance gene as a selectable marker replacing the 
3’ part of the BAC.
Oligo MUDqYIV has the following 5'-3' sequence:
CAGAGATAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAAAGTGAGATC
CAGGAGAGCCAAGGCGCGCCATCTATGTCGGGTGCGGAGAAAGAGGTAATGAAATG
GC^TGAAGGCACGAACCCAGTTGACATAAGCC.
Residues 1-67 (underlined) constitute the homology arm to intron 16. Two rare restriction 
sites were included, an AscI site at positions 67-74 and a Pi-Scel site at positions 75-113 
(italics). The portion of this oligo annealing to the gentamycin resistance gene comprises 
residues 114-142 (in bold).
OligoM/Del2Rhas the following 5-3' sequence:
CTCTGTCGTTTCCTTTCTCTGTTTTTGTCCGTGGAATGAACAATGGAAGTCCGAG
CTCATCGCTATCGGCTTGAACGAATTGTTAGGTGGC.
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Figure 33 Restriction analysis of independent Mil BAC colonies
BamHI digest of 2 independent colonies from a restreak of the original BAC containing cells,
5 independent colonies from a restreak of the batch of competent cells n.3, and 4 independent 
colonies from a restreak of the batch of competent cells n.8, in order to detect intramolecular 
recombination events prior to electroporation with the recombinogenic PCR product.
Cells coming from batch n. 3 and n. 8 display the same one band difference (yellow arrowheads) 
shown in previous experiments (Figure 31 and 32), demonstrating that the intramolecular 
recombination was preexistent to the transformation with the recombinogenic PCR product.
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Residues 1-65 constitute the homology arm to the BAC backbone (underlined). The portion 
of this oligo annealing to the gentamycin resistance gene comprises residues 66-90 (in bold). 
Cells from colonies n.6 and n.7 of the first deletion step (figure 31) were grown in triple 
selection (chloramphenicol 12,5 pg/ml, ampicillin 50 pg/ml and tetracycline 25|Lig/ml) to 
maintain the BAC and the recombinogenic plasmid R6KaPy (which confers tetracycline 
resistance). After induction for 1 hr with L(+)arabinose, they were harvested at ODôoo of 
0.45 and made electrocompetent as described (see Materials and Methods). They were then 
electroporated with the PCR product PCRM/Del2F-M//Del2R and plated under triple 
selection (chloramphenicol 12,5 pg/ml, ampicillin 50 pg/ml and gentamycin 3|Lig/ml). 
Twelve colonies were picked and analysed, 1-9 originating from colony n. 6, and 10-12 from 
colony n.7. From an electrophoresis analysis of their BamHI digests (Figure 34), two 
patterns clearly emerged, one represented by colonies 1, 5, 7 and 8, and the other represented 
by colonies 3, 9 and 12. Parallel analysis of the original colony n.6 (resulting from the first 
deletion step) showed that colony n. 7 was a mixed colony, in which some cells had not 
undergone this second round of deletion. Limited amounts of DNA for colonies 2, 6 and 11 
prevented a clear assignment of their restriction pattern. Colony 10, on the other hand, 
showed a pattern distinct from either one of the two main ones, and since this pattern 
emerged only once, it was not further analysed. To distinguish which one of the two patterns 
reflected the correct deletion event, a sequencing analysis was performed. Sequencing 
primers were designed to display sequence around each end of the integration site, in intron 
16 and in the BAC backbone. This established colony 5, and hence the most prevalent 
pattern also present in 1, 7 and 8, as correct. In colony 3, the PCR product had integrated at a 
site other than intron 16. Interestingly, sequences of colony 3 and 5 were identical at the 3’ 
integration site, meaning that for colonies 3, 9 and 12, the PCR product had integrated
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Figure 34 Second round of Mil BAC shaving (restriction analysis)
BamHI digest on candidate recombined colonies. Competent cells were prepared from 
colony n.6 and n.7 resulting from the first deletion round and were then electroporated 
with the PCR product MllDel2. Two patterns emerged, one represented by colonies 
1, 5, 7 and 8, and the other represented by colonies 3, 9 and 12.
Sequencing analysis established the pattern displayed by colonies 1, 5, 7 and 8 
as the correct one.
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correctly with the 3’ homology arm, but incorrectly with the 5’ one at presumably the same 
place. Thus, contrary to the case discussed above, in this instance, one of the two restriction 
patterns could actually be explained by mistargeting of the PCR product,possibly due to the 
presence of spurious sites with relevant homology to the sequence of the homology arms.
On the basis of these results, the deleted BAC from colony n. 5 (BACD-5) now constituted 
the final backbone into which the two functional knock-in cassettes had to be targeted, the 
TAP-FRT-pA-hygro-PGK-FRT cassette immediately downstream of the initiating ATG, and 
the loxP-sA-IRES-pGeok-pA-loxP cassette in intron 11.
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IX.3.4 Assembly of the knock-in cassette M//-TAP-hygro
An outline of the cloning steps for the generation of the A/7/-TAP-hygro cassette is shown in
figure 35. The knock-in cassette M/-TAP-hygro consists of the following elements:
1) The 5’ MU homology arm (of 49 bp) including the starting ATG of the MU gene and the
46 nucleotides upstream of it.
2) The TAP (Tandem affinity purification) protein tag (see above), which is a fusion of the 
Protein A, the TEV cleavage site and the Calmodulin Binding Domain (CBD)
3) A 5’ FRT site, the target site for the Flp site specific recombinase
4) A module expressing the hygromycin phosphotransferase gene (which confers 
resistance to hygromycin) under the control of both the PGK promoter (for selection in 
mammalian cells) and a prokaryotic promoter (for selection in E. coli). This module is 
placed in an orientation opposite to the direction of transcription of the MU gene, in 
order to minimise the possibility of promoter interference between the endogenous MU 
promoter and the PGK promoter.
5) A 3’ FRT, which, together with the 5’ FRT, allows excision of the hygromycin 
expressing module upon expression of Flp recombinase. The 3’ FRT is followed by a 
single nucleotide inserted before the 3 ’ MU homology arm, so that, after excision of the 
hygromycin module, the reading frame is maintained between the starting ATG, the 
TAP tag, the FRT (left after the recombination reaction) and the rest of MU exon 1, 
including the 3’ MU homology arm.
6) The 3’ MU homology arm, which includes the second codon of MU exon 1 and 66 
nucleotides downstream of it. Together with the 5’ MU homology arm, it directs the 
insertion of the cassette between the first and the second codon of MUl exon 1.
211
Muni
PGK promoter
prokaryotic  p rom oter
ds oligo 115 bp 
F R TM IIH om
;
Hygro
P G K - P - h y g r o
3984p o ly A
Not I
Muni
^  Muni II Not!
Amp
F R T ^  4088
ÇGK promoter bp
pro ka ry o t ic  prom oter
FRT- S' ET homology 
arm to Mil
50
I-------1
Figure 35 Cloning steps for the assembly of the M//-TAP-hygro cassette
Illustration o f  the assem b ly  o f  the M //-T A P -h ygro  cassette to target the first 
exon  o f  M U  v ia  ET recom bination . The backbone w as the P G K -P -h ygro-p o lyA  
m odu le enabling hygrom ycin  se lection  in both E .co li  and ES ce lls .
The TA P tag, flanked by the ET h o m o lo g y  arm on the 5' side and the FRT on  
the 3' side, w as am plified  b y  PC R , y ie ld in g  the palsm id  T O PO -T A G -C . ET  
recom bination w as then used  to su bclone the M llH om 5-T A P-F R T  m od u le  into  
the vector p A C Y C 184, y ie ld in g  the p lasm id  SubTag, w hich  w as subsequently  
repaired with the o lig o  Repair to y ie ld  the construct SubTagRepair. From  this 
plasm id, the M llH om 5-T A P -F R T  cassette w as ex c ised  and su b clon ed  into  
P G K -P -h ygro-F R T M llH om 3, to y ie ld  the final construct 
M llH om 5-T A P -F R T -p A -h ygro -P -P G K -F R T -M llh om 3 (abbreviated  in  
M //-T A P -h y g ro ).
The p lasm id  P G K -P -hygro-F R T M llH om 3 resulted from direct c lo n in g  o f  the 3' 
ET h o m o lo g y  arm flanked b y  the secon d  FRT (o lig o  F R T M llH om 3) into the 
PG K -P -hygro p lasm id, dow nstream  o f  the PG K  prom oter.
The nam es o f  the D N A  m o lecu les  (constructs and PCR products) are in  bold  and 
underlined. The sca le bar in d icates the num ber o f  nucleotid es/cen tim eter. 
S egm ents o f  the constructs accom pan ied  by arrows indicate open reading fram es. 
A bbreviations: (bp) base airs; (C m ) ch loram phenicol resistance gene; (A m p )  
piactam ase gene; (hygro) h ygrom ycin  phosphotransferase gene; (T A P ) tandem  
affin ity  purification; (pA ) p o lyad en y la tion  signal.
S ee text for a full description o f  the c lon in g  strategy.
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The starting backbone for the assembly of this cassette was the plasmid PGK-P-hygro 
(figure 35), in which a prokaryotic promoter (P) had been placed immediately downstream 
of the PGK promoter, to permit hygromycin selection both in eukaryotic and prokaryotic 
systems. This is particularly useful, since it enables one to use the same selectable marker, 
and hence the same cassette, for ET mediated homologous recombination in E. coli and for 
homologous recombination in mouse BS cells.
The first step involved cloning, immediately downstream of the PGK promoter (since the 
hygromycin module had to be oriented opposite to the direction of transcription of the MU 
gene) the 3’ MU homology arm, flanked, on its 5’ side, by an FRT element. To this end, the 
following oligos were synthethized: FRTM/HomF and FRTÂ/7/HomR, which would anneal 
to each other so as to create an Mfel site on the 5’ end and a Notl site on the 3’ end for 
cloning in the corresponding sites of PGK-P-hygro.
Oligo FRTM/HomF has the following 5'-3' sequence:
AATTGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCyfGCGCACAGCTGT
CGGTGGCGCTTCCCCGCCCGACCCGGGACCACCGGGGGCGGCGGCGGCGGGGG
GCGCCGGGGC.
The FRT is located at positions 6 to 39 (in bold).
Residues 41 to 114 (underlined) constitute the region of homology to codons 2 through 26 
of MU exon 1. A single nucleotide was inserted at position 40 (italics) in order to keep the 
reading frame between the starting ATG, the TAP tag, the FRT (left after the recombination 
reaction) and the rest of MU exon 1 after excision of the hygromycin module. The sequence 
AATTG (positions 1-5) provided the upper strand of the Mfel site, while the the terminally 
located GC dinucleotide (positions 114-115) formed the upper strand of the Notl site.
Oligo FRTM/HomR has the following 5'-3' sequence:
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GGCCGCCCCGGCGCCCCCCGCCGCCGCCGCCCCCGGTGGTCCCGGGTCGGGCG
GGGAAGCGCCACCGACAGCTGTGCGCTGAAGTTCCTATACTTTCTAGAGAATAG
GAACTTCC.
It is complementary to FRTM/HomF throughout residues 5 to 114. Upon annealing with 
FRTM/HomF, the GGCC sequence (positions 1-4) constitutes the lower strand of the Notl 
site, while the terminally located C (position 115) forms the lower strand of the Mfel site. 
The two oligos were annealed to each other and then ligated to the vector PGK-P-hygro, 
which had been previously digested with Mfel and Notl. Cells transformed with the ligation 
mixture were grown on double selection (ampicillin lOOpg/ml and hygromycin 50 pg/ml) 
All colonies analysed showed the correct pattern of integration of the FRTM/Hom insert 
into the PGK-P-hygro vector. It has been reported, and it was also observed in some of 
these cloning procedures, that long oligonucleotides (like the ones used in this case) can 
sometimes contain defects (mostly depurination) which can result in deletion of the affected 
residues upon scrutiny by the E.coli DNA repair machinery. Since in this case it was 
absolutely crucial that the sequence of FRTM/Hom be correct, in order to keep the reading 
frame and to maintain the functionality of the FRT site, some recombinant colonies (PGK- 
P-hygro-FRTM//Hom3) were sequenced. Colony n. 2 was found to be correct, and was 
therefore chosen for the subsequent cloning steps.
The problem of mutations and defects in long oligos (particularly with a high GC content) 
was particularly troublesome for the assembly of the 5M/Hom-TAP-FRT portion of the 
M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT-M/Hom3 cassette. Once again, an ET cloning 
based subcloning approach (see below) eventually led to the correct clone.
As a starting point, the TAP tag was amplified from a template by PCR with the following 
oligos: NewM/NTagF and NtagR.
Primer NewM/NtagF has the following 5'-3' sequence:
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TTTGGCGCGCCATTGCGGCCGCTCCCCCCCCTCCGCCTCCCCGCCCCCCTGTGTT
GTCGCCTCTCCCTCTCGCTGCTTCACTTACGGGGCGAACATGCGCGCCGCAGGC
CTTGCGCAACACGATGAAGCCGTGGACAACAAATTCAAC.
Residues 18-94 constitute the arm of homology to the region of MU immediately upstream 
of the initiating ATG, which is also included (positions 95-97). The portion of the oligo 
which anneals to the TAP containing template comprises residues 98 through 148. An AscI 
site (positions 4-11) and a Notl site (positions 15-22) were inserted for further cloning steps 
and, for the Notl site, to release the recombinogenic cassette from the vector backbone prior 
to ET recombination.
Oligo NewNTagR has the following 5'-3' sequence:
TACAGGCGCGCCGGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCCATCAAG
TGCCCCGGAGGATGAGATTTTC.
Residues 14 through 47 constitute the FRT site, while the portion of the oligo which anneals 
to the TAP containing template comprises residues 49 through 76. A single residue (a C at 
position 48) was included in order to maintain the reading frame between the TAP tag anf 
the FRT. An AscI site is present at residues 5-12.
The PCR product was cloned into a PCR-TOPOII vector (commercially available from 
Invitrogen) and transformed into TOP 10 competent cells. In this experiment, two elements 
were a potential source of mutation: defects in oligonucleotide synthesis and the mutation 
rate intrinsic to any PCR reaction. Although a high fidelity Taq polymerase was used, this 
risk can never be fully eliminated. Therefore, of 20 colonies shown to contain an insert of 
the correct size, 8 colonies were sequenced to check the integrity of the 5’ Mil homology 
arm, the TAP tag and the FRT. None of the colonies had the absolutely correct sequence, 
and most mutations were detected in the oligonucleotide portions of the PCR product, 
arguing that their most likely source was a defect during oligonucleotide synthesis. One
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colony (TOPOTAG-C) was almost entirely correct, except for a G to A mismatch at 
position 49 (corresponding to position 59 on the oligo NewMZ/NtagF), and the missed 
incorporation of residues 1-10 of the oligo NewNTagR (including the AscI site) in the 
cloned PCR product. Given the seemingly high rate of mutations occurring in these 
oligonucleotides (regardless of any purification technique employed), and since this colony 
contained almost the full correct sequence, I decided to use an ET subcloning approach to 
repair these mutations without having to undergo a further round of PCR amplification. The 
strategy involved subcloning the correct relevant part of TOPOTAG-C into an acceptor 
plasmid (pACYC184) while at the same time incorporating in the ET oligonucleotides the 
parts which were missing or mutated in TOPOTAG-C. OligosSubtagl and Subtag2 were 
designed:
Oligo Subtagi has the following 5'-3' sequence:
GCGCATGTTCGCCCCGTAAGTGAAGCAGCGAGAGGGAGAGGCGACAACACAGG
CGGCCGCAAAGGCGCGCCACAACTTATATCGTATGG.
Residues 1-53 constitutes the region of homology to the corresponding region of 
TOPOTAG-C. The two sequences are completely identical, except that in the oligo 
Subtagi, a C is inserted at position 42 in order to correct the G to A mismatch in 
TOPOTAG-C. Furthermore, in the new configuration resulting from this subcloning step, 
the actual 5’ MU homology arm has been reduced to 48 nucleotides. This has been shown to 
be sufficient to promote homologous recombination in E.coli; in this case, this shortening 
e xc lu de d  f rom the S u b t a g i  o l igo the GC r i c h  s t r e t ch  
(GCCGCTCCCCCCCCTCCGCCTCCCCGCCCC), which was present in the oligo 
NewM/NtagF and which could have created further problems during the oligo synthesis.
The portion of this oligo which anneals to the pACYC184 template to amplify the 
chloramphenicol resistance gene comprises residues 72 to 89. An AscI site was inserted
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(positions 64-71) for the next cloning step, as well as a Notl site (positions 53-60) to release 
the recombinogenic M//-TAP-hygro cassette from the vector backbone prior to ET 
recombination.
Oligo SubtagR has the following 5'-3' sequence:
GATGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCCGGCGCGCCTTACGCC
CCGCCCTGCCACTC.
Residues 1-41 constitute the arm of homology to the corresponding region in TOPOTAG-C. 
Residues 42-47 (CGCGCC) were inserted in order to reconstitute the AscI site, which had 
been deleted in TOPOTAG-C. The portion of this oligo which anneals to the pACYC184 
template to amplify the chloramphenicol resistance gene comprises residues 48 to 68.
The PCR product features at its ends the two regions of homology to the 5’M/Hom-TAP- 
FRT module of TOPOTAG-C (acting as the donor plasmid).
The PCR product was first digested with Dpnl, an enzyme which cleaves only when its 
restriction site (GATC) is methylated, and thereby serves after the PCR to eliminate the 
template (in this case pACYC184), which could otherwise contribute a serious source of 
antibiotic resistant colonies. Following purification of the Dpnl digest, the PCR product (300 
nanograms) was coelectroporated together with the donor plasmid (TOPOTAG-C) into the 
E.coli strain JC8679, which constitutively expresses the recombinogenic proteins RecE and 
RecT. Cells were then plated on chloramphenicol selection (50 |xg/ml).
Eight out of ten colonies analysed displayed the correct pattern. Colony n.l (Subtagi) was 
selected for further cloning.
In colony SubTag 1, six residues (CGCGCC) occurred immediately downstream of the 
initiating MU ATG, coding for the two amino acids arginine and alanine. This stretch of 
sequence had been incorporated in the oligo NewM/NtagF in order to amplify a previous 
version of the TAP tag containing these two additional amino acids. However, in the final
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version of the TAP tag, these two amino acids are absent, and it was therefore important to 
remove them from the plasmid Subtag 1, since their effect on the overall structure of the tag 
could not be foreseen. To this end, an oligo repair strategy, which relied on the presence of 
unique Notl and StuI sites flanking the region to be modified, was adopted. The RepairF 
and RepairR oligos were synthethized, complementary to each other. Upon annealing, they 
create on the 5’ side a 5’ overhang compatible with a Notl site, and at the 3’ a blunt end 
compatible with an StuI site.
Oligo repair F has the following 5'-3' sequence:
GGCCGCCTGTGTTGTCGCCTCTCCCTCTCGCTGCTTCACTTACGGGGCGAACATG
GCAGG.
The sequence is identical to the corresponding stretch present in Subtag 1, except that 
residues 53 through 60 (ATGGCAGG) replace the longer portion (ATGCGCGCCGCAGG) 
present in SubTagl harbouring the two incorrect residues arginine and alanine.
Oligo RepairR has the following 5'-3' sequence:
CCTGCCATGTTCGCCCCGTAAGTGAAGCAGCGAGAGGGAGAGGCGACAACACA
GGC.
The two oligos were annealed to each other and then ligated to the vector SubTagl, which 
had been previously digested with StuI and Notl. Cells transformed -with the ligation mixture 
were grown on double selection (chloramphenicol 50 p-g/ml) All colonies analysed 
(SubTagRepair 1-6) showed the correct pattern of integration of the Repair oligo insert into 
the SubTagl vector.
Now, the SubtagRepair plasmid harboured the correct version of the 5M/Hom-TAP-FRT 
portion of the knock-in cassette M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT-M/Hom3. To 
finally assemble the whole knock-in cassette M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT- 
M/Hom3, the 5M//Hom-TAP-FRT was excised from the SubtagRepair plasmid by AscI
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digestion, and subcloned by conventional ligation into PGK-P-hygro-FRTM/Hom3 colony 
n.2 (see above). 4 out of 8 colonies had integrated the insert in the correct orientation. 
Colonies n. 5 and n. 8 were sequenced and found to be correct. A maxiprep DNA 
preparation of colony n. 8 was digested with Notl and Asel to perform the ET cloning 
recombination step on the MU shaved backbone. The Notl digest released the 
recombinogenic insert M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT-M//Hom3 from the 
vector backbone, while the Asel site had the purpose of further cleaving the vector backbone 
which could have constituted a source of background upon religation.
IX.3.5 Assembly of the knock-in cassette loxP-PGeok-IoxP
As a preliminary step to the generation of the knock-in cassette loxP-sA-IRES- 
PGeok-pA-loxP, a combination of PCR-mediated cloning and sequencing of relevant introns 
as well as direct BAC sequencing were utilised to sequence the mouse MU region spanning 
exon 10 to 19. This served the purpose of identifying the target region in which to place the 
loxP flanked knock-in cassette, as well as to derive sufficient sequence information for the 
development of a Southern strategy to screen recombinant ES cells.
The mouse sequence from exon 10 to 19 turned out to be 10778 bp long. Intron 11 
was chosen for the following reasons. First, it was known to be one of the most common MU 
introns disrupted by translocations. Furthermore, previous mouse models, aimed at 
recapitulating the Mll-Af9 translocation, had already targeted the gene at this site. The 
genomic breakpoints of three patients carrying MU translocations have been completely 
sequenced, and two of them interrupt intron 11. However, comparison between human and 
mouse sequence in intron 11 did not identify any region of high similarity, providing no 
specific indication as to where the loxP site would best be placed within intron 11.
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The backbone for the assembly of the knock-in cassette loxP-sA-IRES-pGeok-pA-loxP was 
the previously described vector PUX4-sA-IRES-pGeok-pA. As in the Af4  case outlined 
above, direct PGR amplification of the sA-IRES-pGeok-pA cassette with oligos harbouring 
regions of homology to the target sites in intron 11, while theoretically possible, would have 
meant an unacceptably high risk of mutations in functionally relevant regions of the cassette, 
which would not be detected prior to the ES cells or even the mouse experiment. Therefore, 
a strategy was devised, analogous to the one already described for the generation of the Af4 
allele. Homology arms were generated by PGR, followed by restriction digest and 
conventional ligation into the two ends of the targeting vector, using unique restriction sites. 
This assured that the core of the targeting construct was never subjected to PGR 
amplification.
The 5’ homology arm was amplified by PGR from wild type MU BAG DNA using the oligos 
NM//HomlF and M/HomlR. Forward oligo NM /HomlF has the following 5'-3' sequence: 
TTATAGGATGGGGGGGGGGGGGGGGAGAGGTTTGATGTGGGGATTG.
At position 10-17, an AscI site was incorporated for further cloning, while the annealing 
portion includes residues 26-46. Reverse oligo M /H om lR has the following 5'-3' sequence: 
GTGAGGTGGGTTAATTAAATAAGTTGGTATAGGATAGATTATAGGAAGTTATTTT 
TATTTATGTGTATTATGGTG.
At position 11-18, a Pad  site was incorporated for further cloning; the loxP site is located at 
position 19-52, while the annealing portion includes residues 53-75. The resulting PGR 
product (PGRM//Homl), which is 355 nucleotides long and contains 277 nucleotides of 
sequence identity with the region of the BAG to be targeted, was cloned into PUX4-sA- 
IRES-PGeok-pA by AscI and P ad ligation. All colonies showed the correct pattern and 
colony 6 was chosen for the subsequent cloning step (PUX4-M/Homl-sA-IRES-PGeok-pA 
c6.)
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The 3’ homology arm was amplified from MU BAC DNA using the oligos NM/Hom2F and 
M/Hom2R. Forward oligo NM/Hom2F has the following 5'-3' sequence: 
GGCAATCTTCGGTTTAAACATAACTTCGTATAATGTATGCTATACGAAGTTATGG 
CGCGCCGCCCGGGCTAATTATGACCACTGTTTGAGGA.
A Pmel site (position 12-19) was incorporated for further cloning. The loxP site is located at 
position 20-53, while the annealing portion includes residues 70-92. A rare cutter poly linker, 
containing restriction sites for AscI (54-61) and SrfI (63-69) was inserted for the pulsed- 
field-gel-electrophoresis Southern strategy, in order to check whether the whole MU 
targeting construct had integrated on the same allele (see above). Reverse oligo M/Hom2R 
has the following 5'-3' sequence:
ACTAAGATTCCGCGGTGGCGGCCGCTGACGATACAGAGGTTACACAAG.
SacII (10-15) and Notl (17-25) were inserted for further cloning. The annealing portion 
includes residues 26-48. The resulting PCR product (PCRM/Hom2), which is 412 base pairs 
long and contains 333 residues of sequence identity with the region of the BAC to be 
targeted, was cloned into PUX4-M/Homl-sA-IRES-PGeok-pA c6. All colonies showed the 
correct pattern. To check the integrity of the loxP sites, colony 2 (PUX4-A/Z/Homl-sA- 
IRES-PGeok-pA-M/Hom2c.2) was sequenced, found to be correct, and was selected for the 
final ET cloning step into the MU shaved BAC backbone.
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IX.3.6 Targeting of the knock-in cassette loxP-pCeok-IoxP into the M il BAC shaved 
backbone
To generate the final ES targeting construct TAP-M//-LacZ, the shaved BAC 
backbone BACD-5 was sequentially targeted with the loxP-sA-IRES-pCeok-pA-loxP and 
the M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT-M/Hom3 cassettes (figure 36). In order to 
target the knock-in cassette loxP-sA-IRES-pGeok-pA-IoxP, BAC-D5 containing cells were 
made electrocompetent (see Materials and Methods). They were then electroporated with 
about 500 ng of the knock-in cassette loxP-sA-IRES-PGeok-pA-loxP and plated on 
quadruple selection (cholramphenicol 12,5|ig/ml, ampicillin 50 [ig/ml, gentamycin 3 Hg/ml 
and kanamycin 20 |Lig/ml).
In order to screen for the correct recombinant colonies a PCR strategy was devised in which 
the two primers would anneal across the predicted integration site. The following primers 
were synthethized: M/PUXF and M llil IR.
Primer M/PUXF has the following 5'-3' sequence:
AAACCTCCCACACCTCCCCCTGAA.
Primer M llil IR has the following5'-3' sequence:
CACAGAGAAATAATAACCATCGTC
Nine out of ten colonies, screened by colony PCR, showed a band of the correct size (Figure
37). While such a PCR strategy is a fast and efficient way to identify colonies which have
probably undergone the correct recombination reaction, the restriction patterns of the
candidate colonies must still be analysed by agarose gel electrophoresis, in order to exclude
the presence of undesired intramolecular recombination events. As outlined above, this is
rather straightforward. First, if one analyses a sufficient number of independent recombinant
colonies, in most cases a unique, or at least a predominant pattern emerges which enables
one to exclude colonies showing a clearly aberrant pattern. In those cases in which two
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Figure 36 Sequential targeting of the shaved Mil BAC
The shaved Mil BAC (BAC-D5) was targeted sequentially with the loxP-flanked pGeok 
cassette (loxP-sA-IRES-Pgeok-loxP) in intron 11 and with the FRT-flanked TAP-Hygro 
cassette (MllHom5-TAP-FRT-pA-hygro-P-PGK-FRT-Mllhom3) downstream of the 
intiating ATG, to yield the final targeting construct TAP-Mll-LacZ.
The 5' and 3' homology arms mediating ET recombination are shown in green for both 
cassettes.
The names of the DNA molecules (constructs and PCR products) are in bold and 
underlined. The scale bar indicates the number of nucleotides/centimeter.
Segments of the constructs accompanied by arrows indicate open reading frames. 
Abbreviations: (Cm) chloramphenicol resistance gene; (Amp) plactamase gene; (hygro) 
hygromycin phosphotransferase gene; (TAP) tandem affinity purification; (Gent) 
gentamycin resistance gene; (ECMV 1RES) encephalomyocarditis virus internal 
rybosomal entry site; (LacZ-neo) fusion of the p-galactosidase and the neomycin genes; 
(pA) polyadenylation signal; (SV40) simian virus 40;
See text for a full description of the cloning strategy.
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Figure 37 Targeting of the LoxP-flanked (3Geok cassette to the Mil shaved BAC backbone
The loxP-flanked pGeok cassette was targeted by ET recombination to the intron 11 of the 
Mil gene on the "shaved" BAC backbone resulting from the two rounds of ET mediated 
deletion (Figures 29-33).
A. PCR screening of candidate colonies with primers spanning the integration site.
B. Representative BamHI digests of PCR-positive colonies. All 
colonies examined except colony E showed the same restriction pattern
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equally frequent patterns emerge, as in the cases of the first and second deletion rounds 
described above, the correct colonies will usually become apparent by comparison with the 
original wild type BAC and the BACs derived from the previous ET modifications. To this 
end, BamHI digests were carried out on the 9 colonies which had been positive by PCR. All 
of them showed the same restriction pattern, indicating that the ET targeting had occurred in 
the same position in all cases. Sequencing was performed on colonies B and J, and 
confirmed correct integration site in intron 11. Therefore, these two colonies (M/BACD5- 
loxP-sA-IRES-pGeok-pA-loxP n. B and J) were selected for the final step in the assembly of 
the M il targeting construct (ie. targeting of the M/Hom5-TAP-FRT-pA-hygro-P-PGK-FRT- 
M/Hom3 knock-in cassette ).
IX.3.7 Targeting of the knock-in cassette M//-TAP-hygro into MU BAC shaved 
backbone
Cells harbouring the M//BACD5-loxP-sA-IRES-PGeok-pA-loxP BAC (from both batches B 
and J) were transformed with the recombinogenic plasmid R6K-apy plasmid, plated on 
quintuple selection (chlramphenicol 12,5|Xg/ml, ampicillin 50 fig/ml, gentamycin 3 p,g/ml, 
kanamycin 20 pg/ml and tetracycline 25 |Lig/ml), and the correct transformants identified by 
agarose gel electrophoresis to detect the presence of the recombinogenic plasmid. Cells were 
then made electrocompetent, transformed with the M/Hom5-TAP-FRT-pA-hygro-PGK- 
FRT-M /Hom3 cassette, and plated on triple selection (cholramphenicol 12,5p,g/ml, 
kanamycin 20 ^ig/ml and hygromycin lOOpg/ml). 15 colonies were analysed by PCR with an 
analogous strategy to that described for the targeting of the loxP-sA-IRES-PGeok-pA-loxP 
cassette (see above). The following primers were used: TagScreenF2 and NTagR.
Primer TagScreenF2 has the following 5'-3' sequence:
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GGGGTACGGCCATCTGGGCGGCGCCAG 
Primer NTagR has the following 5'-3' sequence:
TACAGGCGCGCCGGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCCATCAAG
TGCCCCGGAGGATGAGATTTTC.
14 out of 15 colonies showed an amplification product of the correct size, and their BamHI 
restriction patterns were analysed through electrophoresis. As shown in figure 38, all 
colonies displayed the same pattern, indicating that no additional, intramolecular 
recombination events had occurred. On the basis of these results, clone JC (TAP-M/-LacZ 
JC) was selected for electroporation in mouse ES cells. DNA was prepared from two liters of 
bacterial cultures, and then digested with Pi-Scel to release the targeting construct from the 
BAC vector. Agarose gel electrophoresis confirmed that digestion had occurred to 
completion, and the size of the actual targeting construct was estimated to be greater than 60 
(Fig 39)
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Figure 38 Targeting of the FRT-flanked TAP-Hygro cassette to the shaved Mil BAC 
backbone
The FRT-flanked TAP-hygro cassette was targeted by ET recombination to the first exon of the 
Mil "shaved" BAC backbone already harbouring the LoxP-flanked pGeok cassette in intron 11.
A. PCR screening of candidate colonies with primers spanning the integration site.
B. Represenatative BamHI digest of PCR-positive colonies. All
colonies examined showed the same restriction pattern. The two additional bands in 
colony F result from retention of the recombinogenic plasmid R6K-aPy.
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In a parallel set of experiments, the same knock-in cassette M/Hom5-TAP-FRT-pA- 
hygro-P-PGK-FRT-M/Hom3 was also targeted to the wild type MU BAC 145L16. The aim 
was to isolate from this modified BAC a simpler targeting construct which, upon ES cell 
electroporation, would simply insert the TAP-FRT-pA-hygro-P-PGK-FRT at the ATG of the 
MU gene. Thereby this conventional targeting construct and the BAC based, longer construct 
can be compared for targeting efficiencies.
To this end, cells containing both the wt MU BAC 145L16 and the recombinogenic 
plasmid R6K-aPy were made electrocompetent and transformed with the M//Hom5-TAP- 
FRT-pA-hygro-PGK-FRT-Af//Hom3 cassette. Cells were plated on double selection 
(cholramphenicol 12,5pg/ml, and hygromycin SOp-g/ml). All 30 colonies picked tested 
positive by PCR using the same primer pair ScreenTagF2 and NTagR. Colony n. 3 
(M//NTag C.3) was sequenced and confirmed to have undergone the correct recombination 
event. On the basis of available sequence, Nhel was selected to digest this targeted BAC and 
subclone the TAP-tag containing Nhel fragment into a high copy vector (in this case pUC34, 
which carries the ampicillin resistance gene) (Benes et al., 1993) by conventional ligation 
and double selection for hygromycin and for the selectable marker of the chosen vector. This 
yielded the second MU targeting vector (hence referred to as M/TAPshort). From colony B, 
DNA was prepared and digested with Nhel to release the targeting construct (M/TAPshort) 
from the pUC34 backbone, prior to ES cell electroporation.
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Figure 39 Pi-Scel digests of the M//-TAP-LacZ targeting construct
Agarose gel electrophoresis of Pi-Scel digests from two independent clones of the 
final Mil targeting construct TAP-M//-LacZ (c. JA and JC). The pattern demonstrates 
complete digestion. The high molecular weight (HMW) DNA marker permits to 
approximately estimate the length of the targeting construct (red arrow). The two 
highest bands of the HMW marker are 48 and 38 kb; thus, the insert fragment is 
likely longer than 60 Kb. The band representing the BAC backbone (increased by 
the addition of the two selectable markers introduced in the ET recombination steps) 
is indicated by a yellow arrow.
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IX.4 ES cell targeting with the MU construct.
Mouse ES cells of the E 14 line were used for the targeting experiment. Cells were 
grown on gelatin coated plates in the presence of LIE (see material and methods). A total of 
80 |Lig of the construct TAP-M//-LacZ were digested with Pi-Scel. DNA was phenol- 
extracted from the digestion mixture, resuspended in (50) pi PBS, and electroporated into 
76 * 10  ^ cells, divided onto 38 10 cm dishes plus 1 dish for cells which had been 
electroporated with only PBS as negative control. The plating density was 2,000,000 
cells/plate. 24 hours after electroporation, drug selection was started on all plates. Four 
selection schemes were devised: G418 only (200 pg/ml); hygromycin only (160 pg/ml); 
G418 (100 pg/ml) plus hygromycin (160 pg/ml); G418 (200 pg/ml) plus hygromycin (160 
pg/ml) Several variables impinged on the experiment.
First, there was no conclusive information about the efficiency with which such a big 
targeting construct would enter ES cells upon electroporation. Very large DNA molecules 
(mostly in the form of YACs) have been introduced into ES cells by spheroplast or whole 
cell fusion, a procedure which is likely to yield different results from electroporation.
Second, ES cells are normally transfected and selected using one drug at a time. 
Previous applications of selection regimens with two different drugs have usually been 
applied to cells already carrying a first resistance gene stably integrated.
A third variable comes from the configuration of this targeting construct, where 
hygromycin resistance is under the control of the PGK promoter, while G418 resistance is 
dependent upon the endogenous MU promoter, whose strength in these experimental 
conditions was unknown.
Fourth, assuming that the construct would enter ES cells at a workable frequency, a 
major question concerned the rate at which the construct would break once inside the cells.
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Breakage would dissociate the two selectable marker cassettes, since, lying near the ends of 
the construct, most rupturing would be expected to occur between them. Under such 
circumstances, G418 resistance would only emerge in those clones where the 3' terminal part 
of the construct had integrated in a locus permissive for the splicing and expression of the 
PGeok cassette, whereas hygromycin resistance would emerge from random integration of 
the 5' end of the construct. By use of either selection alone or in combination, and use of a 
smaller targeting construct carrying only hygromycin selection, the experiment was designed 
to address these variables.
IX.4.1 The M//-TAP-LacZ construct integrates mostly as a unit
To investigate the issue of DNA breakage, colonies which had been initially selected 
with only one drug (either G418 or hygromycin) were replica plated, so that each colony 
could now be assessed for its resistance to the other drug (percentage of co-resistance).
If the construct lands largely intact in the genome, most of the cells initially selected 
for hygromycin are expected to be also resistant to G418 (figure 40). In fact, the construct 
contains the MU promoter and therefore, as long as it stays intact, the activity of this 
promoter should drive G418 resistance. At the same time, most of the cells initially selected 
for G418 only are expected to be also resistant to hygromycin, since it carries its own 
promoter (PGK). Thus, if the construct integrates mostly as a unit, the percentage of co­
resistance among these two populations of cells should be very similar.
On the contrary, if the construct breaks (figure 41), the two selectable marker 
cassettes should behave differently, since the hygromycin cassette carries its own nearby 
promoter, however breakage will separate the pGeok cassette from its very distant promoter, 
creating an intron-trap fragment. Cells initially selected for G418 may or may not also be 
resistant to hygromycin depending on the frequency of unselected random integration
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occurring whilst selecting for an intron-trap. Whereas constructs selected for hygromycin 
resistance only should show relatively lower levels of G418 resistance since this depends on 
rarer, intron-trap, events.
Two general points need to be made before the results can be interpreted. First, fewer 
colonies were observed from hygromycin than G418 selection (figure 42). This concords 
with the greater cytotoxicity and faster killing of hygromycin than GH418. Second, even 
fewer colonies were observed after double selection, a result indicating that the additional 
challenge posed by co-selection reduces the number of double resistant colonies.
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Figure 40 Integration of the intact MU construct in the genome (diagram)
Schematic representation of the integration of the MU construct in the genome.
If the construct landed in the genome mostly intact, the following prediction could be made: 
since the construct contains the MU promoter, the hygromycine cassette carries its own promoter 
while the pGeok cassette is by itself a promoter trap, the majority of clones initially selected in 
either one of the two drugs should be resistant to both.
Analysis of the percentage of coresistance among colonies initially selected only on one of the 
two drugs supports the hypothesis that this type of large targeting construct integrates in most 
cases as a single unit. See text for further details.
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Figure 41 Integration of a eleaved MU construct in the genome (diagram)
Schematic representation of the integration of the MU construct in the genome.
If the construct broke to a great extent before integration, the two selectable cassettes would 
behave largely independent of each other. Hence the following prediction could be made: 
the majority of clones selected in G418 should also be resistant to hygromycin, since this 
cassette carries its own promoter. On the contrary, by selecting only with hygromycin, one 
could expect a significantly lower number of clones to be resistant also to G418, since this 
cassette needs to integrate in a permissive spot of the genome to be properly expressed, an 
event for which there was no selection pressure during treatment with hygromycin alone. 
Analysis of the percentage of coresistance among colonies initially selected only on one of the 
two drugs does not support this hypothesis.
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In both singly selected cases (figure 42), only a minority (up to 17% for G418 and up 
to 24% for hygromycin) of resistant colonies were due to construct breakage and integration 
of only the selected part. On the other hand, the fact that most singly selected colonies were 
co-resistant and that the total number of doubly selected colonies was about half of singly 
selected numbers implies that either (i) the construct remains intact upon integration in most 
cases, or (ii) the frequency of unselected integration after construct breakage is high, or (iii) 
both (i) and (ii) apply. Since the expected difference between unselected G418 and 
hygromycin co-resistance frequencies was present but small, the conclusion (ii) is unlikley to 
account for the majority of events. Hence, conclusion (i) is preferable. It also has the merit of 
being simpler.
Although not quantitative, these results show that this large construct remains intact 
during integration in at least a workable frequency of events, and provide evidence that 
large, BAC based constructs can be used as the platform for the creation of multiply 
mutagenized alleles in ES cells.
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Figure 42 Summary of the Mil ES cell targeting experiment
Three different schemes of selection (panel B) were applied to ES cells transfected with the 
TAP-Mll-LacZ construct (panel A). The results are summarised in panel C. The first row of the 
table shows the absolute number of colonies/plate obtained in the different selection schemes. 
The second row indicates the percentage of coresistance to both drugs of colonies initially 
selected in 0418 only (red) or hygromycin only (green). The similarity of the two coresistance 
indexes (83% vertsus 76%) suggests that the Mll-TAP-LacZ construct integrates in the genome 
mostly intact.
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IX.4.2 Southern hybridisation to identify homologous recombinant clones
The fact that the construct was often incorporated as a unit did not provide per se any 
information on the frequency of homologous recombinants. Although opening options for 
random integration strategies based on assembly in E.coli of a single large construct mutated 
at multiple sites, the application of BACs to simultaneous gene targeting ultimately depends 
on the rate at which homologous recombinants can be recovered. Previous experiments 
(Hasty et al., 1991; Thomas et al., 1992) indicated that the efficiency of homologous 
recombination reached a plateau after about 15 kb of homology arm length. These results 
may not be directly applicable to the strategy described here, since in the TAP-M/-lacZ 
construct, the homology arms respectively upstream of the 5’ cassette and downstream of the 
3’ cassette fall within the normal range (5 kb and 6.6 kb respectively). What is different is 
the presence of about 50 kb of homologous sequence between the two selectable marker 
cassettes.
In order to identify homologous recombinants, a Southern strategy was devised for both the 
5’ and the 3’ side of the targeting vectors. Both strategies rely on probes which are external 
to the construct.
BamHI was chosen to explore correct integration at the 5’ side. A BamHI site is present 
7041 bp upstream of the MU initiating ATG. The next site is 9847 bp downstream. A 
hybridisation probe was amplified by PCR from MU BAC with primers M//5ProbeF and 
M/5ProbeR. M/5Probe F has the following 5’-3’ sequence: 
GGATCAAGAGTAAGCCACATAGCAAGTT 
M/5Probe3 has the following 5’-3’ sequence:
AATTTGTTGTCCACGGCTTCATCG
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The resulting probe is 632 bp long. It detects in all clones a wild type band of 9847 
nucleotides. Since there is no BamHI site in the TAP cassette, correct integration of the 
TAP-M/-LacZ construct results in a higher band of 12176 residues.
Xbal was chosen to explore correct integration at the 3’ side. An Xbal site is present in 
intron 11 8267 bp upstream from the 3’ end of the construct. The next site is in exon 19, 
1505 bp downstream from the 3’ end of the construct. A hybridisation probe was amplified 
by PCR from MU BAC with primers M//3ProbeF and M/3ProbeR. M//3Probe F has the 
following 5’-3’ sequence:
CTGCCAAACTACTTACGGAAAATG 
M/3ProbeRhas the following 5’-3’ sequence:
TTGACACTGAACCACGGAAAAACT
The resulting probe is 858 bp long. It detects in all clones a wild type band of 9773 
nucleotides. Since there is an Xbal site in the loxP-sA-IRES-PGeok-pA-loxP cassette, 
correct integration of the TAP-M/-lacZ construct results in a lower band of 8453 residues.
A total of 29 colonies initially selected in hygromycin (160pg/ml) and G418 
(200pg/ml) were analysed by Southern blot for homologous recombination at the 5' end of 
the locus, using the M//5Probe on BamHI digests. Three colonies (AC4, ADI and DA4) 
showed both the band from the wild type allele (9847 bp) and from the homologously 
recombined one (12176 bp), amounting to a targeting frequency of around 10% (Figure 43).
18 new colonies, again initially selected in hygromycin (160p,g/ml) and G418 
(200p.g/ml), plus 18 colonies already analysed on the 5' side (including the three positives), 
were then screened by Southern blot with the M//3Probe on Xbal digests to check correct 
integration at the 3' side of the locus (figure 44). 4 colonies tested positive (AC4, ADI, DA4 
and DB2), as shown by the presence of both the wild type band (9773 bp) and the
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Figure 43 ES cell targeting with the Mh-TAP-LaeZ construct (5’ side)
A. Schematic representation of the wild type Mil locus, the 5’ part of the Mil targeting construct TAP-Mll-LacZ, and 
the 5’ part of the Mil targeted loeus. The 5’ border of the TAP-Mll-LacZ targeting construet is indicated by a vertieal 
blue line. BamHI sites, on which the Southern strategy was based, are indicated along with their relative position given 
in parenthesis. Black arrows on either side of the DNA moleeules represent flanking genomic regions.
The names of the DNA molecules (eonstructs and PCR products) are in bold and underlined.
The seale bar indicates the number of nucleotides/centimeter.
Segments of the construets accompanied by arrows indicate open reading frames.
Abbreviations; (TAP) tandem affinity purification.
B. Southern blot hybridisation with probe MllSEnd on BamHI digests of 29 colonies selected in hygromycin 
(160 mg/ml) and 0418 (200 mg/ml). Colonies AC4, ADI, and DA4 show the correct pattern of wild type and 
homologously recombined bands (9847 and 12176 bp respectively).
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Figure 44 ES cell targeting with the Mll-TAP-LacZ construct (3’ side)
A. Schematic representation of the wild type MU locus, the 3’ part of the MU targeting construct TAP-Mll-LacZ, 
and the 3’ part of the MU targeted locus. The 3’ border of the TAP-Mll-LacZ targeting construct is indicated by 
a vertical blue line. Xbal sites, on which the Southern strategy was based, are indicated along with their relative 
position given in parenthesis. Black arrows on either side of the DNA molecules represent flanking genomic 
region. The names of the DNA molecules (constructs and PCR products) are in bold and underlined.
The scale bar indicates the number of nucleotides/centimeter.
Segments of the constructs accompanied by arrows indicate open reading frames.
Abbreviations: (LacZ -neo) fusion of the pgalactosidase and the neomycin genes; (pA) polyadenylation signal; 
(sA) splice acceptor element; (ECMV 1RES) encephalomyocarditis virus internal rybosomal entry site.
B. Southern blot hybridisation with probe M113End on BamHI digests of 36 colonies selected in hygromycin 
(160 mg/ml) and G418 (200 mg/ml). Colonies AC4, ADI, DA4 and DB2 show the correct pattern of wild type 
and homologously recombined bands (9773 and 8453 bp respectively).
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homologously targeted one (8453 bp). This corresponds to a homologous recombination 
frequency of about 11%, in good agreement with the results from the 5' side.
3 colonies (AC4, ADI and DA4) had undergone correct integration at both sides, 
which, considering the total number of colonies analysed (47) amounts to a targeting 
frequency of about 6%. This is a very reasonable targeting frequency, similar to, if not 
higher, than that reported for most targeting experiments. It clearly establishes that 
homologous recombination in mouse ES cells with a very large, BAC based targeting 
construct, is practically feasible.
Interestingly, all colonies which tested positive on the 5' side (which contains the 
hygromycin cassette) had also correctly integrated the 3' end, which harbours the G418 
cassette. On the contrary, of the four colonies positive for the G418 cassette, only 3 (75%) 
had also correctly integrated the hygromycin cassette. Since all these colonies were fully 
resistant to both drugs, the most likely explanation for this discrepancy is that in one case the 
construct broke and the hygromycin containing half landed elsewhere in the genome. 
Although this represents a small sample size, this value (75%) corresponds remarkably with 
the results obtained from the co-resistance experiment (see above). Taken together, these 
data suggest that, contrary to previous assumptions, a large DNA molecule can integrate in 
the genome largely as a single unit. This has very important repercussions for the feasibility 
of similar strategies. If the construct did undergo substantial breakage with the two 
mutagenic cassettes integrating independently of each other, the advantage of using a single, 
big targeting construct over multiple smaller ones would be greatly reduced, as many 
colonies would probably need to be screened to identify cells which harboured both 
mutations on the same allele.
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IX.5 Further implications of combinatorial gene alleles
The strategy presented here presents new options to combine multiple 
mutations in a single targeting construct. Ideally, one would want to investigate all mutations 
independently of each other, which obviously calls for a conditional strategy in which only 
selected functions of the gene are ablated at a given time in a given tissue, leaving the other 
domains intact. This can be achieved by flanking relevant domains with site specific 
recombination target sites, so that upon expression of the corresponding recombinase in a 
controlled spatio-temporal manner, this domain will be selectively deleted. Currently, two 
recombinases can be successfully used in vivo in the mouse, Cre and Flp. It is clearly a 
prerequisite for such an approach that other recombinases become available to increase the 
number of mutations which can be conditionally and simultaneously incorporated in the 
same mouse line. This is a daunting task, especially since extensive characterisation of the 
properties of each recombinase is needed for its application as an in vivo genomic 
engineering tool; however, it is already on the agenda of contemporary mouse genetics.
Thus it is likely that this novel approach to controlled in vivo mutagenesis in the mouse will 
eventually merge with other large scale projects of contemporary biology and medicine. A 
framework was recently proposed, along whose lines the sets of data emerging from high- 
throughput projects (transcriptome, proteome, enzymome, localizome, phenome) can be 
regarded as functional maps to be incorporated into a multilayered, tridimensional biological 
atlas (Vidal, 2001). For higher model organisms like the mouse, I propose that an important 
aspect of this effort will be the generation, in the long term for every gene, of a complete set 
of conditional alleles (hereafter referred to as the "conditional alleleome") in which every 
functional domain is flanked by target sites for a different recombinase (Figure 45). In 
parallel, an exhaustive set of mouse lines should be established, which express different site
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Figure 45 Mouse eonditional "alleleome"
Hypothetical diagram of the information generated from a combination of the 
mouse conditional "alleleome" and "recombinome". On the (x) axis each gene is 
depicted with its domains flanked by different site specific recombinase target sites 
(SSRTs), constituting the conditional alleleome. On the (y) axis, mouse lines are 
represented, each of which expresses a certain site specific recombinase (SSR) in 
a spatio-temporal controlled manner. Appropriate erossing between these two arrays 
of mouse lines should enable a proteomic and phenomic analysis centered on the 
role of individual protein domains.
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specific recombinases in different tissues and at different stages of development (hereafter 
referred to as the "Mouse-Recombinome"). Ideally, they would be conditionally regulatable, 
most efficiently through fusion with the ligand binding domain (LED) of nuclear receptors. 
Multiple crossing schemes combining suitable mouse lines from the "conditional alleleome" 
and the "mouse recombinome" would then constitute the basis for an accurate functional 
map of the mouse phenome. If everyone of these alleles includes a protein purification tag, 
the "conditional proteome" of every gene can be defined, enabling one to pinpoint which 
domains are responsible for which interaction. Comparison of the results obtained from the 
"conditional phenome" and "conditional proteome" would yield insight into the (likely) 
multiple molecular mechanisms underlying a given phenotype, contributing to bridging the 
gap between the reductionist and organismic interpretation of biological phenomena.
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X
Engineering of a Cre mouse line under 
the control of the Ikaros gene
X .l Overview o f the strategy
Studies on leukemogenesis both in human disease and mouse models highlight the 
importance of the cellular compartment in which fusion proteins are first expressed. As 
discussed in chapter II.5, the Cre-loxP system offers the potential to explore this central 
issue. The availability of appropriate Cre expressing mouse lines is therefore crucial, and it 
is possible to envision that in a not too distant future, the oncogenic potential of the most 
important translocations could be assessed against a whole blood “Cre zoo” (ie. a collection 
of mouse lines expressing Cre at key developmental stages for every major hematopoietic 
lineage).
I decided to establish a transgenic mouse line expressing Cre recombinase under the 
control of the Ikaros gene. The following section highlights some of the key aspects of 
Ikaros function, which provided the rationale for its choice as the gene driving Cre 
expression.
X.1.1 Ikaros in lymphoid development
Ikaros is the founding member of a family of chromatin regulators which play a pivotal role 
in lymphoid development (Cortes et al., 1999; Georgopoulos et al., 1997; Koipally et al.,
1999a). The family includes also Aiolos and Helios (Kelley et al., 1998; Morgan et al.,
1997). Its expression is restricted to cells of the hematopietic lineage, with the exception of
the striatum in the CNS (Georgopoulos et al., 1992; Morgan et al., 1997). It is present
throughout hematopoiesis starting at E8.5 in the mesodermal precursors of the
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splanchnopleura which will give rise to all blood lineages, continuing through both yolk sac 
and fetal liver hematopoiesis, as well as lymphoid development in the bone marrow and in 
the thymus. In mature blood cells, Ikaros is expressed in granulocytes, T, B and NK cells, 
while it is not expressed in macrophages, mast cells and erythrocytes.
The Ikaros gene can give rise, by alternative splicing, to at least eight protein isoforms which 
mainly differ in the relative content of Kriippel-like zinc fingers, through which Ikaros 
regulates expression of its target genes and homo or heterodoimerizes with itself or members 
of the family (Hahm et al., 1994; Molnar and Georgopoulos, 1994). All Ikaros isoforms
share the two carboxyterminal Zn fingers required for protein-protein interaction. At the 
aminoterminus, only some isoforms contain the minimum of two Zn fingers required for 
binding, with different affinity, to DNA sequences showing variations of the core consensus 
c/TGGGAAT/c. As multiple copies of Ikaros have been shown to interact in multimeric 
complexes, the variants which cannot bind DNA are usually referred to as dominant negative 
isoforms, since their inclusion in such complexes reduces, and eventually abolishes, DNA 
binding capability (Hahm et al., 1998; Kim et al., 1999; Morgan et al., 1997; Sun et al.,
1996).
The relevance of DNA binding for Ikaros function was established by studying loss of 
function and dominant negative alleles in mice. A null phenotype was generated with a 
carboxyterminal deletion (Wang et al., 1996). In these mice, B cells and their precursors 
completely failed to develop, and T cell precursors were also absent throughout fetal 
development. After birth, however, increasing numbers of thymocytes appeared, although 
they showed preferential CD4 differentiation and underwent clonal expansions starting from 
the double positive stage of differentiation. NK cells were also completely lacking, and 
dendritic cells severely reduced.
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Mice homozygous for a dominant negative knock-in allele of Ikaros, in which the DNA 
binding domain is deleted, had an even more severe phenotype, completely lacking also all 
T cells and succumbing soon after birth to a range of fulminating infections (Georgopoulos
et al., 1994). This increased severity is very likely due to a dominant negative effect of this 
Ikaros allele on other members of the family, thus preventing rescue by any possible 
redundant pathway.
Interestingly, mice heterozygous for this same mutation developed T cell malignancies with 
100% penetrance, with eventual loss also of the wild type allele (Winandy et al., 1995).
In the last few years, the molecular mechanism of Ikaros action has been investigated in 
great detail. Ikaros seems to function both as an activator and a repressor of transcription. It 
has been found to be associated with at least two distinct multiprotein complexes, the NuRD 
complex and a Brg-1 based SWI/SNF related complex (Kim et al., 1999). In mature T cells,
its relative distribution among these two complexes is approximately 5 to 1. In addition, a 
small fraction of the total Ikaros protein was found to be associated with Sin3 proteins, 
which function as transcriptional corepressors (Koipally et al., 1999b). Importantly, these
three Ikaros containing complexes have distinct subnuclear distributions which vary with the 
activation status of the cell. In particular, upon T cell activation, the Ikaros fraction 
associated with NuRD moves to heterochromatic domains forming toroidal structures 
visualised by immunofluorescence (Kim et al., 1999). Concomitantly, the SWI/SNF
complex shows a diffused pattern. Consistent with these localisation studies, there is a direct 
correlation between the levels of Ikaro.9 in a mature T cells, and the intensity of signal 
required for activation; the less Ikaros, the more responsive the cell is to activation, which in 
turn leads to faster entry and progression through the cell cycle (Avitahl et al., 1999). The
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consequence is the accumulation of chromosomal aberrations, likely the molecular 
explanation for the occurrence of T cell malignancies in heterozygous dominant negative 
mice.
Recently, several studies have reported the presence of predominantly dominant negative 
isoforms of Ikaros in infant acute lymphoblastic leukemias, a particularly intriguing finding 
in view of the acute lymphoid leukemias arising very early in dominant negative Ikaros mice 
(Nakase et al., 2000; Olivero et al., 2000; Sun et al., 1999a; Sun et al., 1999b; Sun et al.,
1999c). With variable frequencies among the different leukemias analysed, all these studies
demonstrate that blasts from ALL patients express high levels of the dominant negative 
isoforms Ik-4, Ik-7 and Ik-8, which do not bind DNA and show mainly a cytoplasmic 
distribution, in agreement with previous results (Sun et al., 1996). On the contrary, normal
lymphocytes from a variety of sources (bone marrow, thymus and fetal liver) only expressed 
Ik-1 and Ik-2 isoforms. This is in agreement with the mouse results, which showed that in 
normal hematopoetic cells and mature lymphocytes the DNA-binding isoforms make up for 
the majority of Ikaros proteins expressed.
Of note, in one of these studies, five of five MLL-AF4+ infants showed this profile of Ikaros 
isoforms expression, and it has been hypothesized that disruption of normal Ikaros function 
through upregulation of these dominant negative variants could play an important role in 
ALL, particularly of the infant type (Sun et al., 1999c). Currently, there is no evidence that
MLL rearrangements are the primaiy triggering event behind the expression of these splicing 
variants, mostly because similar ratios of dominant negative vs. full isoforms have been 
identified also in leukemias characterised by different aberrations. Moreover, the statistics 
are probably still too small to derive precise correlations. However, the general observation
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of an increased level of dominant negative variants holds its validity and appears to be a 
likely cofactor in leukemogenesis.
Due to its early hematopoietic expression pattern, Ikaros is an ideal gene to drive Cre 
recombinase for loxP modelling of MLL leukemias, since they present amplifications of 
mixed, hence early, lineages. In particular, the leukemic phenotype of MLL-AF4 is 
predominantly, but not exclusively, lymphoid, arrested at a pre-B stage of development that 
also shows concomitant expression of at least one myeloid antigen. A faithful Ikaros Cre 
line should express Cre throughout lymphoid development, including very early stage 
hematopoietic stem cells, and continuing to mature lymphocytes continously generated in 
the adult animal.
In the project undertaken here, the suitability of the Ikaros expression pattern, 
through the use of Ikaros-CvQ mice for induction of the MLL-AF4 translocation, is pursued. 
The strategy is a novel extension of the recombinase-steroid hormone ligand binding domain 
(LBD) fusion protein strategy pioneered in the Stewart lab. It aims to combine the advantage 
of both Cre-LBDs and Cre-only strategies by use of the Pipe recombinase (Buchholz et al., 
1998; Rodriguez et al., 2000). With the use of both Cre-LBD and Cre-only to promote the 
translocation, it should in principle be possible to directly assess the effect of the 
translocation on the appearance of the alternatively spliced isoforms of Ikaros, for example, 
amongst other markers.
X.1.2 BAG transgenesis
A BAC transgenesis approach was chosen to express Cre recombinase under the 
control of the Ikaros gene. There are several advantages for using BACs in mouse
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transgenesis. The most important one is that, given the large size of the cloned inserts, most 
or all regulatory regions required for appropriate expression 'will be contained in the BAC, 
assuring faithful expression of the desired cassette. Use of a BAC avoids the need to map 
regulatory regions. Moreover, even if all regulatory elements for a given gene are known, 
their spatial organisation along the gene locus could be important, thereby preventing cut- 
and-paste approaches which group regulatory regions within smaller transgenic constructs.
Furthermore, native arrays of regulatory elements in large transgenic constructs are 
less sensitive to the chromatin organisation at new sites of genome integration. Small 
transgenic constructs, on the contrary, seem to be sensitive to the integration locus, leading 
to mosaicism and unpredictable expression patterns. Consequently, a higher number of 
founder animals need to be analysed in order to identify the appropriately expressing ones.
Another advantage in using BACs or YACs in mouse transgenesis comes form the 
experience that it is easier to obtain single copy integrants than with smaller, conventional 
transgenic constructs.
Among the disadvantages of using large genomic clones in transgenesis is the 
possibility that other genes could also be present in the clone that are dosage sensitive and 
thereby result in an independent phenotype of their own upon transgenic expression. A 
related, possibly more dangerous scenario is that truncated genes could be present in the 
BAC or YAC, coding for proteins which would then act as dominant negative and 
specifically interfere with various cellular process. While these dangers are real and warrant 
careful consideration, the experience so far using large genomic clones (BACs or YACs) in 
mouse trangenesis has shown that they occur very infrequently.
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X.1.3 Outline of the "matching pair" Cre-LBD, Cre only strategy
Figure 46 describes the strategy adopted. An improved version of Cre recombinase (in which 
the codons have been optimized for mammalian usage) was fused to mutated ligand binding 
domains (LEDs*, where the asterisk indicates the mutation) of either the glucocorticoid 
receptor (GR) or the estrogen receptor (ER). The fusion of Cre recombinase to nuclear 
receptor ligand binding domains has been successfully used in diverse experimental settings 
to regulate Cre mediated recombination through administration of the appropriate ligand, 
both in cell culture and in vivo (see chapter II.5.2).
The novelty of the approach outlined here consists in the introduction of two FRT 
sites which flank the ligand binding domain. The first FRT site is placed in frame between 
the Cre recombinase and the LBD*. The second FRT is placed immediately after the LBD* 
upstream of the poly adénylation signal (pA). This FRT is flanked on its 3’ side by a nuclear 
localisation signal, followed by a STOP codon. Upon Flp recombination, the LBD* is 
deleted, and the resulting cassette should now result in the translation of a constitutively 
active form of Cre recombinase, fused in frame to an FRT (left after the recombination 
reaction) and to a nuclear localisation signal for appropriate intracellular targeting. After 
establishment of transgenic lines carrying an Æar o j-Cre-FRT-LBD * -FRT-nls BAC, mice 
can be crossed to a Flpe deleter to remove the FRT flanked cassette, hence possibly creating 
a "matching pair" of CreLBD* and Cre-only.
The functional flexibility of this design constitutes a potential improvement in the
engineering of Cre expressing mouse lines. In fact, while in some experimental settings, it is
highly desirable to have regulated Cre activity, other strategies might require constitutive
Cre activity. In the case of the Mll-Af4 leukemia model, for example, it could be interesting
to compare one or multiple pulses of Cre activity (induced by administration of the
appropriate ligand) with constitutive Cre activity, with respect to the efficiency of
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Figure 46 Outline of the "matching pair" Cre-LBD, Cre-only strategy
The Ikaros BAC was targeted with a cassette in which an improved version of Cre 
recombinase was fused to mutated ligand binding domains of either the glucocorticoid or 
the estrogen receptor. The ligand binding domains were flanked by FRT sites, resulting, 
upon Flp recombination, in their deletion and hence in constitutive Cre activity.
The plactamase gene was used to select for the integration of the cassette into the Ikaros 
BAC via ET recombination. It was flanked by TRT sites (recognition sites for TnPI 
recombinase) to allow removal of the selectable marker prior to oocyte microinjection. 
The names of the DNA molecules are in bold and underlined. The scale bar indicates the 
number of nucleotides/centimeter.
Segments of the constructs accompanied by arrows indicate open reading frames. 
Abbreviations: (Amp) piactamase gene; (iCre) improved version of Cre recombinase; 
(LBD*) ligand binding domain of the glucocorticoid or estrogen receptor;(nls) nuclear 
localization signal; (FRT) target site for Flp recombinase; (TRT) target site for the Tnpl 
recombinase (pA) polyadenylation signal.
See text for a full description of the cloning strategy.
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interchromosomal translocation. In turn, this could correlate with the frequency of 
leukemia development, and thus constitute a useful model to address the issue of how many 
mutated cells are required in vivo for cancer development. As virtually all neoplastic 
diseases in humans are clonal in origin, it is thought that a single cell needs to be hit by the 
oncogenic event(s) for the neoplasm to develop. However it remains possible that within an 
organism, multiple cells need to undergo a certain genetic lesion before one clone effectively 
manages to establish a tumor.
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X.2 Assem bly o f the Ikaros-Cr^ BAC transgenes
X.2.1 Assembly of the CreFRTGBD*FRT construct
As a preliminary step, the core components of this conditional-constitutive Cre 
cassette were assembled in the construct pBKC-iCreFRTGBD*FRTNLS.
The starting point was the construct pBKC-iCreFRTGBD*, which had been previously 
generated (Michael Hübner, unpublished results). The FRT-NLS-STOP module was cloned 
in pBKC-iCreFRTGBD* by KpnI-PflMI ligation. For this, the following oligonucleotides 
were designed: FRTNLSupper and FRTNLSlower.
Oligonucleotide FRTNLSupper has the following 5'-3' sequence:
TTGGACTAGAGGTACCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCAÇÇ
AAAGAAGAAGCGAAAGGTCTG^CACAGTAC.
The FRT (in bold) is located at positions 17-50. A single nucleotide (dATP, in bold and 
underlined) is inserted immediately downstream of it to maintain the reading frame with the 
nuclear localisation signal (PKKKRKV), coded by residues 52-72 (underlined). A STOP 
codon is inserted at position 73-75 (italics). The first four residues (TTGG at position 1-4) 
constitute the upper strand of the PflMI 3’ overhang for cloning into pBKC-iCreFRTGBD*. 
The last five residues (AGTAC at position 79-83) constitute the upper strand of the Kpnl 5’ 
overhang for cloning into pBKC-iCreFRTGBD*. The A at position 79, which replaces the 
G, was inserted to destroy the Kpnl site to permit subsequent cloning steps.
Oligonucleotide FRTNLSlower has the following 5-3' sequence:
TGTGTCAGACCTTTCGCTTCTTCTTTGGTGAAGTTCCTATACTTTCTAGAGAATAG
GAACTTCGGTACCTCTAGTCCAAGTC.
It is complementary to the sequence of FRTNLSupper. At the 5’ and 3’ ends, it creates the 
appropriate lower strand overhangs for cloning into PflMI and Kpnl sites respectively.
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The two primers FRTNLSupper and FRTNLSlower were annealed to each other and ligated 
into pBKC-iCreFRTGBD*, to yield pBKC-iCreFRTGBD*FRTNLS-STOP. 8 colonies were 
analysed by EcoRI and Xbal digestion and showed the correct pattern. Colony n.8 (pBKC- 
iCreFRTGBD*FRTNLS-STOP c8) was sequenced to check the integrity of both the Cre 
cassette and the FRTNLS-STOP module and selected for the successive cloning steps.
The next step involved ET mediated insertion of the Cre cassette under the control of 
the Ikaros regulatory regions present in the two different Ikaros BACs.
Both Ikaros BACs (see above) contained the initiating ATG of the Ikaros gene. A 
full contig of 11409 bp had been sequenced previously and found to be present in both 
BACs (data from Dr. Meinrad Busslinger). It includes 6729 bp upstream of the initiating 
ATG, and 4614 bp downstream of it. The ET cloning strategy involved placing the Cre 
cassette immediately downstream of the Ikaros ATG, so that it would be transcribed under 
the full array of regulatory elements of the Ikaros gene. Therefore, the 5’ homology arm was 
designed so that it would encompass 61 nucleotides upstream of the ATG. As for the 3’ 
homology arm, it would have been possible to leave intact the rest of the first exon by 
targeting the cassette between the first and the second codon of exon 1. However, in this 
configuration, splicing could have taken place between exon 1, now harbouring the Cre 
cassette, and the rest of the gene. Although the presence of a polyadenylation signal within 
the Cre cassette would theoretically stop transcription, aberrant splicing could have resulted 
in the production of a chimeric protein containing portions of the CreLBD* cassette 
upstream of the Ikaros domains, which might have interfered with normal function. In order 
to reduce the possibility of aberrant splicing, the 3’ homology arm was designed to include 
61 residues starting 6 bp after the start of intron 1. Homologous recombination would thus 
result in the deletion of the first exon and the first six residues of intron 1.
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To place the Cre cassette immediately downstream of the Ikaros ATG, PCR was 
avoided by cloning the 5’ ET homology arm between the EcoRI and Hindlll sites located 
upstream of the starting ATG of the Cre gene. The original Ikaros sequence upstream of the 
ATG was left intact, immediately followed by the twelve nucleotides downstream of the 
Hindlll sites in pBKC-iCreFRTGBD*FRTNLS-STOP which precede the starting ATG of 
the Cre gene. The insertion of twelve nucleotides between the whole Ikaros regulatory 
region and the initiating ATG of Cre should not have any impact on transcription or 
translation of the Cre protein. Furthermore, in terms of translation efficiency, the sequence 
immediately upstream of the ATG is a better match to the Kozak consensus sequence than 
the original Ikaros one. Whereas the original Ikaros sequence reads 5’GAAGACA 3’, the 
Cre ATG is preceded by the sequence 5’ GTCCACC 3’, where ACC is a perfect match for 
the Kozak consensus (Kozak, 1986; Kozak, 1987).
To clone the 5’ ET homology arm into pBKC-iCreFRTGBD*FRTNLS-STOP, the following 
oligonucleotides were designed: IKHOMF and IKHOMR.
Oligonucleotide IKHOMF has the following 5'-3' sequence:
AATTCGCGGCCGCCATATTTTTGGTTTAAAGTAAAATCCATTTCTCTCTTCTC
TTCTCAGATAACCTGAAGACAA.
Residues 13 through 74 constitute the arm of homology to the 61 residues upstream of the 
intiating ATG of the Ikaros gene. A Notl site (positions 6-12, italics) was inserted to release 
the recombinogenic cassette iCreFRTGBD*FRTNLS-STOP from the pBKC vector. The 
first five residues (AATTC) and the last residue (A) constitute the upper strand overhangs 
for cloning respectively into the EcoRI and Hindlll sites of pBKC-iCreFRTGBD*FRTNLS- 
STOP.
Oligonucleotide IKHOMR has the following 5'-3' sequence:
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AGCTTTGTCTTCAGGTTATCTGAGAAGAGAAGAGAGAAATGGATTTTACTTTAA
ACCAAAAATATGGCGGCCGCG.
It is complementary to the sequence of IKHOMF. At the 5’ and 3’ ends, it creates the 
appropriate lower strand overhangs for cloning into EcoRI and Hindlll sites respectively.
The two oligonucleotides were annealed and ligated into pBKC-iCreFRTGBD*FRTNLS- 
STOP c8. Six colonies were analysed through Dral digestion and showed the correct pattern. 
Colony n.l (pBKC-5TKH0M-iCreFRTGBD*FRTNLS-ST0P c l)  was selected for the 
subsequent rounds of cloning.
In order to be able to select for the ET mediated recombination of the Cre cassette
into the Ikaros BAC, a resistance marker gene was needed. The p-lactamase gene which
confers resistance to ampicillin was chosen and placed immediately upstream of the 3’ ET
homology arm. However, selectable marker cassettes can affect the expression pattern of
neighbouring or targeted genes (Fiering et al., 1993; Kim et al., 1992; Olson et al., 1996),
and long-range interferences at distances greater than 100 kb have been reported (Pham et
al., 1996). Furthermore, the neo resistance gene contains cryptic splice acceptor sites
(Carmeliet et al., 1996; Meyers et al., 1998; Nagy et al., 1998). Although in the
configuration of the Cre cassette the selectable marker would lie downstream of the
polyadenylation signal, secondary effects on transcriptional regulation could not be
excluded. Therefore, it was desirable to remove the selectable marker from the modified
BAC after ET recombination, so that the final targeted BAC injected into mouse oocytes
would only contain the Cre cassette. Usually, removal of a selectable marker is achieved by
flanking it with recognition sites for a site specific recombinase (like Cre or Flp), which then
mediate its excision. However, the design of the Cre cassette described above prevented
utilisation of either Cre or Flp. In fact, the presence of the FRT sites flanking the LBD*
ruled out Flp as a possibility. LoxP sites could have been used, but upon recombination one
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would have been left in the targeted BAC and eventually inserted in the mouse genome. This 
could cause undesired chromosomal aberrations when the Ikaros-CxQ mouse line would be 
crossed to any mouse line already harbouring loxP sites in the genome.
This difficulty highlights the increased need to develop more recombinases as tools 
in genome engineering. This is of immediate importance for DNA engineering in E.coli, 
where, as exemplified here, the usefulness of Cre and Flp was already saturated. In the 
mouse, the recombinational power of Cre and Flp is at present far from its limit, but it is 
conceivable that in a not too distant future, strategies like the one described for the 
multifunctional MU allele will become widespread. As these strategies rely on the 
availability of multiple SSRs target sites (SSRTs) to simultaneously flank different portions 
of a gene, the need for additional SSRs active in mammalian organisms will also become 
apparent.
In the case of the Ikaros Cre cassette, the problem was solved by using the Tnpl 
recombinase, thereby providing evidence for the usefulness of this recombinase in BAC 
engineering (see section X.2.5). A PCR strategy was developed which incorporated in the 
oligonucleotides both the 3’ ET homology arm, the newly defined Tnpl recognition sites 
(TRTs) flanking the p-lactamase gene, and the portion annealing to the P-lactamase 
template.
The following oligos were designed: TRTAmpF and TRTAmpR.
Oligo TRTAmpF has the following 5'-3' sequence:
TTAGGTTC^CGCG7TAATACAACACAATATTAATTGTGTTGTArrÆ4rLL4TGA
AGACGAAAGGGCCTCGTGATACGCC
The TRT site (in bold) is located at position 15-46. A P ad  site was inserted (position 43-50,
italic) to facilitate identification of colonies having undergone ET recombination. The Mlu I
site (residues 9-14, italic) was placed to enable cloning of the PCR product into the Mlul site
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of pBKC-5TKH0M-iCreFRTGBD*FRTNLS-ST0P. As a source of template for the P- 
lactamase gene, the pACYC177 vector was used. The portion of this oligo which anneals to 
pACYC177 includes residues 52-79 (underlined).
Oligo TRTAmpR has the following 5'-3' sequence:
TGCAACG^CGCGTGCGGCCGCCTTGCTAGCTTCCCCAAGGACAGCTAGCACA
ACTTCTGGACATACAACTATCACCCAAGGTAATACAACACAATTAATATTGT
GTTGTATTAATCAATCTAAAGTATATATGAGTAAACTTG.
Residues 20 through 81 (in bold) comprise the arm of homology to the region of the Ikaros 
BAC immediately downstream of exon 1 (corresponding to residues 6838 to 6899 of the 
Ikaros contig). The TRT site is located at positions 82-113 (in bold and underlined). The 
Mlu I site (residues 8-13, italic) was placed to enable cloning of the PCR product into the 
Mlul site ofpBKC-5TKHOM-iCreFRTGBD*FRTNLS-STOP. A N otl site (positions 6-12, 
italic) was inserted as an anchor point to release the recombinogenic cassette 
iCreFRTGBD*FRTNLS-STOP from the pBKC vector. The portion of this oligo which 
anneals to pACYC177 includes residues 114-143 (underlined).
The resulting PCR product (TRTAmpTRTIKH0M3) was cloned into the Mlul site of BKC- 
5TKH0M-iCreFRTGBD*FRTNLS-ST0P cl. Ten colonies were analysed through XmnI 
digestion and half had integrated the PCR product in the correct orientation. Colony 6 was 
sequenced to check the integrity of the TRT sites and selected for ET recombination into the 
two Ikaros BACs.
X.2.2 Assembly of the CreFRTEBD*FRT construct
As an alternative to the 5IKHOM-iCreFRTGBD*FRTNLS-TRTAmpTRT3IKHOM, 
another construct was assembled in which the improved Cre recombinase was fused to the
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triple mutated version of the estrogen receptor ligand binding domain (EBD*)(Feil et al.,
1997; Indra et al., 1999). The cloning strategy involved PCR amplification of the triple
m utant EBD* m odule follow ed by subcloning into pB K C -5’IK H 0M - 
iCreFRTGBD*FRTNLS-STOP-TRTAmpTRTIKHOM3-c6 to exactly replace the GBD* 
with the EBD*. The triple mutated EBD* module was amplified by PCR (template was a 
gift of Dr. Gunther Schütz) using the following oligos: NewEBDF and NewEBDR.
Oligo NewEBDF has the following 5'-3' sequence:
TGGGGACGL4CGGGGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCTGÇÇA
ACCTTTGGCCAAGCCCGCTCATG.
A BsiWI site was inserted at position 7-12 (italic) to allow directional cloning into the 
corresponding BsiWI site present in the 5IKH0M -iCreFRTGBD*FRTNLS- 
TRTAmpTRT3IKH0M. The FRT was inserted in the oligo (positions 15-48, in bold), 
immediately followed by the portion of the oligo which anneals to the EBD* containing 
template (residues 49-76, underlined).
Oligo NewEBDR has the following 5'-3' sequence:
AACTTCGG7WCCTCTAGTCCAATCAGACTGTGGCAGGGAAACCCTCTGC.
A Kpnl site was inserted at position 7-12 (italic) to allow directional cloning into the 
corresponding Kpnl site present in the 5IKH0M -iCreFRTGBD*FRTNLS- 
TRTAmpTRT3IKH0M. The portion of this oligo annealing to the EBD* containing 
template comprises residues 23 through 49 (underlined).
The resulting PCR product (NewEBD*) was subcloned into the BsiWI and Kpnl sites of 
5IKHOM-iCreFRTGBD*FRTNLS-TRTAmpTRT3IKHOM. Recombinant colonies were 
analysed by Hindlll digestion. Positive colonies were sequenced to exclude the presence of 
mutations in the EBD* introduced during PCR amplification and Colony n.5 (5IKH0M-
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iCreFRTEBD*FRTNLS-TRTAmpTRT3IKH0M c5) was selected for ET recombination 
into both Ikaros BACs.
X.2.3 ET mediated targeting of the Cre cassettes into the Ikaros BACs
Two different Ikaros BACs (n.6 and n.3) were obtained (Dr. Meinrad Busslinger, 
unpublished results). As a preliminary step, both BACs were analysed with a panel of 
restriction digests (Pad, BamHI, Notl, Spel, Sbfl). Figure 47 shows that the two BACs share 
as expected some common bands, but overall they have clearly different patterns. Since no 
information was available about the respective amount of Ikaros  regulatory regions 
contained in each BAC, it was decided to target both BACs with the Cre-LBD* cassettes.
Prior to injection into fertlised mouse oocytes, both BACs had to undergo three 
rounds of modification.
First, the CreLBD* cassette was inserted into exon 1 of the Ikaros gene in the first 
ET mediated recombination step.
Second, the loxP site present in the BAC backbone had to be eliminated to avoid
undesired chromosomal rearrangements when the Ikaros-Cro mouse line would be crossed to
any mouse line harbouring loxP sites. There would be two approaches to address this
problem. The targeted BAC insert could be released from the BAC backbone prior to
injection, for example by digestion with the Notl sites also present in the BAC vector, or the
loxP site could be deleted through ET recombination. As shown in figure 47, it seemed
likely that a Notl site could also be present in the BAC inserts of the two Ikaros BACs, thus
preventing their use for linearisation. Moreover, although injection of a linearised transgene
is the standard procedure for normal-size constructs, in the case of BACs the use of a
linearised construct increases viscosity (thus making injection more difficult and less
controllable) and reduces the average number of transgenic founders. Plus, it would be
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Figure 47 Restriction digests of Ikaros BACs
0.4% agarose gel electrophoresis of multiple restriction digests from 
two independent Ikaros BACs as a preliminary step for their characterisation 
and subsequent manipulation via ET recombination.
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valuable to have a transgenic constuct which could be injected both in a supercoiled 
or linearised format to compare the results. Thus, the two Ikaros BACs, after having been 
targeted with the Cre cassettes, underwent a second round of ET recombination to replace 
the loxP site with a selectable marker.
Third, cells carrying the doubly targeted BACs were transformed with a plasmid 
expressing the Tnpl recombinase, in order to delete the p-lactamase gene from the Cre 
cassette.
For the first ET recombination step, HS996 cells harbouring either of the two Ikaros 
BACs were transformed with the recombinogenic plasmid R6K-apy. Electrocompetent cells 
were prepared from one colony for each BAC (Colony E for BAC n.6 and colony H for 
BAC n.3), electroporated with the recom binogenic cassette 5IK H 0M - 
iCreFRTGBD*FRTNLS-TRTAmpTRT3IKH0M and plated under double selection 
(chloramphenicol 12,5 pg/ml and ampicillin 50 pg/ml).
Recombinant colonies were preliminarily identified by PCR screening with the following 
primers: IkaroslV and IKProbelR. These primers yield an amplification product only if the 
Crc cassette has been integrated in the correct site in the Ikaros BACs.
Primer IkaroslV has the following 5'-3' sequence:
ATTCACAGTCCCAAGGCTCATTTC.
It anneals to the beginning of the PolyA signal in the Cre cassette cassette.
Primer IKProbelR has the following 5'-3' sequence: 
AAAATGCAAACTTACAAACAAATCAA.
It anneals to the Ikaros contig 1645 residues downstream of the 3’ ET homology arm. The 
resulting PCR product is 2193 bp long.
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10 colonies were analysed for each Ikaros BAC, and all tested positive for the presence of 
the correct amplification product (Figure 48). 4 colonies (n. 1 and n. 10 from the BAC 3H, 
and n. 3 and n.8 from BAC 6E) were sequenced to check the correctness of the integration 
point, and all yielded the correct result. After checking that they still contained the 
recombinogenic plasmid R6K-(xPy, competent cells were prepared from all four colonies for 
the subsequent ET recombination step.
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Figure 48 PCR screening of Ikaros BACs targeted with the CreGBD* cassette
Analysis of 20 candidate colonies after ET mediated insertion of the CreGBD* 
cassette in the two Ikaros BACs n.3 and n.6. PCR amplification with primers 
Ikaros2F and IKProbelR yields a product of 2193 bps.
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X.2.4 ET mediated deletion of the BAC vector loxP site
To delete the loxP site present in the BAC backbone, the gentamycin resistance gene was 
chosen as a selectable marker. Oligos were designed to amplify a product where the 
gentamycin resistance gene was flanked on both sides by homology arms to direct its 
integration into the BAC backbone. Oligo M//Del2R has been described above for the 
second deletion step in the assembly of the MU construct. Residues 1-65 constitute the 
homology arm to the BAC backbone. The portion of the oligo annealing to the gentamycin 
resistance gene (from plasmid pBADaPy-Gentamycin) comprises residues 66-90.
Oligo BACgentF has the following sequence 5-3':
GCCCCGACACCCGCCAACACCCGCTGACGCGAACCCCTTGCGGCCGCATCG
AATGCCCGGGCTAGGGATAACAGGGTAATCTATGTCGGGTCtCCtCtAGAAAGAGG
TAATG AP^TG G CTGAAGGCACGAACCCAGTTGACATAAGCC.
Residues 1 through 54 (in bold) constitute the 5’ arm of homology to the BAC backbone,
immediately upstream of the loxP site. A rare cutter poly linker (positions 55-116,
underlined) was inserted to permit eventual linearisation of the targeting cosntruct prior to
oocyte microinjection. It features the following restriction enzyme recognition sites: Srfl
(55-62), I-Scel (63-80) and Pi-Scel (79-116). The portion of the oligo which anneals to the
Gentamycin resistance gene template includes residues 117-145 (italics).
The resulting PCR product (BACGent) was electroporated into competent cells
prepared from the four colonies originating from the previous ET cloning step (n. 1 and n. 10
from the BAC 3H, and n. 3 and n.8 from BAC 6E). Cells were plated on triple selection
(chloramphenicol 12,5 p,g/ml, ampicillin 50 pg/ml and gentamycin 3pg/ml).
Recombinant colonies were preliminarily identified through a PCR screening with the
following primers: GentF and BACRecR. These primers yield an amplification product only
if the gentamycin cassette has been integrated in the correct site in the BAC backbone.
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Primer GentF has the following 5-3' sequence:
ACGATGTTACGCAGCAGGGCAGTC.
Primer BACRecR has the following 5'-3' sequence:
CGTCGGTCTGATTATTAGTCTGGA.
The resulting amplification product is 1384 bp long. Sequence analysis was initially 
performed on representative PCR positive colonies originating from BAC n.6 (from both 
batches of competent cells n. 3 and n. 8). Colony O was found to be correct (IK6E-CreGBD- 
Gent-C.3/0) and was chosen as such for injecting into mouse oocytes. This targeted BAC 
still harboured the p-lactamase gene downstream of the Cre cassette.
In a parallel set of ET targeting experiments, the conditional CreEBD* cassette was 
placed into both Ikaros BACs, with the same procedure described for the conditional 
CreGBD cassette. The recombinogenic cassette 5IKH0M-iCreFRTEBD*FRTNLS- 
TRTAmpTRT3IKH0M was electroporated into the Ikaros BAC competent cells (Colony E 
for BAC n.6 and colony H for BAC n.3), and cells were plated on double selection 
(chloramphenicol 12,5 pg/ml and ampicillin 50 pg/ml).
To identify correct recombinants, the same PCR screening strategy described above was 
applied, which relies on primers IkaroslV and IKProbelR. 9/10 colonies originating from 
BAC n.3 and 10/10 colonies originating from BAC n.6 showed the correct amplification 
band.
For the subsequent ET cloning step, from 6 independent colonies originating from BAC n.3 
(C. n.1,2,3,4,5 and 6), and 4 independent colonies originating from BAC n.6 (C. n.l 1, 13, 14 
and 15), which still contained the recombinogenic plasmid R6R-aPy, electrocompetent cells 
were prepared and electroporated with the PCR product BACGent. Positive colonies were
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screened by PCR using primers GentScreenF and GentScreenR, which had been shown to 
yield a more robust PCR amplification than primers GentF and BACRecR.
Primer GentScreenF has the following 5'-3' sequence:
GCCTGATGCGGTATTTTCTCCT.
Primer GentScreenR has the following 5'-3' sequence:
CCTCTGTCGTTTCCTTTCTCTG.
The resulting amplification product is 1066 bp long. As with primers GentF and BACRecR, 
also these primers yield an amplification product only if the gentamycin cassette has been 
integrated in the correct site in the BAC backbone. On average, 57% colonies showed the 
correct band, and were therefore further characterised.
Colony n.26 (IK3H-CreEBD *-Gent-c.6/26) originating from BAC n. 3 resulted correct upon 
sequence analysis, and was selected as such for injection into mouse oocytes. Also in this 
case, as with colony O originating from BAC n.6, the targeted BAC still harboured the P- 
lactamase gene downstream of the Cre cassette.
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X.2.5 Tnpl is a novel recombinase for BAC engineering
Tnpl recombinase is encoded by the Tn4430 transposon from Bacillus thuringensis 
(Mahillon and Lereclus, 1988). This is a 4149 bp transposon which codes for two proteins. A 
113 K-Da protein (TnpA), homologous to the transposases of Tn3, Tn21 and Tn501, 
catalyses the formation of cointegrants between the donor and target replicon. The second 
protein (Tnpl), 32 KDa, catalyses the resolution of the co-integrate and has homology to the 
site specific recombinases of the integrase family, like the Int recombinase of bacteriophage 
lambda, Cre from bacteriophage PI and TnpA and TnpB from the Tn554 transposon. 
Previous studies had established the usefulness of Tnpl recombination to remove antibiotic 
resistance markers from genetically modified Bacillus thuringensis strains (Sanchis et al.,
1997).
Within the internal resolution site (1RS), a 32 bp sequence was identified consisting 
of two inverted repeats of 14 bp each separated by a symmetric spacer of 4 nucleotides. This 
configuration led to the hypothesis that this site could represent the minimal recognition 
element for Tnpl, in analogy to the loxP and FRT sites for Cre and Flp respectively. 
Experiments using reporter plasmids carrying a selectable marker flanked by these minimal 
recognition sites (called TRTs for Tnpl recognition targets) demonstrated that Tnpl can 
successfully mediate recombination between these shortened recognition elements (Youhua 
Deng et al., unpublished observations). The small size is of great practical relevance, 
because it allows to include these sites directly into oligonucleotides for any cloning 
purpose.
These experiments prompted to test whether the same reaction could be catalysed efficiently 
also on BACs, adding a novel component to the BAC engineering "toolkit". The following 
experiments describe the successful application of Tnpl to the removal of the selectable
marker cassette from the Ikaros-CxQ modified BACs.
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To this end, the same colony IK3H-CreEBD*-Gent-c.6/26 was transformed with a 
plasmid expressing Tnpl recombinase under an arabinose inducible promoter. Cells were 
grown on double selection (chloramphenicol 12,5 pg/ml and kanamycin 50 |Lig/ml). Colonies 
were then picked and grown overnight in selective medium (chloramphenicol 12,5 pg/ml 
and kanamycin 50 pg/ml) plus L(+)arabinose (at a final concentration of 0.2%).
In principle, a fast method to detect cells which had undergone Tnpl mediated recombination 
would have been to isolate single colonies after arabinose induction, and to replica plate 
them on plates with and without ampicillin respectively, since Tnpl recombination would 
result in the loss of the P-lactamase cassette.
However, pilot experiments applying this methods systematically failed, and all colonies 
grew equally well on plates with and without ampicillin selection. This strongly argued that 
Tnpl recombination was not 100% efficient, at least in BACs, and that each colony was 
actually a mixture of recombined and unrecombined cells. Under such circumstances, a 
screening method based on ampicillin sensitivity was obviously not sensitive enough, 
especially since the P-lactamase protein is secreted outside the cell, thereby masking the 
presence of cells having undergone removal of the P-lactamase cassette.
In order to overcome this problem, a PCR assay was developed based on the same primer 
pair described above {Ikaros2¥ and IKProbelR). After replacement of Ikaros exonl by the 
CreLBD* cassette, amplification with these two primers results in a product 2193 bp, which 
spans the TRT flanked P-lactamase cassette. After Tnpl mediated recombination between 
the two TRT sites, amplification with these primers is expected to yield a shorter band of 
1052 bp. If the mixed colony hypothesis originating from the ampicillin sensitivity 
experiments was correct, one would expect that colony PCR with this primer pair results in
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the amplification of both unrecombined and recombined bands. This turned out indeed to be 
the case.
PCR was performed on liquid culture from 10 colonies grown in arabinose 0.2%. All 
colonies showed the expected double band (figure 49). Colonies n.l and n.8 were then 
streaked to isolate colonies harbouring only the recombined BAC. From each plate, 8 
colonies were picked and subjected to a second round of growth in arabinose 0.2%. PCR on 
these colonies showed that about half of them had lost the upper band, indicating complete 
Tnpl mediated recombination. Colonies 8G and 1A were chosen for further characterisation. 
Sequence analysis was performed and confirmed that the P-lactamase gene had been 
precisely deleted leaving only one TRT site behind.
These experiments establish the usefulness of Tnpl as a novel recombinase in BAC 
engineering.
Before injecting the final Tnp-deleted targeted BAC IK3H-CreEBD*-Gent-c.6/26-TnplA 
into mouse oocytes, it was necessary to obtain a pure preparation of the BAC without any 
contamination with the high copy plasmid expressing Tnpl. In fact, in a mixed DNA 
preparation, the relative ratio of this high copy plasmid to the desired BAC may have 
dramatically decreased the chances of obtaining BAC transgenic founders. Furthermore, 
cointegration in the genome of the Tnpl expressing cassette could have resulted in 
unprecedented effects.
Thus, since the Tnpl expressing plasmid was not spontaneously lost from cells harbouring
the targeted BAC IK3H-CreEBD*-Gent-c.6/26-TnpIA, even after extensive culture in the
absence of kanamycin selection, cultures were streaked on a double selection plate
(chloramphenicol 12,5 pg/ml ampicillin 50 p-g/ml). 85 colonies were picked and replica
plated on plates with and without kanamycin respectively, to retrieve kanamycin sensitive
271
colonies. Five colonies were sensitive to kanamycin, and were therefore checked by gel 
electrophoresis to confirm the absence of the Tnpl plasmid. All of them showed the presence 
of the targeted BAC without any additional plasmids. Importantly, all of them showed the 
same restriction pattern indicating that no undesired intramolecular recombination had 
occurred either during Tnpl mediated recombination or during the subsequent rounds of 
culture to eliminate the Tnpl plasmid. Thus, in the conditions tested, the targeted BAC 
IK3H-CreEBD*-Gent-c.6/26-TnplA was a very stable molecule. Colony n. 2 and n. 55 were 
then selected for injection into mouse oocytes.
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Figure 49 Tnpl effectively deletes TRT flanked cassettes from BACs
A PCR assay was used to identify colonies in which the p-lactamase cassette 
flanked by the Tnpl recognition sites (TRTs) had been deleted from the Ikaros 
BACs.
A. After one round of Tnpl expression, all colonies show both 
the unrecombined (red arrow) and the recombined band (green 
arrow).
B. After the second round of Tnpl expression, 50% of the 
colonies have undergone complete recombination.
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X.3 Establishm ent o f Ikaros Cre transgenic founder lines
Prior to oocyte microinjection, BAC DNA was prepared as described (Materials and 
Methods) and then quantitated by both UV spectrophotometry and gel electrophoresis. The 
latter was very useful to fine tune the low concentrations needed for microinjection by 
comparing serial dilutions with known reference standards, as described by Hammes and 
colleagues (Hammes et al., 2000). Following injection of the Ikaros-CxQ BAC constructs 
into fertilized mouse oocytes, the following results were obtained (figures 50-52).
For the Ikaros BAC n.6 carrying the Cre FRTGBD*FRT cassette, 2 founders were obtained 
out of 9 animals born, which amounts to a frequency of 22% (figure 50). The concentration 
of DNA used was 2 ng/pl.
For the Ikaros BAC n.3 carrying the Cre FRTEBD*FRT cassette, 2 out of 3 transfers yielded 
founder animals. From one transfer 1 founder was identified out of 11 animals (9% 
frequency) (figure 51), while in the second experiment one founder was obtained out of 5 
animals (20% frequency). In both cases, the concentration of DNA was 0.2ng/|il.
For the Ikaros BAC n.3 carrying the Cre FRTEBD*FRT cassette after Tnpl recombination 
(colony 2), two transfers resulted in the following results: 1 founder out of 6 animals bom, 
amounting to 16% frequency, and 2 founders out of 21 animals bom, which amounts to a 
frequency of 9.5%. The concentration of DNA used was 2 ng/pl.
For the Ikaros BAC n.3 carrying the Cre FRTEBD*FRT cassette after Tnpl recombination 
(colony 55), two transfers resulted in the following results: 1 founder out of 5 animals bom, 
amounting to 20% frequency, and no founders out of 27 animals bom. The concentration of 
DNA used were respectively 1 and 1.5 ng/pl.
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Candidate founders were screened both by PCR and Southern blot hybridisation. PCR 
utilized the primers iCreF and iCreR which specifically detect the presence of the improved 
version of Cre recombinase. Primer iCreF has the following 5-3' sequence: 
GCCTGCCCTCCCTGTGGATGCCACCT 
Primer iCreR has the following 5'-3' sequence:
GTGGCAGAAGGGGCAGCCACACCATT
Southern hybridisation was used both to confirm the PCR results and to estimate the number 
of copies integrated into the genome. This is an important consideration for all transgenic 
experiments, especially when the expression of the gene under study needs to be maintained 
at physiological or para-physiological levels. In this case, fidelity in expression levels was 
not a particular concern, since the aim was to efficiently express Cre recombinase under the 
Ikaros promoter regardless of the number of copies integrated per cell. However, it has been 
demonstrated that multiple integrations, which virtually always occur as tandem integrants, 
result in decreased expression of the transgene (Garrick et al., 1998). This is independent of 
the site of integration, and correlates with increased chromatin compaction and méthylation 
at the transgene locus.
To determine the copy number, a Southern strategy was devised in which the probe detects 
bands of different sizes for the wild type copy of the gene and for the transgene. The probe 
was synthethised with primers IkProbelF and IkProbelR.
Primer IkProbelF has the following 5'-3' sequence: 
TCCCAAGTGAGATTAGGTAGTGTGAA 
Primer IkProbelR has the following 5'-3' sequence: 
AAAATGCAAACTTACAAACAAATCAA
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Following EcoRI digestion of genomic DNA from mouse tails, the probe detects a band of 
1480 bp for the wild type locus, a band of 5266 for the transgene still harbouring the p- 
lactamase gene, and a band of 4125 for the Tnpl treated transgene. As shown in figure 52 
comparison of the wild type and the recombined band reveals that the various founders differ 
over a wide range of transgene copy number. Thus, both n. 540161 and 540178 are high 
copy number founders, followed by 540204, 540196, 540206, 540188, 540243 and finally 
540233. 540188, 540206 and 540233 could be very likely single copy integrants.
In view of the above considerations, it will be very interesting to compare the expression 
levels obtained in these different lines.
These results also demonstrate that supercolied Ikaros-CxQ BAC DNA was consistently 
integrated into the mouse genome, and the efficiencies were comparable to those normally 
reported for supercoiled plasmid DNA.
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Figure 50 Southern blot screening of Ikaros-CreGBD* founders
Southern blot analysis to identify founder mice carrying the Ikaros BAC n.6 
engineered with the CreFRTGBD*FRT cassette. The probe used permits to detect both 
the wild type and the transgenic band. From one transfer which yielded 9 anumals,
2 founder mice were obtained, amounting to a frequency of 22%.
Abbreviations: E (EcoRl); sm (selectable marker); pA (polyadenylation signal);
NTS (nuclear localisation signal).
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Figure 51 Southern blot screening of Ikaros-CreEBD* founders (1)
Southern blot analysis to identify founder mice carrying the Ikaros BAC n.3 
engineered with the CreFRTEBD*FRT cassette. The probe used permits to detect both 
the wild type and the transgenic band. 1 mouse shows the recombined band, amounting 
to a founder frequency of 9%.
Abbreviations: E (EcoRI); sm (selectable marker); pA (polyadenylation signal);
NTS (nuclear localisation signal).
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Figure 52 Southern blot screening of Ikaros-CreEBD* founders (2)
Southern blot analysis of additional founder mice carrying the Ikaros BAC n.3 
engineered with the CreFRTEBD*FRT cassette.
Founders 540188-540243 have integrated the Ikaros-CreEBD* transgene in which 
the p-lactamase gene had been deleted by Tnpl recombination, resulting in a lower 
band (green arrow).
The probe used permits to estimate the copy number of transgenes integrated.
ID 540161 and 540178 have integrated a very high number of copies. ID 540188, 
540206 and 540233 could be single copy integrants.
See text for further details.
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XI
Conclusions
The work presented in this thesis describes novel genome engineering approaches to 
analyse gene function in the mouse. Three mouse lines were designed with the long term 
objective of a completely conditional mouse model of the human leukemia associated with 
the t(4; 11 )(q21 ;q23) translocation.
In all three cases, the targeting constructs were assembled starting from BACs using an array 
of large scale cloning technologies centered on the ET recombination system.
For the AF4 gene, a multifunctional allele was established, which can be used in the 
translocation model, as well as to analyse a potential loss of function phenotype and report 
the endogenous expression of the gene. The main results obtained from this strategy can be 
summarized as follows:
1) ET recombination can be used to direct simple, efficient subcloning from BACs
into higher copy vectors, for a variety of downstream applications. The subcloning of the 28
kb intron 3 of the mouse Af4  BAC was the first application of gap repair using ET
recombination. This success promoted a variety of equally successful subcloning exercises
across a wide range of fragment sizes from different types of target molecules.
One of these exercises was the subcloning of the desired genomic backbone for the ES cell
Af4  targeting construct, chosen after design of a Southern blot strategy to screen for
homologous recombinants in ES cells. This constitutes the first example of a new way of
generating mouse targeting constructs, in which the length and the location of the homology
arms were chosen to suit requirements. The availability of saturating mouse BAC libraries
and the expected completion of the mouse genome sequencing project will make this
strategy a prime choice for engineering mouse targeting constructs. It represents a substantial
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improvement over traditional approaches where elaborate cloning steps have been required.
2) A universal promoter-trap intronic knock-in cassette was developed, which can be 
targeted to any mouse gene regardless of its expression in ES cells. This was achieved by 
combining a promoterless Pgeok fusion, including a splice acceptor and an 1RES element, 
with an autonomously expressed hygromycin resistance module for genes which are not 
expressed in ES cells. The advantage of this approach is that as soon as the gene is activated 
during development or adult life, the Pgeok marker reports its expression through Beta- 
galactosidase staining, while at the same time ablating its function by subverting its normal 
RNA processing. Targeting of the mouse Af4 gene demonstrated that this double seleetion 
cassette was functional in ES cells, and that insertion of the pgeok with the SV40 late 
polyadenylation signal in an intron results in the absence of the wild type, full length 
transcript.
3) Mice homozygous for the 4/^-LacZ allele, which results in the absenee of the full 
length transcript, are bom at the expected Mendelian frequeney, indieating that, in agreement 
with previous reports, this gene is not essential for embryonic development. Early results 
with these mice, however, indicate phenotypic differences that may accord with an intron 3 
tmncation (this study) or an exon 11 deletion (Isnard et al., 2000).
For the MLL gene, a multivalent targeting construet was engineered, which provides 
several entry points for the functional characterisation of this gene. The main features are a 
protein purification tag at the aminoterminus combined with a conditional, splice-trapping 
cassette in intron 11. Sinee these two targeting sites are about 60 kb apart, two selectable 
markers were used. Both selectable marker cassettes were flanked by target sites for Cre and 
Flp. Hence, the combinatorial use of these two recombinases, in ES cells and in the mouse.
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can yield four different allele configurations as a versatile platform for the following 
experiments: ablation of MLL gene function (prior to Cre and Flp recombination); isolation 
of the native protein complex assembled around the aminoterminal domains of MLL (after 
Flp recombination); isolation of the endogenous MLL protein complex, in different tissues 
and at different developmental stages (after Cre and Flp recombination); possible isolation of 
the protein complex of the leukemogenic MLL-AF4 fusion protein (after Cre and Flp 
recombination followed by interchromosomal translocation with the 4/^-LoxP mouse line).
This strategy to engineer a mouse has several implieations, including;
1) Due to the size of most eukaryotic genes, BACs constitute a good starting 
platform for the assembly of complex targeting eonstruets. Using ET recombination BACs 
can be simply engineered in two ways. First, deletion of superfluous regions from a BAC to 
generate a suitable backbone for the ES targeting procedure, since most unmodified BACs 
are likely to have homology arms of exeessive length which would prevent any Southern 
strategy from distinguishing homologous recombinants from random integrants. Second, 
appropriate marker cassettes are targeted to the regions of interest within this modified BAC 
backbone. The results obtained for MU show that 5 different selectable markers could be 
introduced on the same BAC, and the host bacteria eould be successfully grown under 
simultaneous selection with all five drugs.
2) The goal of targeting via homologous recombination in ES cells two different 
regions of a gene of interest presents a substantial challenge. Classically, different targeting 
constructs have to be assembled, and the cells subjeeted to repeated rounds of targeting. The 
requirement for the two mutations to be integrated on the same allele further diminishes the 
fluency of this approach.
The strategy outlined here for MU used a very large targeting construct (at least 65
Kb) for homologous recombination in ES cells to simultaneously target two different regions
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of a gene. Two lines of evidence, the percentage of co-resistance in the double seleetion 
scheme and Southern blot analysis, indicate that the construct integrated mostly intact, 
without undergoing substantial breakdown; thus, these types of construct constitute a 
preferred route to efficiently place two mutations on the same allele. The overall frequency 
of homologous recombination (6.5%) is well within the range deseribed in the literature, 
whose variability likely reflects the different efficieney of homologous recombination at 
different genomic loci.
These experiments provide both a conceptual and practical framework for the use of 
BACs in complex, multifunetional mouse alleles. Most modifications take place in E. coli 
and rely on the ET homologous recombination system. As shown by many experiments 
presented in this thesis, as well as previously reported, this methodology assures precision, 
fidelity and ease of manipulation in all applications of BAC engineering. Combined with the 
flexibility of site specific recombination, an array of mutations can be simultaneously 
introduced in any mouse gene, and their isolated or combined effect assessed in vivo in a 
completely conditional manner. Furthermore, a BAC vector configuration, which features 
two selectable marker cassettes at the two ends of the construct, represents a superior way to 
introduee single base substitutions in any mouse locus than previous strategies. They have 
been ineffieient since the desired mutation, which usually had to be targeted to an exon, 
eould not be strietly coupled to the seleetion marker in order not to interfere with the reading 
frame; under such circumstances, the frequency at which the single base mutation was 
correctly integrated decreased as a function of its distance from the seleetable marker 
cassette. Recently, ET recombination was adopted to introduce single base substitutions in 
BACs (Muyrers et al., 2000a). In combination with the strategy described above, it becomes 
possible, by selecting for the integration of both ends of the eonstruct, to ensure that a single
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base substitution previously engineered into the BAC baekbone is reliably targeted to the 
endogenous locus.
Mouse lines were established expressing Cre reeombinase under the control of the 
Ikaros gene. A BAC transgenesis approach was chosen, and ET recombination was used to 
engineer two different Ikaros BACs. The following results can be outlined:
1) A novel Cre expression cassette was designed which consists of a fusion of Cre 
with different FRT-flanked LBD*s of nuclear hormone receptors. By appropriately 
regulating the expression of Flpe recombinase, this can be flexibly employed to achieve 
either constitutive or regulated Cre activity starting from the same original mouse line.
2) ET recombination was successfully used to target these Cre cassettes to the first 
exon of the Ikaros gene present in the BAC, as well as to delete the loxP site contained in the 
BAC vector. Removal of this loxP site is necessary for conditional transgenic approaches in 
which the random integration of a loxP in the genome is clearly undesired, and the ET based 
method described in this thesis is a fast and efficient way to avoid the problem.
3) Tnpl recombinase from transposon Tn4430 was employed to remove the 
seleetable marker cassette from the targeted BACs prior to oocyte injection. These 
experiments examined its usefulness as an additional tool for BAC engineering.
4) Following BAC injections, 10 founders were obtained, covering a wide range 
from single to multiple copy integrants. This should allow the establishment of lines with 
distinct levels of Cre expression.
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XII
Materials and Methods
XII. 1 Materials 
XII.1.1 Enzymes
Restriction enzymes were purchased from New England Biolabs (NEB), USA or from 
Boehringer Mannheim, Germany. T4 DNA ligase was from NEB. Shrimp alkaline 
phosphatease (SAP) was from Unites States Bioehemical (USB). T3 and T7 RNA 
polymerases, RQl DNAsel and recombinant human RNAsin were purchased from Promega. 
RNAse A, Proteinase K and BOvine Serum Albumin (BSA) were from Sigma. Amplitaq 
DNA polymerase and the High Fidelity PCR system were from Roche.
XII. 1.2 Synthetic oligonucleotides
Synthethic oligonucleotides were synthethised by the Oligo facility of EMBL, the ARK and 
the Biosprings companies. When relevant, they were 5' phosphorylated or HPLC purified.
For complex ET eloning exercises, when the synthesis of particularly long oligos was 
required, I obtained the best results with the HPLC purified oligos from Biosprings.
XII. 1.3 High Density Mouse BAC membranes
The high density mouse BAC membranes were purchased from Research Genetics, Inc, 
along with the reference hybridisation probe.
XII. 1.4 BAC E, coli hosts
E.coli cells of the strain HS996 containing the BACs of interest were obtained as agar stabs 
from Research Genetics, Inc.
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XIL1.5 Reagents for bacterial cultures
Bacterial media for routine use were prepared by the EMBL bacterial service. Antibiotics 
were purchased from Boehringer Mannheim. L(+)arabinose was purchased from Sigma.
XII. 1.6 Mouse embryonic stem cells (ES) and Mouse embryonic fibroblasts 
(MEFs)
Mouse ES cells from two different lines were employed: the E14 line established in Klaus 
Rajewsky's lab, and the El line established in the lab of Austin G. Smith. Wild-type, G418 
and hygromycin resistant MEFs were purchased from Genome Systems.
XII.1.7 Cell culture reagents
Reagents for the culture of mouse ES cells were purchased from Gibco-BRL (LIE, 
Glutamine, Sodium Pyruvate, Fetal Bovine Serum, Trypsin-EDTA), Sigma (Glucose, 
PMercapto-ethanol), NEN (Non essential aminoacids). Plasticware for cell culture was 
purchased from Falcon, Nunc, Greiner or Waki.
XII. 1.8 Radioactive Isotopes
^^P-a-dCTP (3000Ci/mmol) and ^^P-a-dUTP (800Ci/mmol) were obtained from Amersham, 
UK.
XII. 1.9 ET recombination plasmids
The ET reeombination plasmids pBADabg and pR6Kl 16/BAD/abg were described in 
(Muyrers et al., 1999; Zhang et al., 2000). Additional information is available at the 
following web address: http://www.embl-heidelberg.de/ExternalInfo/stewart/plasmids.html.
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XII.2 Methods
XII.2.1 Restriction enzyme digestions
Restriction enzyme digestions of double stranded DNA were carried out according to the 
instructions of the suppliers, using the buffers provided. Ineubation was at least 3 hours and 
the reaction volume was usually 50 pi.
XII.2.2 Ligations
Ligations were set up by mixing vector and insert DNA (usually with insert in at least 3 fold 
molar excess to vector) in a volume of 15 pi with 1 unit of DNA T4 ligase and the buffer 
provided by the supplier. The reaction was incubated at 16 °C for at least 12 hours.
XII.2.3 Mini preparations of plasmid DNA
Small scale DNA preparations of regular plasmids for analytical purposes were made from 
1.5 ml of overnight eulture and proeessed with the miniprep kit available from Qiagen, 
Germany.
For the minipreparation of BAC DNA, the protocol suggested by Research Genetics was 
used. Cells from a 1.5 ml overnight culture were pelleted by 30 seconds centrifugation in an 
eppendorf centrifuge at full speed. After medium removal, cells were resuspenden in 100 pi 
solution I (50mM glucose, 20 mM Tris-Cl, pH 8.0, 10 mM EDTA, pH 8.0) and mixed by 
pipetting. 200 pi freshly prepared solution II (0.2N NaOH, 1% SDS) were added, contents 
mixed and the tubes placed on ice. 150 pi solution III (KAc, pH 4.8) were added and after 
mixing, the cell lysates were cleared by 6' centrifugation at full speed. BAC DNA was then 
ethanol precipitated and the pellet washed with 70% ethanol. After complete drying, the
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pellet was resuspended in 20 pi TE. Routinely, 5 pi were used for analytical restriction 
digestion.
XIL2.4 Maxi preparations of plasmid DNA
Large scale DNA preparations from regular plasmids were made from 500 ml overnight 
culture using the cartridge Maxiprep Kit available from Qiagen. Large scale preparations of 
BAC DNA for sequeneing, analytical gel electrophoresis, oocyte injeetion and ES cell 
transfection were prepared from 500 ml overnight culture using the Large Construct 
Maxiprep Kit available from Qiagen, which includes an additional step of exonuclease 
digestion to remove all contaminant genomic DNA as well as nicked BAC molecules.
At the end of the preparation, DNA was resuspended in TE and quantitized by measuring 
UV absorbance at 260 nm. In the case of oocyte mieroinjeetion, in order to aceurately 
determine very low concentrations of DNA (down to 2 ng/pl), serials dilutions of the 
maxiprep DNA were compared by agarose gel electrophoresis with known reference 
standards.
XIL2.5 Polymerase Chain Reaction
PCR reactions were carried out in a total volume of 50 pi with 0.2 mM dNTPs, primers (0.5- 
1 pM), amplification template (in various amounts depending on the source), Taq 
polymerase (2.5-5 Units/reaction) and the appropriate buffer provided by the supplier. 
Reaction conditions varied among different experiments, but usually eonformed to the 
following cycling pattern: 1 minute initial dénaturation at 94 °C, 30 to 35 cycles consisting 
of 1 minute dénaturation at 94 °C, 1 minute of annealing at the relevant temperatures
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(depending on the primers used) and variable times of extension at 72 °C. The last cyele was 
followed by 10 minutes of additional extension at 72 °C.
PCR produets were purified with the PCR extraction kit from Qiagen, according to the 
instruetions of the manufacturer.
XII.2.6 RNA extraction
RNA was extraeted from mouse organs with RNAzol (Molecular Research Center, Inc.) 
according to the instructions of the manufacturer.
XII.2.7 Reverse transcription
Total RNA from mouse organs was used to synthethize cDNA with the Reverse 
Transcriptase SuperScriptll (from Gibco, BRL). In a total volume of 12 pi, 4 pi of total 
RNA were combined with 1 pi 01igo(dT)(500 pg/ml), and 1 pi of a dNTP mix at a 
concentration of 10 mM each. The mixture was heated at 65 °C for 5 minutes and quickly 
chilled on ice before adding the following components: 4 pi of 5X First-Strand Buffer 
(provided by the supplier), 2 pi of DTT (0.1 M) and 1 pi of RNAse inhibitor RNAseOUT 
(40 units/pl). The components were mixed and incubated at 42 °C, before adding 1 pi of 
Reverse Trancriptase (200 units). The reaction was allowed to proceed for 50 minutes at 42 
°C. The reaction was then inactivated by heating at 70 °C for 15 minutes. To remove the 
RNA from the DNA-RNA hybrid, 1 pi (2 units) of E. coli RNAseH was added, and the 
reaction incubated at 37 °C for 20 minutes.
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XII.2.8 Preparation and transformation of competent cells for ET cloning 
experiments
A detailed protocol for the preparation of competent eells for ET cloning experiments can be 
found at the following web address:
http://www.embl-heidelberg.de/ExternalInfo/stewart/ETprotoeols.html. Here the most 
relevant steps are summarised.
E.Coli cells harbouring the relevant BAC were transformed with the ET expression plasmid 
by standard procedures and plated. Single colonies were picked and grown in 5 ml L 
medium overnight. 0.7ml of culture were then transferred into 70 ml of LB medium (without 
glucose) and grown at 37 °C shaking. Meanwhile, 10% glycerol with dH20 was prepared, 
and eooled down on iee for at least 3 hours before using. When the cells reaehed OD600 = 
0.1-0,15, 0.7ml of a 10% L-arabinose solution were added to induee ET protein expression. 
After a further 45-60 minutes, the cells should be at OD600 of 0.3-0.4 and ready for harvest. 
For BAC experiments, lower CDs (around 2.5) have aetually yielded even better results. The 
centrifuge and the rotors SA600 or SS34 (Sorvall) were eooled by centrifuging for 10 min at 
-5 °C at 4,000 rpm. 35 mis of cells were spun in a first round of centrifugation for 10 min at 
7,000 rpm at -5 °C, while keeping the other 35 mis on iee. After pouring away the 
supernatant, seeond 35 mis were added and respun. After pouring away supernatant, tubes 
were put on iee, and the cells resuspended in 5 to 10 mis ice cold 10% glycerol with an ice 
cold 5/10 mis pipette. 25 more mis of 10% glyeerol were added and cells centrifuged. This 
step was repeated twice. At the end, after pouring away supernatant, the tubes were 
immediately dried with Kleenex tissue taking care not to touch the pellet. Cells were then 
resuspended in the remaining liquid (the final resuspended volume usually amounted to 
lOOpil). 50 |il of cells were transferred into each pre-cooled eppendorf tube and frozen in
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liquid N2 or used immediately. The same protocol applies, omitting the L(+) arabinose 
induction, for the strains like JC8679 which consitutively express the recombinogenic 
proteins.
For transformation, competent cells were thawed on ice and mixed with 1 to 2 pi of the 
recombinogenic linear DNA fragment (PCR product or a fragment excised from a plasmid). 
Electroporation cuvettes were precooled on ice for least 5 min. Cells were electroporated at 
2.3 kV (Bio-Rad Gene Puiser) (25 pF with pulse controller set to 200 ohms), with time 
constants between 4.5 and 4.8. 1 ml of LB medium was added and transferrd back into the 
eppendorf tube. Cells were then incubated at 37 °C for 1 to 1.5 hours with shaking, and 
plated on suitable antibiotic selection plates.
XIL2.9 Preparation of competent cells for routine cloning
DKl, XL-IB or HBlOl cells were made competent for transformation as follows. 2 mis of 
an overnight culture were diluted in 100 ml of L-Broth without antibiotics and grown at 37 
°C up to an ODôoo of 0.35-0.5. All subsequent steps were done at 4 °C in the cold room. 
Cells were spun down at 3000 rpm for 10 minutes and resuspended in 20 mis of freshly 
prepared, ice cold RbCl buffer (60 mM CaCL , 40 mM KAc, 15% Sucrose, 1.2 % RbCl, 
0.045M M nC y. They were then spun again for 10 minutes at 300 rpm. Finally, they were 
resuspended in 10 ml of ice cold RbCl buffer, and 400 pi of DMSO were added. Aliquots of 
200 pi were snap frozen in liquid nitrogen, and stored at -80 °C.
XIL2.10 Agarose gel electrophoresis
Agarose gel electrophoresis, used for analysis (and purification) of DNA fragments was 
carried out as described (Sambrook and Maniatis, 1989). The required weight of agarose for
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0.4% (used for BAC restriction analysis) to 2% (w/v) gels was dissolved in IX TAB (90 nM 
Tris-Cl pH 8.3, 90 mM acetic acid, 1 mM EDTA) by heating in a microwave oven. The 
solution was cooled and ethidium bromide was added to a concentration of 0.05 pg/ml 
before pouring. Alternatively, gels were stained with Ethidium Bromide (at the same 
concentration) after running.
Gels were run submerged in IX TAB at variable speeds (10-15 volts/cm for minigels and 
2.5-5 volts/cm for 20cmX20cm gels).
XII.2.11 Pulsed-field-gel electrophoresis
Pulsed-field-gel electrophoresis was performed on a Biorad CHEF-DRII with the following 
parameters: temperature (14 °C); pulse 1 (0.5 seconds); pulse 2(10 seconds). Samples were 
run on a 1% agarose gel in 0.5 TBE for 18 hours at a voltage of 6 V/cm.
XII.2.12 Southern blotting
After electrophoresis, DNA gels were incubated with gentle shaking in 0.25M HCl for 10 to 
30 minutes, resulting in partial depurination and facilitated transfer of the larger molecules. 
The gel was then transferred to 0.4N NaOH for three 15 minutes washes, to denature the 
DNA. The gel was then incubated in 20X SSC (3M NaCL, 0.3M NaCitrate) for 20 minutes 
prior to blotting onto a nylon membrane (purchased from Dupont). The gel was inverted and 
DNA transfer was mediated by capillary action in 20XSSC overnight. The membrane was 
then rinsed in 25 mM NaH2P0 4  pH 7.2, and baked in a vacuum oven at 80 °C for at least 
two hours to crosslink the DNA to the membrane.
Hybridisation was performed in a glass tube in a hybridisation oven equipped with a rotating 
wheel. Filters were first prehybridised in Church and Gilbert buffer (7% SDS, 250 mM
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NaH2P0 4  1% BSA, ImM EDTA) for 30 to 60 minutes incubation at the relevant temperature 
(65 °C to 72 °C depending on the probe), and then hybridised in the same buffer upon 
addition of the relevant RNA or DNA probe for 16 hours at the relevant temperature.
DNA probes were made by random prime labelling with the ready-to-go kit available from 
Pharmacia, according to the instructions of the manufacturer. Up tp 50 nanograms of DNA 
were labelled per reaction. After incorporation of radiolabelled dCTP, unincorporated DNTP 
were removed with purification colums (Pharmacia). Incorporation of radioactive dCTP was 
monitored by thin layer chromatography (TEC). For this, 0,2 jLil of the reaction were spotted 
onto 0.1 mm cellulose polyethyleneimine TEC paper before and after incubation at 37 °C. 
Unincorporated and incorporated dCTP were resolved by chromatography in 0.75M KPO4 
pH 3.5, and the chromatograph dried and exposed for 5 minutes.
RNA probes were made from DNA templates carrying a T3 or T7 promoter. 1 |xg of 
template DNA linearized with an appropriate restriction enzyme was incubated in a 15 pil 
volume with 3 |xl transcription buffer (Promega), 2 jxl 3.3 mM each ATP, GTP and CTP, 6 
|il ^^P-a-UTP (800Ci/mmol), 1 p-1 RNAsin and 20 units of T3 or T7 polymerase. The 
reaction was incubated at 37 °C for 15 minutes, followed by addition of 40 units of RQl 
DNAse 1 and further incubation at 37 °C for 15 minutes. Incorporation of UTP was 
monitored with TEC, as described above.
After hybridisation, the filters were rinsed with washing buffer (20 mM NaH2P0 4  1% SDS 
ImM EDTA) at room temperature, followed by two to four washes of 15 minutes each at the 
same temperature used for hybridisation.
Finally, autoradiography was performed by exposing the filter either to film (Kodak) or to 
Phosphoimager plates (Fuji).
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XII.2.13 Screening o f high density mouse BAG library
Hybridisation membranes from a mouse BAG library were purchased from Research 
Genetics, Inc. and screened according to the manufacturer's instructions. Determination of 
the identity of the BAG clone was performed according to the instructions of the 
manufacturer.
XII.2.14 BAG sequencing
Sequencing of BAGs was performed at the EMBL sequencing facility (Dr. Vladimir Benes) 
with the direct primer walking technique described in (Benes et ah, 1997).
XII.2.15 Gulture of mouse ES cells and mouse embryonic fibroblasts 
(MEFs)
Mouse ES cells and MEFs were grown essentially as described (Matise et ah, 1999). To 
prepare the ES cell medium, the following components were added to 500 ml of DMEM, 
High glucose: 90 ml of Fetal calf Serum; 6 ml of Penicillin/Streptomycin (100 units/ml), 6 
ml of non essential aminoacids (10 mM), 6 ml of Sodium Pyruvate (100 mM), 6 ml of P~ 
Mercaptoethanol (10 mM), 6 ml of L-Glutamine (200 mM) and 60 jxl of LIF (from Gibco 
BRL) (10^ units/ml).
XII.2.16 X-gal staining of ES cells
Gells were rinsed twice with PBS, before incubating for 2 minutes in fixative solution. They 
were then washed three times with PBS, before adding the staining solution and incubating 
at 37 °G from a few hours to overnight.
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The fixative solution was prepared as follows: for a total volume of 50 ml, to 47,1 ml of PBS 
were added 2,7 ml of Formaldehyde (37%) and 200 |xl of Gultaraldehyde (25%).
The staining solution was prepared as follows: for a total volume of 50 ml, 39.6 ml of PBS 
were combined with 250 |il of X-gal (200 mg/ml), 100 |xl of MgCb (IM), 5 ml of Potassium 
Ferricyanide (50 mM) and 5 ml of Potassium Ferrocyanide (50 mM).
XII.2.17 ES cell blastocyst injection
All ES cells injections were performed by the EMBL Transgenic service, according to 
standard procedures.
XII.2.18 Oocyte microinjection
All injections of BAG DNA into mouse fertilized oocytes were performed by the EMBL 
transgenic service according to standard procedures.
XII.2.19 Isolation of genomic DNA from ES cells and mouse tails
Genomic DNA was extracted from ES cells and mouse tails according to established 
methods (Matise, M.P. et al. 1999; Hammes, A. et al. 2000).
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